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Depressive disorder is one of the most disabling diseases in the world (Üstün 
et al., 2004). Lifetime prevalence rates of major depressive disorder are about 
17% in the USA; one in six persons will have a diagnosable depression at some 
point in their lives (Blazer et al., 1994). However numbers may differ between 
countries (Hammen, 1997). More women than men are affected by depressive 
disorders worldwide (with a ratio of 2:1). The rates of onset and current 
depression are highest in late adolescence and early twenties (Hammen, 1997). 
The core symptoms of depression are low mood and anhedonia (the inability 
to gain pleasure from normally pleasurable experiences). Other symptoms may 
include a decreased appetite, difficulties sleeping, fatigue, feelings of 
worthlessness, diminished ability to concentrate and thoughts of death or 
suicide. Table 1 represents the diagnostic criteria for a Major Depressive 
Episode, as stated by the Diagnostic and Statistical Manual of Mental 
Disorders-IV (American Psychiatric Association, 1994).  
The most effective treatments for depression are antidepressant 
medication, structured forms of psychotherapy (eg. cognitive behavioural 
therapy), or a combination of both.  Selective serotonin reuptake inhibitors 
(SSRIs) form the most widely used pharmacological treatment for depression 
(Petersen et al., 2002). 
Since rates of relapse and recurrence in depressive disorder are high 
(Judd, 1997), extensive research is done on the mechanisms that may play a 
role in the development and maintenance of depressive disorder. Vulnerability 
to depression may include cognitive, biological, psycho-social and genetic 
factors (Hammen, 1997). In terms of biological vulnerability to depression, 
neurotransmitter dysfunction (serotonin, dopamine, norepinephrine) is thought 
to play an important role (Maes & Meltzer, 1995). This thesis focuses on the 
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role that the neurotransmitter serotonin (5- hydroxy-triptamine; 5-HT) plays in 
depression, especially in mood and cognitive processing. The link between 
serotonin and two biological vulnerability factors (the cortisol response to 
stress and heart rate variability) associated with depression will also be 
investigated.
The role of serotonin in depressive disorder
The notion that a dysfunctional serotonergic system is involved in the 
pathophysiology of depression is supported by a wide range of experimental 
studies (Delgado et al., 1990; Maes & Meltzer, 1995). Abnormalities in the 5-
HT system can occur at different levels: availability of the serotonin precursor 
tryptophan (Cowen et al., 1989), serotonin synthesis, release, reuptake or 
metabolism, or at the pre- or postsynaptic receptors (Cleare et al., 1998; Maes 
& Meltzer, 1995). This ‘serotonergic vulnerability’ may be caused by a variety 
of factors such as innate factors (genetic factors, family history, personality, 
gender, sex hormones); environmental factors (stress, immune system and 
cytokines, drug use), and bio-psychological interactions (Jans et al., 2007).
Some serotonin abnormalities are not only found in acutely depressed 
but also in remitted depressed patients and subjects with a family history of 
depression (Bhagwagar et al., 2006; Flory et al., 1998). This suggests that either 
a dysfunctional serotonin system or an increased sensitivity of the serotonin 
system is a trait abnormality in depression. However, not all depressed patients 
show all abnormalities in 5-HT function (Van Praag, 2004).
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Table 1. The diagnostic criteria for Major Depressive Episode according to the 
DSM-IV 
___________________________________________________________________
A. Five (or more) of the following symptoms have been present during the same 2-
week period and represent a change from previous functioning; at least one of the 
symptoms is either (1) depressed mood or (2) loss of interest or pleasure.
(1) depressed mood most of the day, nearly every day, as indicated by either subjective 
report (e.g., feels sad or empty) or observation made by others (e.g., appears tearful).
(2) markedly diminished interest or pleasure in all, or almost all, activities most of the 
day, nearly every day (as indicated by either subjective account or observation made by 
others).
(3) significant weight loss when not dieting or weight gain (e.g., a change of more than 
5% of body weight in a month), or decrease or increase in appetite nearly every day.
(4) insomnia or hypersomnia nearly every day
(5) psychomotor agitation or retardation nearly every day (observable by others, not 
merely subjective feelings of restlessness or being slowed down)
(6) fatigue or loss of energy nearly every day
(7) feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-reproach or guilt about being sick)
(8) diminished ability to think or concentrate, or indecisiveness, nearly every day 
(either by subjective account or as observed by others)
(9) recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing suicide
B. The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning.
C. The symptoms are not due to the direct physiological effects of a substance (e.g., a 




The neurobiological basis of depression has been linked to the 
mechanism of action of antidepressant medication: serotonergic 
antidepressants increase brain serotonin function by inhibiting the re-uptake of 
the neurotransmitter serotonin (Blier & de Montigny, 1994; Delgado, 2000).
Since a direct measurement of serotonin in humans is problematic, 
research into serotonin function is based on indirect methods. Experimentally 
manipulating serotonin levels in humans makes it possible to study the role of 
serotonin function in depression and antidepressant action. In this thesis, two 
different interventions are used to manipulate serotonin activity in humans: 




Serotonin synthesis depends on dietary intake of its precursor, the essential 
amino acid tryptophan. At the blood-brain barrier, tryptophan has to compete 
for entry with the other large neutral amino acids (LNAAs; tyrosine, 
phenylalanine, leucine, isoleucine and valine). Once tryptophan has entered the 
brain, it is synthesized in a rate limiting step by tryptophan-hydroxylase into 5-
hydroxytryptophan (5-HTP) and then into serotonin. See Figure 1.
Acute tryptophan depletion (ATD) is a method to experimentally lower 
serotonin function by depleting the brain from its precursor tryptophan. This 
is done through administration of an amino-acid mixture devoid of tryptophan 
(Young et al., 1985). The most common ATD method involves a low-
tryptophan diet during the 24 hours before the test session, followed by an 
overnight fast. In the morning of the test day, subjects are asked to consume a 
drink containing a 100g load of 15 amino-acids that does not contain 
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tryptophan (Bell et al., 2001), mostly mixed with water and artificial flavour. 
After five to six hours, ATD results in peak reductions of plasma tryptophan 
levels (+/- 70%) and ratio tryptophan/LNAA, which is an index of central 5-
HT turnover, (+/- 90%). Therefore, ATD is a useful tool to investigate the 
effects of lowered serotonin function in humans. ATD results in significant 
behavioural effects, including a lowering of mood (Young et al., 1985), changes 
in cognitive performance (Park et al., 1994; Schmitt et al., 2000), increased 
impulsive behaviour (Young, 1986) and changes in sleep architecture (Bhatti et 
al., 1998). It is important to note that differential effects of ATD are found in 
healthy vs. depression vulnerable subjects. Mood effects of ATD are only 
found in remitted depressed patients taking SSRIs (Booij et al., 2002; Delgado 
et al., 1990) and in healthy subjects with a family history of depressive 
disorders (Benkelfat et al., 1994; Klaassen et al., 1999). Some of the other 
effects (on cognition, sleep) are not restricted to these groups, but may also 
occur in healthy volunteers.
The effects of ATD are usually compared to an amino acid mixture 
with tryptophan (Murphy et al., 2002; Park et al., 1994; Rubinsztein et al., 
2001). This ‘control’ mixture generally results in a considerable but highly 
variable increase in plasma tryptophan and the tryptophan/LNAA ratio, 
thereby forming an active control condition instead of a placebo condition. 
This is especially undesirable when investigating subtle effects. An alternative 
was developed by Krahn et al. (1996): a quarter-strength amino acid mixture 
containing the same amino acids as the ATD mixture, again without 
tryptophan. The alternative was necessary because tryptophan was banned 
from the US market for several years after 1990. This mixture is also not a 
neutral control condition, but results in a predictable moderate reduction of 
the plasma tryptophan/LNAA ratio. Since this ‘low-dose’ mixture has been 
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found not to affect mood (e.g. Booij et al., 2005a), it allows for an investigation 
of the dose-response effects of lowered serotonin function and thus seems to 
be a better control condition for some research questions. Recently, different 
studies (Hayward et al., 2005; Munafò et al., 2006) have reported effects of a 
different low-dose tryptophan depletion method, using a mixture containing 
eight amino acids instead of the regular fifteen amino acids. The low-dose 
tryptophan depletion method is further discussed in Chapter 5.  
  
Dietary interventions
Carbohydrate-rich diets have been found to increase the tryptophan/LNAA 
ratio and thus increase central serotonin function. This is due to a carbohydrate 
induced insulin response that stimulates the uptake of LNAA in skeletal 
muscles with the exception of tryptophan (Fernstrom & Wurtman, 1971). 
However, these increases are only found under rather extreme dieting 
conditions (Yokogoshi & Wurtman, 1986). Carbohydrate-rich, protein-poor 
diets have been found to increase the tryptophan/LNAA ratio by 42% 
compared to a control diet (Markus et al., 1998) and to prevent stress induced 
deterioration of mood and cortisol response but only in stress-vulnerable 
subjects (Markus et al., 1998). Also, carbohydrate intake improves cognitive 
performance of stress-vulnerable subjects under controllable laboratory stress 
(Markus et al., 1999). Overall, the effects of carbohydrate-rich diet  seem to 
depend on factors such as the time of day, the type of task and the 
vulnerability of the population (Dye et al., 2000).
Another way to manipulate tryptophan levels is a diet rich in the milk-
whey alpha-lactalbumin (Heine et al., 1996). Diet rich in alpha-lactalbumin 
leads to an increase in plasma tryptophan/LNAA ratio of 48% compared to a 
casein (placebo) diet (Markus et al., 2000), thereby raising brain serotonin 
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activity. Diet enriched with alpha-lactalbumin has been found to prevent 
stress-induced cortisol and mood response (Markus et al., 2000) and to 
improve cognitive performance (Markus et al., 2002), but again only in stress-
vulnerable individuals. 
Cognitive and biological vulnerability to depression
Cognitive function
Problems concentrating and making decisions are part of the diagnostic criteria 
of Major Depressive Disorder (American Psychiatric Association, 1994). 
Experimental research has shown that memory, learning, attention, motor 
function and problem solving may also be affected in depressed patients 
(Austin et al., 2001; Elliott, 1998; Weiland-Fiedler et al., 2004). In terms of 
impairments in emotional (as opposed to neutral) information processing, the 
recognition of facial expressions of emotions has been found to be affected in 
depressed patients (Bouhuys et al., 1999; Gur et al., 1992).  Also an increased 
attentional bias for negative information (Williams et al., 1996) and an 
increased level of dysfunctional attitudes (Ingram et al., 1998) are found 
compared to healthy controls.  
Some of these cognitive impairments persist into the euthymic phase; 
however research on cognitive impairments in recovered depressed patients 
has shown conflicting results (Paelecke-Habermann et al., 2005; Paradiso et al., 
1997; Weiland-Fiedler et al., 2004). Recently, evidence indicates that persisting 
impairments may exist in the specificity of autobiographical memory 
(Spinhoven et al., 2006), the recognition of facial emotions (Bouhuys et al., 
1999) and attentional bias (Williams et al., 1996).
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Serotonin synthesis can be influenced at three levels: by restricting the dietary intake of 
tryptophan (1); by increasing the competition with the other large neutral amino acids 
(2); and by inhibition of tryptophan-hydroxylase which synthesizes tryptophan into 5-





 Some of these impairments are also related to risk of relapse (Bouhuys et al., 
1999; Williams et al., 1996), suggesting that some aspects of emotional 
information processing may be vulnerability markers for depression.
Evidence from animal and human studies has linked serotonin to 
cognitive function, especially learning and memory (McEntee & Crook, 1991; 
Sirviö et al., 1995). ATD studies have supported these findings. In healthy 
volunteers, ATD selectively impairs learning (Park et al., 1994), memory 
retrieval and consolidation (Klaassen et al., 2002; Park et al., 1994; Riedel et al., 
1999) and ATD improves attention in healthy samples (Schmitt et al., 2000) 
and patients (Booij et al., 2005a). Recently, interest has been paid to the effects 
of ATD on emotional information processing; ATD impaired the recognition 
of facial expressions of fear in female healthy volunteers (Harmer et al., 2003c) 
and increases emotional interference in both healthy and recovered depressed 
patients (Hayward et al., 2005; Munafò et al., 2006). 
Research on the effects of antidepressant medication also supports the 
link between serotonin and cognition (Amado-Boccara et al., 1995; Harmer et 
al., 2003b; Thompson, 1991). Very brief (one day or one week) treatment with 
a serotonergic antidepressant causes selective changes in emotional 
information processing, in particular in the recognition of facial expressions of 
emotions, in both healthy volunteers and recovered depressed women 
(Bhagwagar et al., 2004; Harmer et al., 2003a; Harmer et al., 2004; Harmer et 
al., 2006a). 
Stress and cortisol 
Depressive episodes are often preceded by stressful life events (Brown et al., 
1987; Kendler et al., 1999). Elevated cortisol levels, caused by stressful life 
events, may lower brain serotonin function and in turn lead to a depressed 
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state (Cowen, 2002). High cortisol levels may initially cause higher central 
nervous system turnover; however during continuous or frequent stress the 
availability of brain tryptophan and serotonin may diminish and vulnerability to 
depression may increase (Markus, 2003).
This makes cortisol an important biological mediator through which stress 
lowers serotonin function and thereby causes depression in vulnerable 
individuals. Cortisol is controlled by the hypothalamo-pituitary-adrenal (HPA) 
axis with which the central serotonergic system interacts. The finding of HPA-
axis hyperactivity in depression appears to be consistent, although it is not 
found in all patients (Jans et al., 2007). 
To study neuroendocrine dysfunction in depression, neuroendocrine 
challenge tests are used, such as d-fenfluramine (Cleare et al., 1998) or the 
dexamethasone/ corticotrophin releasing hormone (CRH) test (Baghai et al., 
2002). Evidence from challenge studies indicates that depressed and remitted 
depressed patients show blunted neuroendocrine responses to drugs that 
stimulate serotonin turnover, suggesting decreased serotonin responsiveness 
(Bhagwagar et al., 2002a; Bhagwagar et al., 2002b; Flory et al., 1998; Riedel et 
al., 2002). These results indicate that blunted cortisol responses to a 
neuroendocrine challenge may be a vulnerability marker for depression. 
Heart rate variability
Cardiovascular disease (CVD) is the leading cause of death in the United States 
(American Heart Association, 2006). Depression has been found to be an 
independent risk factor for CVD (see for a review Rugulies, 2002). Depression 
after a myocardial infarction also predicts mortality (Anda et al., 1993). 
Decreased heart rate variability (HRV) is a risk factor for CVD (Stein & 
Kleiger, 1999) and has also been associated with depression and may thus 
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underlie the increased risk of cardiovascular disease in depression (Gorman & 
Sloan, 2000; Grippo & Johnson, 2002; Musselman et al., 1998). HRV is a 
measure of autonomic regulation of the heart (Krantz & McCeney, 2002). 
HRV reflects the capacity of the autonomic nervous system to vary the 
intervals between consecutive heartbeats (Grippo & Johnson, 2002). 
Reductions in HRV are not exclusively related to depression (Agelink et al., 
2002; Rechlin et al., 1994) but are also associated with generalized anxiety 
disorder (Thayer & Lane, 2000), impulse control disorders such as ADHD 
(Beauchaine et al., 2001), and alcoholism (Ingjaldsson et al., 2003).  Negative 
results have also been found (Gehi et al., 2005). Serotonin dysfunction is 
suggested to play an etiological role in both depression and cardiac dysfunction 
(Grippo & Johnson, 2002), and may thus underlie the association between 
HRV and depression.
Considering the different vulnerability factors for depression that were 
discussed above and the fact that serotonin plays an important role in the 
pathophysiology and the treatment of depressive disorders, it would be 
interesting to investigate the specific role that serotonin plays in the cognitive 
and biological vulnerability to depression. Experimental manipulations of 
serotonin function may influence cognitive and/ or biological factors in 
individuals that are vulnerable to depression (e.g. remitted or recovered 
depressed patients). Since serotonin is linked to cognitive performance, the 
cortisol response to stress and heart rate variability, experimental changes in 





This thesis will investigate the effects of three different serotonin 
manipulations (an alpha-lactalbumin enriched diet, low-dose ATD, high-dose 
ATD) on mood and cognitive processing in euthymic patients with a history of 
depressive disorder and healthy controls. The literature regarding a possible 
link between serotonin induced changes in mood and emotional information 
processing will also be discussed. 
The first project that was carried out as part of the current thesis 
investigated the effects of an alpha-lactalbumin enriched diet, which increases 
serotonin activity, on mood and different aspects of neutral information 
processing in recovered depressed patients and healthy controls. The second 
project focussed on the effects of acute tryptophan depletion, which lowers 
serotonin function, on mood and neutral as well as emotional information 
processing in medicated remitted depressed patients. In addition to these two 
empirical studies, an overview of the literature is given on the effects of 
serotonin manipulations on mood and emotional information processing, to 
evaluate a possible link between serotonin induced changes in mood and 
emotional information processing. Apart from the effects of serotonin 
manipulations on cognitive processing, the link between serotonin activity and 
two different biological vulnerability factors for depression was also 
investigated. The first study additionally investigated the effects of alpha-
lactalbumin on stress-induced cortisol response and the second study also 
looked at the effect of acute tryptophan depletion on heart rate variability.
Outline of this thesis
In Chapter 2, results of a study are reported in which remitted depressed 
patients are compared to healthy controls to investigate possible residual 
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cognitive impairments that persist into the euthymic phase. Chapter 3 will 
describe the effects of an alpha-lactalbumin enriched diet on cognitive 
performance in unmedicated recovered depressed patients and healthy 
controls. In Chapter 4 the effects of alpha-lactalbumin on mood and stress-
induced cortisol response in unmedicated recovered depressed patients and 
healthy controls are reported. Chapter 5 describes the effects of low-dose and 
high-dose ATD on mood and neutral as well as emotional information 
processing in medicated remitted depressed patients. In Chapter 6, the effects 
of low-dose and high-dose tryptophan depletion on individual plasma 
tryptophan levels and the ratio tryptophan/LNAA will be discussed. In 
Chapter 7 the effects of ATD on heart rate variability in medicated remitted 
depressed patients are reported. A literature overview of studies investigating 
the effects of serotonin manipulations on emotional information processing 
and mood is given in Chapter 8. Also, evidence for a possible sequential link 
between serotonin induced changes in emotional information processing and 
mood is evaluated. Chapter 9 contains a summary and integration of the main 
findings, as well as methodological strengths and limitations, directions for 
future research and clinical implications of the findings reported in this thesis.
2
Residual cognitive impairments in remitted 
depressed patients
W. Merens, L. Booij, A.J. W. Van der Does. 




Depressive disorders are associated with various cognitive impairments. 
Studies on whether or not these impairments persist into the euthymic phase 
have shown conflicting results, due to differences in test versions and in study 
samples. In the current paper we aimed to compare the cognitive performance 
of remitted depressed patients with that of age- and gender matched healthy 
volunteers across a wide range of cognitive domains. In two studies we found 
few differences on neutral as well as emotional information processing tests. 
The findings indicate that remitted depressed patients who use antidepressant 
medication still show an increased recognition of facial expression of fear 
compared to healthy controls. Patients also performed worse on a test of 
recognition of abstract visual information from long-term memory. No other 
residual cognitive impairments were found. These results indicate that most of 
the cognitive impairments associated with depression resolve with recovery 
through medication, even when recovery is incomplete. Considering the 
finding that remitted depressed patients have higher levels of cognitive 
reactivity future studies may investigate the possibility that these cognitive 
impairments have not resolved but have become latent, and may therefore 




Problems concentrating and making decisions are part of the diagnostic criteria 
of major depressive disorder (American Psychiatric Association, 1994). 
Experimental research has shown that memory, learning, attention, motor 
function and problem solving may also be affected in depressed patients 
(Austin et al., 2001; Elliott, 1998; Weiland-Fiedler et al., 2004). The cognitive 
functions that are most impaired in depression are those which require 
effortful executive functioning, which is highly dependent on the prefrontal 
cortex (Elliott, 1998). Some studies have focused on impairments in emotional 
(as opposed to neutral) information processing in depressed patients. For 
example, the recognition of facial expressions of emotions has been found to 
be affected in depressed patients (Bouhuys et al., 1999; Gur et al., 1992).  Also 
an increased attentional bias for negative information (Williams et al., 1996) 
and an increased level of dysfunctional attitudes (Ingram et al., 1998) are found 
compared to healthy controls.  
Given the high risk of relapse in depression, it is important to 
investigate whether cognitive impairments persist into the euthymic phase and 
if so, whether these impairments may be predictive of depressive relapse. 
Research on cognitive impairments in recovered depressed patients has shown 
conflicting results. These conflicting results may be a function of differences in 
study sample, such as gender distribution, age, education level, residual 
depressive symptoms, medication status, and diagnosis. Marcos et al. found 
differences on tests measuring paired learning, immediate and delayed visual 
memory, delayed logical memory and block design between euthymic patients 
and healthy controls (Marcos et al., 1994). Part of the patient sample was 
medicated with imipramine, part of the sample was unmedicated at the time of 
study. The two groups consisted of both men and women and were equal in 
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age (mean ages 54 and 52 years) and education level. In another study, 
differences between depressed and non-depressed subjects on different 
memory tests (verbal memory, immediate and delayed recall, learning, retrieval) 
disappeared following imipramine treatment, but only in treatment responders. 
Improvement in depressive symptoms led to significant improvement in 
memory performance (Peselow et al., 1991). Again both groups were equal in 
age (mean 48-50 years), gender distribution (both men and women were tested) 
and level of intelligence. Paradiso et al. (1997) compared cognitive 
performance of patients with a –relatively chronic- history of unipolar and 
bipolar depressive disorder to that of age- (mean age 50-57 years) and 
education matched controls. Only male subjects were included and almost all 
patients were taking some form of psychotropic medication (benzodiazepines, 
tricyclics, trazodone). They found that euthymic unipolar patients performed 
worse on tasks measuring executive function (Trail Making B, Stroop CWT), 
visual-motor sequencing (Trail Making A), immediate memory (word-list 
memory test) and attention (digit symbols) compared to healthy controls.  In 
another study, unmedicated male and female remitted depressed patients were 
impaired on tasks of rapid visual information processing (sustained attention), 
psychomotor speed and spatial working memory compared to healthy controls 
(Weiland-Fiedler et al., 2004). However, after correcting for residual depressive 
symptoms, only the difference in sustained attention remained significant. In 
this study mean ages were 36 and 38 years and all patients had been taking 
antidepressant medication in the past. These results were supported by another 
study that found medicated and unmedicated euthymic patients to be impaired 
in attentional and executive function (Paelecke-Habermann et al., 2005).
Regarding emotional information processing, persisting impairments 
have been found in the specificity of autobiographical memory (Spinhoven et 
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al., 2006), the recognition of facial emotions (Bouhuys et al., 1999) and 
attentional bias (Williams et al., 1996). Some of these impairments are also 
related to risk of relapse (Bouhuys et al., 1999; Williams et al., 1996). 
Overall, depressed patients show cognitive impairments across a wide 
range of domains. Some of these impairments improve with clinical recovery, 
while others may persist into the euthymic phase. Some cognitive impairments 
may even be related to depressive relapse. However, following the results of 
Weiland-Fiedler et al. (2004), it remains questionable whether remitted
depressed patients show any cognitive impairments in comparison to an 
adequately matched control group and, most importantly, when residual 
depressive symptoms are taken into account. The current study investigated 
cognitive performance in medicated, remitted depressed patients, who are 
expected to show relatively high levels of residual depressive symptoms, and 
two matched control groups. To cover a wide range of tests, two separate 
studies were undertaken. The two studies differed in the type of information 
processing that was assessed. Study 1 included mainly tests of emotional 
information processing; study 2 included tests that assessed neutral 
information processing. To check for possible differences between the study 
samples, both studies included a fluency test and a measure of attentional bias. 







Patients: As part of a larger study, two samples of remitted depressed 
patients were recruited from a Mood Disorders Program. Participants were 
male and female outpatients (of the Mood Disorders Program of Parnassia 
Psycho-medical Center, The Hague). Patients were at different stages in 
treatment, but were referred to the study only when their therapist thought 
they would meet criteria for remitted or recovered depression. Age limits were 
18 to 65 years. Participants had to fulfill the following inclusion criteria: 
primary intake diagnosis of DSM-IV major depressive disorder; no longer 
fulfilling DSM-IV criteria for depression and Hamilton-17 scores lower than or 
equal to 15 (Frank et al., 1991); ongoing treatment with a selective serotonin 
reuptake inhibitor (SSRI) or selective serotonin and noradrenalin reuptake 
inhibitor (SSNRI) for at least four weeks; no history or current psychotic 
disorder; no substance abuse in the past 3 months, based on DSM-IV criteria; 
BMI equal or higher than 18; free of neuro-endocrine or neurological disease; 
no pregnancy or lactation (females). 1
Controls: Healthy control participants were recruited through 
advertisements in local newspapers. Participants were matched to the patient 
group on age and gender. Inclusion criteria were: no mood disorders (lifetime); 
no first degree relatives with a mood disorder (lifetime); no history or current 
psychotic disorder; no substance abuse in the past 3 months, based on DSM-
IV criteria; no use of psychotropic medication, free of neuro-endocrine or 
neurological disease. 
1 The patients in Study 1 are the same sample as in Merens et al. (Journal of Psychopharmacoly, in 
press); those in Study 2 are the same as in Booij et al. (2005), Journal of Psychopharmacoly 19, 267-
275. The present data are slightly different, because in these two reports, baseline data were 




Self-report: The Beck Depression Inventory (Beck et al., 1996) is a self-
rating scale that assesses the presence and severity of depressive symptoms. 
The Dutch version was used (BDI-II-NL, Van der Does, 2002b). The 
Dysfunctional Attitudes Scale (DAS, Weissman, 1979) assesses the level of 
dysfunctional attitudes. A 22 item version was used, based on the original form 
A.  The Leiden Index of Depression Sensitivity (LEIDS) (Van der Does, 
2002a) consists of 34 items and assesses the effects of dysphoric mood on 
cognitions (‘cognitive reactivity’). 
Depression severity: The Hamilton Depression Rating Scale (HAM-D-17) 
was administered to patients to assess the severity of depressive symptoms 
(Hamilton, 1967).
Cognition: The cognitive test-battery took about 50 minutes to complete. 
Word Learning Test (Saan & Deelman, 1986): A list of 15 unrelated, 
neutral words was presented on a tape. Immediate recall was tested after each 
of five consecutive presentations. After the fifth trial, subjects continued with a 
non-verbal task. Fifteen minutes later delayed recall was tested. Immediate 
recall performance was defined as the total of correct words remembered over 
the five trials. Delayed recall performance was defined as the number of 
correct words produced at delayed recall. 
Verbal fluency: This task is a measure of strategy-driven retrieval from 
semantic memory within a fixed time span (Schmitt et al., 2000). Participants 
were instructed to produce as many correct four letter words as possible with 
the same initial letter within one minute. The starting letters were H, M, R or 
L; these were randomized over the participants. The total number of correct 
reported words was registered.   
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Implicit Association Test: The IAT is a sorting task that assesses implicit 
associations on the basis of reaction times (Egloff & Schmukle, 2002; 
Greenwald et al., 1998). This test is extensively used in social psychological 
research to assess stereotypes (Greenwald & Banaji, 1995). Participants are 
asked to sort stimuli representing four categories by pressing the appropriate 
key (each response key was assigned to two categories). If two categories are 
strongly related, the sorting task will be easier (i.e. faster RTs) when the 
categories share the same response key than when they share different 
response keys. We used an emotional and a neutral version of this task. Only 
median latencies for correct responses were included in the analyses. Reaction 
times to congruent (e.g. self and positive stimuli, insect and negative stimuli) 
and incongruent stimuli (e.g. self and negative stimuli, flowers and negative 
stimuli) were calculated.
Dot-probe test: This task measures attentional bias to emotional stimuli 
(MacLeod et al., 1986). Word pairs (threat words with neutral words and 
depression related words with positive words) were presented on a computer 
screen for 500 ms, one in the upper part of the screen and one below. 
Following the termination of that display, a dot appeared on the location of 
either word. Participants had to indicate the location of the dot by pressing a 
key. All word pairs were preceded by a white fixation cross for 500 ms. To 
control for possible outliers, only median latencies for correct responses were 
included in the analyses. Attentional bias was calculated by subtracting the RT 
for positive (neutral) words from the RT for depressive (threatening) words. 
Facial Expression Recognition test: The facial expression recognition task, 
adapted from Harmer et al. (2003c), features examples of five basic 
emotions—happiness, sadness, fear, anger, and disgust (Ekman & Friesen, 
1976). Emotional expression intensity was averaged between neutral (0%) and 
Chapter 2
  31
emotional standard (100%) in 10% steps, providing a range of emotional 
intensities. Each emotion-intensity was presented by two examples (one male 
and one female face) in random order. Each face was presented on a computer 
screen for 500 ms. and immediately replaced by a blank screen. Participants 
made their response by pressing a labeled key, after which the next face 
appeared on the screen. They were instructed to respond as quickly and 
accurately as possible. Accuracy of recognition was calculated over the 
different intensity levels in five (20%) blocks. Reaction times for correct 
responses were calculated. 
Procedure
Patients: After showing interest in taking part, all volunteers were given 
oral and written information about the study. Informed consent was obtained 
and participants who seemed to meet criteria were invited for the first session. 
During this session, the SCID-IV interview was administered to ensure 
patients no longer fulfilled criteria for MDD (First et al., 1995). Participants 
filled out all questionnaires and afterwards the cognitive tests were done. The 
session lasted two to three hours. Clinical background information was 
checked in medical records. The study was approved by an independent 
medical ethics committee (METIGG, Utrecht).
Controls:  The healthy control subjects came in for one session in which 
the SCID-IV interview was administered to check the absence of mood 
disorders and other exclusion criteria. All questionnaires were filled out and the 





In- and exclusion criteria, methods and procedures were identical to study 1. 
However, the DAS was not filled out and the LEIDS was only completed by 
patients and therefore not reported here. 
Cognition: The cognitive tests took approximately 60 min. 
Verbal Fluency: This test was identical to the fluency test in study 1.  
Stroop Colour Word test: This test measures focused attention and 
response inhibition. Names of colours (red, yellow, blue and green) printed in 
black were presented one by one for a maximum of 1500 ms on a computer 
screen. Participants were instructed to read these words as fast as possible 
(Condition I). Next, coloured patches were presented (Condition II). Finally, 
the names of colours printed in an incongruent colour were presented and 
participants were instructed to name the colour of the ink (Condition III). 
Median reaction times (RTs) were recorded. Interference was defined as the 
extra time needed for condition III relative to the average of conditions I and 
II. 
Emotional Stroop test: This test was used to assess attentional bias for 
emotional material. The stimuli were positive, neutral or depression-related 
words. Words printed in colour were presented consecutively on a computer 
screen. Participants were asked to name the colours as quickly as possible. The 
order of the word categories was randomized over the patients. The order of 
the words within each category was randomized. 
Left/Right Choice RT: This test assesses motor speed and response 
inhibition as a function of task difficulty. The word ‘left’ or ‘right’ was 
presented in randomized order (1000 ms) either at the left or the right side of 
the screen. Participants were instructed to respond to the meaning of the word 
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but to ignore its location, as fast as possible. Correct responses and RTs were 
registered. 
Tower of London (TOL): The TOL (Owen et al., 1995a) is a planning task 
consisting of three coloured balls (red, yellow and blue) placed on three sticks 
in various arrangements. Two arrangements were presented on the upper and 
lower half of the screen. The patient was instructed to indicate the minimal 
number of moves necessary to change the first arrangement into the second 
(two to five moves). Correct responses and RTs were registered.
Abstract Patterns Recognition task (APRT): The APRT (Rubinsztein et al., 
2001) measures (speed of) recognition of non-verbal abstract information from 
short- and long-term memory. Sixteen abstract patterns were presented 
consecutively for 3000 ms, with 500 ms intervals. Participants were instructed 
to memorize the patterns. After three presentations of the complete series, two 
patterns were presented simultaneously; one that had been learned and a new 
pattern. Participants had to indicate as fast as possible which one had been 
previously presented. The recognition procedure was repeated after 35 min, 
during which verbal tasks were administered. Sensitivity measures (A’ ) were 
calculated for the proportion of correctly recognized patterns, corrected for 
response tendency by the formula: A’ = 1 – ¼ [fr/ cr + (1-cr) / (1– fr)], in 
which fr = the proportion of falsely recognized patterns and cr = proportion 
of correctly recognized patterns, following signal detection theory (Pollack & 
Norman, 1964). 
Statistical analysis
Data were first screened for missing values, outliers, normal distributions and 
homogeneity of variance. Differences between patients and controls were 
analyzed with GLM ANOVA with Group as a fixed factor and BDI-II total 
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score as a covariate. Since matching for Level of education was unsuccessful in 
study 1, this variable was also entered as a covariate in the analyses of the 
cognitive measures from study 1. Data from the Facial Emotion Recognition 
task were analyzed with GLM repeated measures analysis with Emotion 
(happiness, sadness, fear, anger, and disgust) as a within-subjects factor and 
Group (controls vs. remitted depressed patients) as a between-subjects factor 
and BDI-II and Level of education as covariates. The TOL was also analyzed 
using GLM repeated measures with Steps (2, 3, 4, 5) as a within-subjects factor 
and Group as a between-subjects factor and BDI-II as a covariate. Data are 
reported as means ± standard deviations. All tests were corrected for multiple 




On the Facial Expression Recognition task, reaction time data were missing for 
one emotion in two control participants, one of whom did not recognize any 
sad faces correctly, the other did not recognize any angry faces correctly. On 
the Word Learning Test, data were missing for one control subject for the 
immediate recall, due to technical problems. One control subject was an outlier 
on the Word Learning Test as well as the IAT Neutral. Another control was an 
outlier on the Dot-probe test. Analyses were conducted with and without 




Twenty healthy controls and nineteen remitted depressed subjects were 
included in the study. Participants were well matched on age and gender, 
however the control group had a higher level of education compared to the 
patient group (χ2 = 10.6, p = .005). Current comorbid diagnoses in the remitted 
depressed group were Social phobia (n = 1), Specific phobia (n = 2), chronic 
PTSD (n = 1) and Dysthymia (n = 4). Table 1 and 2 show clinical and 
demographical characteristics of both patients and controls of Study 1 and 
Study 2.
Self report measures
Recovered depressed patients scored higher on the BDI-II (t(19.6) = -5.5, p <
.001) compared to controls. Patients also scored higher on the DAS (t(37) = -
3.7, p = .001) and on some subscales of the LEIDS compared to the control 
group: Harm Avoidance (t(37) = -6.6, p < .001), Rumination (t(37) = -9.6, p <
.001), Hopelessness (t(37) = -2.2, p = .037) and on the Total score (t(37) = -4.2, 
p < .001). Controls scored higher on Acceptance/Coping (t(37) = 2.3, p = 
.026) and Aggression (t(37) = 2.2, p = .031). When controlled for residual 
depressive symptoms, only the differences on the LEIDS Total score (F(1,36) 
= 7.3, p = .010), Rumination (F(1,36) = 39.9, p < .001) and Harm Avoidance 
(F(1,36) = 16.5, p < .001) remained significant.
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Age (SD) 47.7 (14.1) 44.2 (13.0) 0.8 37 .426
BDI-II 1.4 (1.7) 11.7 (8.0) -5.5 19.6 .000**
LEIDS totalscore 24.7 (12.6) 40.0 (9.7) -4.2 37 .000**
DAS 58.8 (15.9) 80.2 (19.8) -3.7 37 .001**
χ2 df p
M/F 1/19 2/17 0.4 1 .517
Education level 10.6 2 .005**
- low n = 2 n = 7
- medium n = 8 n = 11







Age 44.1 (10.2) 48.7 (7.9) -1.6 39 .114
BDI-II 5.2 (5.3) 12.9 (10.1) -3.0 28.4 .006**
χ2 df p
M/F 9/12 11/9 0.6 1 .437
Education level 0.8 2 .665
- low n = 5 n = 3
- medium n = 6 n = 8
- high n = 10 n = 9
BDI-II = Beck Depression Inventory, 2nd edition; LEIDS = Leiden Index for 
Depression Sensitivity; DAS = Dysfunctional Attitudes Scale
** p < .010
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Table 2. Clinical characteristics of both patient groups (mean ± SD)
Study 1 (n = 19) Study 2 (n = 20)
HAM-D17 7.7 ± 3.6 [range 1-13] 5.6 ± 3.8 [range 0-13]
Type of medication
- SSRI n = 13 n = 13 †
- SSNRI n = 6 (150-375 mg) n = 7 (75–225 mg)
Type of remission1:
- partial remission n = 8 n = 13
- full remission n = 11 n = 7
Duration of remission 





Number of episodes ± SD 4.9 ± 4.1 [range 1-15] 4.8 ± 4.4 [range 1-16]
Single / recurrent episode(s) 2 / 17 4 / 16
Diagnosis, subtype2:
- MDD, melancholic 
- MDD, atypical 
- MDD, seasonal 
pattern










HAM-D = Hamilton Rating Scale for Depression; SSRI = Selective Serotonin 
Reuptake Inhibitor; SSNRI = Selective Serotonin and Noradrenalin Reuptake 
Inhibitor; † two SSRI treatment free for 1 month; 1:  according to the criteria of Frank 
et al. 1991; †† this wide range is caused by one patient who had been recovered for 





See Table 3a for the cognitive tests of study 1.
Facial Expression Recognition test: Only a significant effect of Emotion 
(F(3.9,137.6) = 10.3 , p < .001) was found on the overall accuracy data, 
indicating that participants were better at recognizing certain emotions 
compared to others (see Figure 1). The main effect of Group was not 
significant (F(1,35) = 1.5, p = .233). Separate analyses per Emotion revealed a 
significant effect of Group (F(1,35) = 5.5, p = .024) for the recognition of fear, 
indicating that remitted depressed patients were better at recognizing facial 
expressions of fear compared to controls. Univariate analyses on fear accuracy 
per intensity level (in five 20% blocks) showed that the effect of Group was 
significant or borderline significant for all levels, except for the 30-40% 
intensity level: 10-20% F(1,35) = 4.2, p = .049; 30-40% F(1,35) = 0.1, p = .788; 
50-60% F(1,35) = 4.1, p = .049; 70-80% F(1,35) = 7.2, p = .011; 90-100% 
F(1,35) = 4.1, p = .051  (see Figure 2). No significant main and interaction 
effects were found for the other emotions.
Regarding the reaction time data, a significant effect of Emotion was 
found (F(2.7,88.0) = 4.1,  p = .011). The main effect of Group was not 
significant (F(1,33) = 0.0, p = .834). When analyzed per emotion, no significant 
effects of Group or Group x Emotion were found.
No other significant differences between the groups on cognitive 
performance were found in study 1. 
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52.0 (9.0) 49.6 (11.0) 0.3 1,34 .581
delayed recall 
# correct
11.1 (2.2) 10.8 (2.7) 1.3 1,35 .260
Verbal Fluency
# correct 12.4 (3.6) 9.9 (3.5) 0.03 1,35 .868
IAT Neutral2
RT congruent (ms) 685.7 (107.8) 663.3 (126.4) 2.4 1,35 .134
RT incongruent (ms) 1139.8 (271.2) 1049.0 (273.6) 1.1 1.35 .294
IAT Emotional
RT congruent (ms) 828.6 (209.2) 897.3 (304.2) 0.1 1,35 .717




-2.3 (20.5) -1.3 (22.9) 0.0 1,35 .904
AB anxious - neutral 
(ms)
-1.4 (18.1) -6.0 (16.5) 0.4 1,35 .524
FERT
- Accuracy 1.5 1,35 .233
Anger 1.6 (0.8) 1.7 (0.6) 0.5 1,35 .505
Fear 1.8 (0.6) 2.0 (0.5) 5.5 1,35 .024*
Sadness 1.3 (0.8) 1.4 (0.7) 1.3 1,35 .268
Happiness 2.7 (0.4) 2.8 (0.3) 0.2 1,35 .669
Disgust 2.5 (0.5) 2.5 (0.6) 0.0 1,35 .836
- Speed (ms) 0.0 1,33 .834
Anger 1061.1 (344.2) 1205.2 (305.4) 0.1 1,34 .783
Fear 1123.9 (525.6) 1212.1 (464.9) 0.3 1,35 .578
Sadness 1459.6 (495.5) 1514.2 (981.0) 0.3 1,34 .568
Happiness 805.1 (190.5) 870.9 (233.6) 0.0 1,35 .999
Disgust 907.8 (263.1) 1114.9 (691.3) 0.4 1,35 .542
AB = attentional bias, FERT = Facial Expression Recognition Test, IAT = Implicit 
Attitudes Test, RT = reaction time, WLT = Word Learning Test, * p < .05, F values 
present the main effect of Group; 2: analyses without one outlier are presented. All 
analyses were performed with Bonferroni corrections.
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Figure 1. Facial emotion recognition for controls and remitted depressed 






















































One patient missed all 4- and 5-step problems of the TOL. One control 
participant missed all 5-step problems of the TOL. Data for another control 
participant are missing for all positive words on the Emotional Stroop task. 
Cases with missing data were omitted separately by analysis. Outliers were 
found on the APRT, Stroop CWT, and Emotional Stroop test. Analyses were 
conducted with and without statistical outliers, however results were similar.  
The Verbal Fluency data were successfully log 10 transformed because of a 
non-normal distribution. 
Participants: 
Twenty-one controls and twenty remitted depressed patients were included in 
this study. The control group did not differ from the patient group in terms of 
gender, age and education level. Past comorbid diagnoses in the remitted 
depressed patient group were Panic disorder (n = 3, of whom one in partial 
remission), Social phobia (n = 1) and Anorexia nervosa (n =1). 
Self-report
The remitted group had higher BDI-II scores compared to the control group 
(F(1,39) = 9.19, p = .004).
Cognition
See Table 3b for the cognitive tests of study 2.
APRT: A significant effect of Group was found for the recognition 
from long term memory (A’): F(1,38) = 5.0, p = .030. Patients appeared to 
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perform worse than controls at recognition of abstract visual information from 
long term memory.
Discussion
The current results indicate that medicated remitted depressed patients show 
an increased recognition of facial expressions of fear compared to healthy 
controls, even after statistical correction for differences in depressive 
symptoms. Also, patients scored higher on a self-report measure of cognitive 
reactivity and performed worse than controls at a task measuring recognition 
of abstract information from long term memory. No other residual cognitive 
impairments were found on a wide range of tests, despite the fact that the 
patients still suffered from residual depressive symptoms and were relatively 
chronic. The BDI-II scores of patients were higher than those of healthy 
controls, although both groups’ scores were within the normal range (Van der 
Does, 2002b). These findings support the view that most cognitive deficits 
associated with depression are associated with clinical status, rather than a 
persisting vulnerability factor (Weiland-Fiedler et al., 2004). Some deficits may 
be more persistent however, and the higher cognitive reactivity scores suggest 
that the deficits may have become ‘latent’. 
A number of studies have shown that cognitive deficits may not be 
apparent when they are only assessed at ‘resting’ state (Lau et al., 2004). This 
implies that negative information processing biases may be rather easily 
activated by dysphoric mood states – either naturally occurring or induced in 
the laboratory. This process is called cognitive reactivity. Cognitive reactivity is an 











# correct 10.4 (3.9) 12.1 (5.1) 0.1 1,38 .720
Stroop CWT
Condition I (ms) 567.0 (76.9) 552.5 (72.8) 0.2 1,38 .664
Condition II (ms) 487.5 (62.5) 490.2 (56.0) 0.1 1,38 .784
Condition III (ms) 775.7 (156.4) 792.0 (109.8) 0.0 1,38 .906
Interference (%) 47.3 (23.8) 52.3 (16.7) 0.1 1,38 .774
Emotional Stroop Task
Negative words (ms) 712.3 (88.2) 749.6 (115.0) 0.0 1,38 .895
Neutral words (ms) 693.7 (91.4) 722.5 (74.3) 0.1 1,38 .741
Positive words (ms) 702.1 (124.1) 705.3 (83.4) 0.1 1,37 .729
Interference negative 
(%)
3.1 (9.2) 3.7 (9.9) 0.1 1,38 .780
Interference positive 
(%)
1.7 (10.7) -2.3 (6.7) 1.1 1,37 .295
Left/right task
Congruent (ms) 634.9 (94.2) 678.4 (58.9) 0.9 1,38 .353
Incongruent (ms) 652.0 (97.7) 700.4 (54.6) 2.0 1,38 .168
Tower of London
- % correct 0.3 1,36 .584
2 steps 88.1 (17.5) 84.5 (16.7)
3 steps 85.2 (19.4) 78.5 (11.8)
4 steps 72.9 (15.5) 75.8 (21.2)
5 steps 65.0 (24.0) 54.7 (29.9)
- RT (ms) 0.1 1,36 .812
2 steps 5337.3 (1190.4) 6733.6 (2001.4)
3 steps 7359.3 (2424.0) 8101.8 (3388.0)









A’ STM (%) 83.0 (9.7) 78.3 (11.7) 1.5 1,38 .226
A’ LTM (%) 80.5 (9.9) 74.9 (14.2) 5.0 1,38 .030*
RT STM (ms) 2164.2 (805.6) 2308.0 (802.9) 0.8 1,38 .380
RT LTM (ms) 1976.4 (715.5) 2107.9 (597.3) 0.1 1,38 .808
CWT = Colour Word Test; APRT = Abstract Visual Patterns Task; RT = reaction 
time; STM = short term memory; LTM = long term memory; F values represent the 
main effect of Group. All analyses were performed with Bonferroni corrections.
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The finding of the current study that the difference between remitted 
depressed patients and controls in DAS scores became non-significant after 
controlling for residual symptoms is in line with Miranda et al. (1990) who 
have already shown that dysfunctional attitudes are mood-state dependent for 
subjects with a history of depression. The group differences on the LEIDS, 
which aim to measure reactivity of cognitions, remained significant after 
correction. The current findings therefore suggest that some of the other 
cognitive deficits might also be more easily triggered in remitted depressed 
patients than in never-depressed individuals. In line with our findings, Gemar 
et al. (2001) did not find any baseline differences when they studied implicit 
attitudes in formerly depressed and never depressed subjects.  Only after a sad 
mood induction, a shift was found toward a negative evaluative bias in the 
formerly depressed group, again supporting the suggestion that cognitive 
impairments may become latently present following clinical recovery. 
Interestingly, the finding that remitted depressed patients were better in 
recognizing fear indicates that facial expression recognition may be a scar and a 
persisting vulnerability factor for relapse to depression. Bhagwagar et al. (2004) 
also found increased recognition of fear in recovered depressed subjects 
relative to controls; however administration of a single dose of citalopram 
normalized this increased fear recognition. In contrast, our patients were 
already medicated for more than four weeks before entering the study. 
Bouhuys et al. (1999) found that increased perception of negative emotions is 
related to relapse, although the recognition of negative emotions decreased 
from the acute to the remitted phase. The conceptualization of fear recognition 
as a vulnerability marker was further supported in a study by Masurier et al. 
(2007) who found faster recognition of facial expressions of fear in female 
first-degree relatives of depressed patients compared to controls without a 
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family history of depression. Biases in the processing of emotional information 
may thus be a stable trait characteristic, even occurring before the onset of a 
first depressive episode (Leppänen, 2006; review).
Finally, the finding that the remitted depressed patients performed 
worse on a test measuring recognition from long-term visual memory is in line 
with previous studies which have shown persisting impairments in memory 
processes in euthymic patients (Marcos et al., 1994.) 
In the current studies, remitted depressed patients were not impaired 
on tests measuring attentional bias. Studies in recovered depressed subjects 
mainly used the Stroop Colour Word task to measure attentional bias. Both 
Paradiso et al. (1997) and Trichard et al. (1995) found persisting impairments 
in Stroop performance in recovered depressed patients. Attentional bias is 
thought to be not only a symptom of depression, but also to be important in 
the development and maintenance of depressive disorders (Williams et al., 
1996). Our results do not support this position, since no impairments were 
found on neutral and emotional Stroop interference as well as on attentional 
bias measured with the Dot-probe test. However, the literature on attentional 
bias in depression is contradictory, which may be explained by the differences 
in stimulus presentation- times (Mathews et al., 1996; Mogg et al., 1995). 
Studies using the Dot-probe test have found attentional biases in depression 
using relatively long stimulus presentations (1 sec or more) (Mogg et al., 1995). 
When stimuli are presented for shorter durations, results are mixed (Bradley et 
al., 1997; Mathews et al., 1996). Our stimulus presentation time of 500 ms. was 
probably not optimal to detect group differences.
One factor that might limit interpretation of the data is that patients 
were treated with serotonergic antidepressants when participating in the study. 
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Serotonergic antidepressants may have some sedative side effects, but these 
tend to wear off in the first two weeks of treatment (Amado-Boccara et al., 
1995) and the effects on memory and psychomotor performance are of low 
intensity (Gorenstein et al., 2006; Thompson, 1991). In contrast, SSRIs have 
been found to positively affect neutral and emotional information processing 
acutely and after 7 to14 days (Bhagwagar et al., 2004; Harmer et al., 2002; 
Harmer et al., 2003a; Harmer et al., 2004; Harmer et al., 2006a). However, 
unmedicated recovered depressed patients also did not show any  differences 
in neutral information processing compared to healthy controls (Booij et al., 
2006a), although these groups did differ on cognitive reactivity (Merens et al., 
2005). The latter studies used a considerable younger and less chronic sample 
however.  How chronic SSRI use affects emotional processing is still unclear, 
so it may be possible that some cognitive impairments were remediated by 
SSRI treatment. 
It also has to be considered that the lack of differences between groups 
in the current study may have been caused by insufficient statistical power. 
Sample sizes in both studies are relatively small and replication in larger 
samples is warranted. The fact that both patient groups were not completely 
asymptomatic only strengthens our conclusion that remitted depressed patients 
do not suffer from many cognitive impairments. Also, remission status (partial 
vs. full) did not affect the facial expression recognition data.  
Future research may investigate the influence of clinical variables 
(chronicity, age of onset, treatment modality etc.) on cognitive performance of 
remitted depressed patients, to clarify possible mediating factors leading to 
cognitive impairment in depression. Finally, as cognitive function was not 
assessed during the acute phase of the depressive episode, it cannot be ruled 
out that we selected groups of remitted depressed patients who showed little 
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cognitive impairments even in a depressed state. However, this seems very 
unlikely since cognitive impairments in depression are common (Austin et al., 
2001; Elliott, 1998) and both patients groups were relatively chronic. 
3
The effects of a diet enriched with alpha-
lactalbumin on mood and cortisol response 
in unmedicated recovered depressed 
subjects and controls
W. Merens, L. Booij, C.R. Markus, F.G. Zitman, W. Onkenhout 




Alpha-lactalbumin is a tryptophan-rich protein fraction. A diet enriched with 
alpha-lactalbumin increases the ratio of tryptophan to the other large neutral 
amino acids (LNAA), which may in turn increase brain serotonin content. In 
stress-vulnerable individuals, alpha-lactalbumin improved mood and attenuated 
the cortisol response after experimental stress. The aim of the present study 
was to investigate the effects of an alpha-lactalbumin-enriched diet on mood 
and stress response in recovered depressed subjects and healthy controls. 
Forty-three subjects (twenty-three recovered depressed and twenty healthy 
subjects) received alpha-lactalbumin and casein (placebo) on separate days, in a 
double-blind randomised crossover design. On both occasions, subjects 
underwent a stress test (an unsolvable mental arithmetic task with loud noise). 
The stress test affected mood in both conditions. Although the alpha-
lactalbumin diet led to the expected rises in tryptophan and tryptophan/LNAA 
ratio, only minimal effects were found on mood and cortisol response to 
experimental stress. The results were the same for recovered depressed patients 
and controls. A one-day diet enriched with alpha-lactalbumin is not sufficient 
to prevent stress-induced mood deterioration or a cortisol response in 
unmedicated, recovered depressed subjects. Future studies may investigate the 





There is abundant evidence that serotonin (5-hydroxytryptamine; 5-HT) plays 
an important role in stress-related disorders such as major depression (Maes & 
Meltzer, 1995; Meltzer & Lowy, 1987). For instance, medications that augment 
5-HT activity, such as selective serotonin reuptake inhibitors and monoamine 
oxidase inhibitors, are effective antidepressants (Blier & de Montigny, 1998; 
Nutt et al., 1999). Furthermore, experimental depletion of the 5-HT precursor 
L-tryptophan induces symptoms in depression-vulnerable subjects (patients in 
remission or family members of patients) but not in healthy subjects (Bell et al., 
2001; Van der Does, 2001a). Conversely, tryptophan administration increases 
5-HT synthesis in the brain in both human subjects and rats, and these effects 
are large enough to influence mood and behaviour (Young, 1996). For 
example, tryptophan decreased aggression and quarrelsome behaviour, and 
increased dominant behaviour, in healthy volunteers (Marsh et al., 2002; 
Moskowitz et al., 2001; Young & Leyton, 2002). In healthy females, tryptophan 
improved emotion recognition (Attenburrow et al., 2003). Tryptophan also has 
some therapeutic effect in mild to moderate depression, but it is not effective 
in more severe depression (Young, 1986; Young, 1996). It is clear, however, 
that boosting or depleting the 5-HT system has opposite effects on mood, 
although some of these effects are only observable in depression-vulnerable 
subjects.  
Several studies have attempted to increase 5-HT concentrations 
through dietary interventions. Although selective serotonin reuptake inhibitors 
have fewer side-effects than other antidepressants, and are not toxic in 
overdose, a sizable number of patients do not tolerate them or fail to benefit 
from them (Fava, 2000). Survey data show that many patients prematurely stop 
their medications because of side-effects (Consumer Reports, 2004). So, if 
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effective and feasible, dietary interventions may comprise a viable addition or 
alternative to antidepressant medications. A carbohydrate-rich/protein-poor 
diet has been shown to increase the ratio of tryptophan/large neutral amino 
acids (LNAA). The diet prevented stress-induced mood deterioration and 
cortisol response in individuals vulnerable to stress (defined by high 
neuroticism scores; Markus et al., 1998). Carbohydrate-rich/protein-poor diets 
are, however, not healthy on a day-to-day basis (Christensen, 1997), and even a 
small amount of protein blocks the rise of tryptophan/LNAA.
Recently, an even larger effect on stress response was obtained with a 
diet containing tryptophan-rich alpha-lactalbumin protein. Alpha-lactalbumin
has the highest tryptophan concentration of all protein fractions (Heine et al., 
1996). This diet increased plasma tryptophan/LNAA by 43–48%, which is 
twice the augmentation found with a carbohydrate- rich/protein-poor diet 
(Markus et al., 2000; Markus et al., 2002), or after 7 d of daily tryptophan 
treatment (Chouinard et al., 1985). Alpha-lactalbumin had no side-effects, and 
improved mood and attenuated cortisol responses to stress in stress-vulnerable 
subjects (students with high neuroticism scores) but not in controls (low 
neuroticism; Markus et al., 2000). Orosco et al. (2004) found that alpha-
lactalbumin had an anxiolytic effect in rats and increased 5-HT turnover in 
hippocampal areas. Since depression-vulnerable individuals are most likely to 
be affected by 5-HT manipulations, it seems worthwhile exploring the effects 
of alpha-lactalbumin in this group.
The present study was designed to investigate the effects of alpha-
lactalbumin in depression-vulnerable individuals and in healthy, non-vulnerable 
controls. Based on previous research (Markus et al., 2000; Markus et al., 2002), 
we expected to find a protective effect of alpha-lactalbumin on stress-induced 
mood deterioration and cortisol response, rather than a direct effect on mood. 
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Eligible subjects were between 18 and 65 years of age and had either a history 
of a major depressive episode (patient group) or no history of mental disorder 
and no first-degree relative with a major depressive disorder (control group). 
Subjects were euthymic and were selected not on the basis of neuroticism 
scores (Markus et al., 2000; Markus et al., 2002) but on a history of depression. 
Approximately 60% of people with high neuroticism scores actually develop a 
depression (Gallagher, 1990; Kendler et al., 2004; Ormel et al., 2001). Since 
long-term studies have shown that up to 85% of recovered depressed patients 
experience a recurrence (Mueller et al., 1999), a past history of depression is a 
better marker of vulnerability. 
In both groups, exclusion criteria were: current mental disorder; past 
psychotic disorder; substance abuse in the past 3 months or excessive dieting 
or binge eating, as defined by the Diagnostic and Statistical Manual of Mental 
Disorders-IV (DSM-IV; American Psychiatric Association, 1994). 
Furthermore, subjects in both groups had low levels of depressive symptoms 
(Montgomery Asberg Depression Rating Scale (MADRS score < 8), were not 
colour-blind or dyslexic, had been free of antidepressant medication for at least 
three months, had a normal body weight (BMI 18–27 kg/m2), kept to a regular
diet and were free of neuroendocrine or neurological disease. Female subjects 
were not pregnant or lactating, had a regular menstrual cycle or were 
postmenopausal. Pre-menopausal women who were not taking a contraceptive 
pill were tested during their mid-to-late follicular phase (days 4–10), whereas 
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pre-menopausal women taking a contraceptive pill participated during the 
period in which they actually took the pill. The groups were matched on 
gender, age and education level. 
Design
The study was conducted according to a double-blind crossover design. 
Subjects were given balanced isoenergetic meals containing alpha-lactalbumin-
enriched whey protein or casein protein (placebo). Treatment order was 
balanced over two sessions, separated by four weeks. 
Instruments
Standardised, validated instruments were used to assess diagnosis, depressive 
symptoms, mood states and personality. The Structured Clinical Interview for 
DSM-IV (First et al., 1995) was used to verify diagnostic inclusion and 
exclusion criteria. Depressive symptoms were measured with the MADRS 
(Montgomery & Asberg, 1979), a ten-item interviewer-rating scale, and the 
self-rating Beck Depression Inventory (BDI-II; Beck et al., 1996; Van der 
Does, 2002b). 
The Profile of Mood States (POMS; McNair et al., 1971; Wald & 
Mellenbergh, 1990) measures ‘depression’, ‘anger’, ‘fatigue’, ‘tension’ and 
‘vigor’. Neuroticism was measured to facilitate comparison with previous 
research (Markus et al., 2000; Markus et al., 2002); the Eysenck Personality 
Questionnaire (Eysenck et al., 1985) was used. Cognitive reactivity, a 
psychological vulnerability marker of depression, was also measured, using the 
Depressed States Checklist (DSC; Teasdale & Cox, 2001) and the Leiden Index 
of Depression Sensitivity (Van der Does, 2002a). The DSC consists of items 
that ‘objectively’ describe a depressed mood (e.g. sad, unhappy), and items that 
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also have a self-devaluative denotation (e.g. useless, a failure). Cognitive 
reactivity is the ratio of the endorsed self-devaluative and objective items 
(Teasdale & Cox, 2001). The Leiden Index of Depression Sensitivity is a self-
rating scale of cognitive reactivity, with subscales ‘hopelessness’, ‘rumination’, 
‘harm avoidance’, ‘aggression’, ‘control/ perfectionism’ and 
‘acceptance/coping’ (Van der Does, 2002a).
Procedure
Depressed patients who had participated in a psychotherapy trial 1–2 years 
earlier were sent information and invited to participate. Subjects were also 
recruited through advertisements in a local newspaper, and through 
advertisements and leaflets at the local mental health centre and at several 
university buildings. Individuals who expressed interest were interviewed by 
telephone. If the inclusion and exclusion criteria appeared to be met, more 
information was sent, and people were invited for a screening session at the 
hospital, during which the Structured Clinical Interview for DSM-IV and 
MADRS was administered by trained clinical psychologists. Information about 
previous antidepressant treatments and the course and duration of depressive 
episodes was also obtained, and questionnaires were completed. Subjects gave 
informed consent to participate prior to filling out the questionnaires. The first 
session was scheduled for approximately 1 week after the screening session, or 
somewhat later depending on the menstrual cycle phase.
Subjects arrived at the laboratory at 9.00 am after fasting overnight. 
They were   instructed not to use alcohol for 24 hours prior to the sessions and 
to arrive well rested. They received breakfast and lunch including either alpha-
lactalbumin or casein. In the morning and afternoon, a battery of cognitive 
tests was administered, the results of which are reported elsewhere (Booij et al., 
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2006a). During the day, two blood samples and four cortisol samples were
taken. The session finished at around 3.30 pm, and subjects were instructed to 
resume their regular meals. The outline of sessions is shown in Table 1. 
Subjects were paid € 80 for participation. Subjects were tested individually at a 
clinical research unit of Leiden University Medical Centre.
Table 1. Scheme of the sessions
Time (hrs) Assessment
09.00 am t -1 Arrival, BDI-II, DSC, POMS, blood sample
10.00 t 0 Breakfast
12.00 t 2 Lunch
1.30 pm t 3.5 Cortisol (1), blood sample,  POMS, DSC
2.35             t 4.5 Cortisol (2), POMS,
2.40 Stress Induction
3.00 t 5 Cortisol (3), POMS,  DSC
3.10 t 5.2 Cortisol (4), Debriefing
BDI-II = Beck Depression Inventory-II; DSC = Depressed States Checklist; POMS 
= Profile of Mood States
Intervention
The alpha-lactalbumin and casein diets used in the present study were identical 
to the diets used by Markus et al. (2000; 2002). Diets contained 1229 kJ with 
5.2% energy as protein, 84.2% energy as carbohydrate and 10.6% energy as fat, 
composed of standard products (Netherlands Nutrition Centre). Each 
breakfast and lunch consisted of one slice of bread, 10 g butter, 15 g fruit jelly, 
200 ml grape juice and a chocolate drink. The two diets were similar in 
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appearance and in macronutrient content with the exception of the 
composition of the chocolate-flavoured drink, for which the protein sources 
differed. Apart from breakfast and lunch, subjects were only allowed to drink 
water and one cup of tea or coffee. 
The nutrient composition and amino acid profile of both chocolate 
drinks are displayed in Table 2. The amounts of tryptophan in the alpha-
lactalbumin and casein diets were 12.3 g/kg (tryptophan/LNAA 8.7) and 9.5 
g/kg (tryptophan/LNAA 4.7), respectively. The chocolate drink was prepared 
within 20 min before breakfast (first drink) and 20 min before lunch (second 
drink). To compensate for any taste differences, sugar was added to all the 
drinks (10 g; see Table 2). All meals were supervised to make sure that all foods 
were consumed.
Table 2. Composition of the chocolate drinks used in the alpha-lactalbumin 
and casein diets
α-lactalbumin diet casein diet
Composition (g)
α-lactalbumin-enriched whey protein 20 0
Sodium caseinate 0 20
Cocoa 3.5 3.5
Granulated Sugar 10 10
Water 200 200







Tryptophan/LNAA (weight %) 8.70 4.70




An impossible mental arithmetic task, performed under noise stimulation, was 
used as an experimental stressor. Subjects were given eighteen successive 1 min 
trials, during which they had to do mental arithmetic under time constraints, 
while different levels of industrial noise (65, 70 or 80 dB) were presented 
through a headphone. Multiple choice questions were presented on a computer 
screen one at a time. A specified number of calculations (called the criterion) 
had to be solved correctly. Subjects were led to believe that they could control 
the intensity of noise by their performance. If they failed the criterion, the 
computer would set the noise level higher during the next trial; if, however, 
they met the criterion, they could choose the noise level themselves. Before the 
actual test, subjects were given two practice trials during which they had to 
solve a few calculations without noise and then with each of the three noise 
levels successively. The credibility of the task as well as motivation were 
enhanced by providing the subjects with constant on-screen feedback about 
the criterion in a particular trial, the number of calculations correctly solved 
and the time left for that trial. 
Experimental stress was induced by manipulating the criterion so that 
all subjects continued to fail on each trial and thus could not choose the noise 
level for the next trial. The criterion was always set at one sum above what 
subjects could manage, as calculated from the average time per sum needed on 
the previous trial. This task has been demonstrated to be uncontrollable and to 
induce transient psychological and physiological stress (Markus et al., 1999; 
Markus et al., 2000; Markus et al., 2002; Peters et al., 1998). The stress task 
proved to be sensitive in crossover designs in studies by Markus et al. In 
addition, the test affects perceived stress as well as systolic and diastolic blood 




Cortisol samples were obtained with the Salivette sampling device (Sarstedt, 
Nümbrecht, Germany). With this procedure, saliva was collected in small 
cotton swabs and stored in special Salivette tubes at -30 °C until centrifugation. 
Saliva samples were centrifuged at 3000 rpm for 3 min at 20 °C. Cortisol 
concentrations were determined without extraction using a competitive 
chemiluminescence immunoassay. 
A 20 μl sample of saliva was pipetted into microtitre plate wells coated 
with rabbit anti-cortisol antibodies. After the addition of 100 μl cortisol 
conjugated with horseradish peroxidase (enzyme conjugate), the mixture was 
incubated for 3 h at room temperature, and the cells were washed to stop the 
competition reaction. After addition of the chemiluminescence substrate 
solution containing peroxide and luminol, luminescence measurements were 
performed using a Berthold microtitre plate luminometer (Medical 
Laboratories, Mönchengladbach, Germany).
Blood assessments
Total tryptophan and its concentration ratio to LNAA (valine, isoleucine, 
leucine, tyrosine and phenylalanine) were determined by amino acid analysis. 
Blood was collected in 4 ml EDTA-containing tubes, and plasma was isolated 
after centrifugation at 2650 g at 20 °C for 20 min. For the determination of 
(total) tryptophan and LNAA, 400 μl plasma was deproteinised using an equal 
volume of 0.075 (w/v) sulphosalicylic acid in water, which concomitantly 
contained 382 μmol/l of the internal standard L-2,4-diamino- butyric acid 
(Fluka, Milan, Italy). The supernatant was isolated after centrifugation at 8000 g 
at 20 °C for 2 min, filtered through Millex 0.22 μm, 25 mm membrane filter 
units (Millipore, Billerica, MA, USA); 60 μl of this was analysed in 170 min by 
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means of ion-exchange chromatography and ninhydrin derivatisation on a 
Biochrom 20 automated amino acid analyzer (Pharmacia, Uppsala, Sweden) 
using standard conditions for physiological amino acid separation.
Statistical analyses
Group differences in demographic characteristics were examined with 
independent-sample t-tests. The effects of the interventions on cortisol 
response were analysed by means of repeated-measures ANOVA using general 
linear models. Within-subjects factors were Intervention (alpha-lactalbumin v. 
casein) and Time of assessment (before and after stress); the between-subjects 
factor was Group (recovered depressed v. controls). All mood scores were 
analysed using non-parametric tests (Wilcoxon and Mann–Whitney U). A test 
was considered to be significant when the p value was .05 or less. SPSS 11.5 
(SPSS Inc., Chicago IL, USA) was used. 
Ethical considerations 
The study was approved by the Medical Ethics Committee of Leiden 
University Medical Center. Previous studies using casein or alpha-lactalbumin
diets have shown that the procedure is safe, with no side-effects (Markus et al., 
2000; Markus et al., 2002). Prior studies have used the stress induction task 
(Markus et al., 1999; Markus et al., 2000; Markus et al., 2002; Peters et al., 
1998). There are no indications that the cognitive tasks or the stress task elicit 





A very small number of missing values on items of the symptom 
questionnaires were replaced by the grand mean. No statistical outliers were 
detected. Twenty-two blood samples (13% of the total) were not available 
owing to difficulties with venepuncture. The amino acid levels and ratios were 
all normally distributed. Cortisol values and the scores on the mood subscales 
were not; these data were log10 transformed. Subscales of the POMS and DSC 
were analysed using non-parametric tests as the data were highly skewed and 
transformations were unsuccessful. 
Sample characteristics
Fifty-seven individuals were invited for the screening session, eight of whom 
did not meet the inclusion and exclusion criteria. Three eligible subjects 
dropped out after the screening session, and another three dropped out after 
the first test day for various reasons. A total of forty-three subjects completed 
both test days. As shown in Table 3, there were no significant differences in 
age, education and gender distribution between groups. MADRS scores in 
both groups were low and did not differ significantly. The only significant 
difference was found on BDI-II scores at screening, with recovered depressed 
subjects having higher scores. However, BDI-II scores were low and well 
within the normal range in both groups. As shown in Table 4, the recovered 
depressed patient group had a mean age of depression onset at 19.9 years. The 
mean number of episodes was two. Approximately one-third had taken 












t  / Z df p
Age 30.0 ± 9.7 27.0 ± 10.1 .99 41 .32
Female % 91.3 85 (χ²) .41 1 .52
Education level¹ 4.9 ± .8 5.1 ± .6 -1.07 41 .29
BMI (kg/m2) 22.8 ± 2.5 21.7 ± 2.1 1.60 41 .12
MADRS 1.3 ± 1.6 0.8 ± 1.6 1.03 41 .31
BDI-II 4.4 ± 4.5 1.5 ± 2.2 2.83 41 .008
EPQ-R  
- Psychoticism 3.2 ± 1.7 2.6 ± 1.3 1.29 41 .20
- Extraversion 7.6 ± 3.4 9.7 ± 2.3 -2.31 41 .03
- Neuroticism 5.6 ± 2.3 2.6 ± 2.0 4.43 41 < .001
- Social desirableness 5.7 ± 2.1 5.8 ± 2.1 -.10 41 .92
LEIDS  
- Hopelessness 4.6 ± 3.0 1.4 ± 1.0 4.76 41 < .001
- Aggression 5.8 ± 3.9 3.1 ± 3.1 2.45 41 .02
- Perfectionism 8.0 ± 4.7 4.1 ± 3.3 3.18 41 .003
- Harm avoidance 9.5 ± 4.8 3.5 ± 2.6 5.23 41 < .001
- Rumination 10.7 ± 4.9 5.6 ± 2.5 4.39 41 < .001
- Acceptance/coping 2.2 ± 3.9 1.0 ± 1.7 1.38 41 .18
- Total score 40.8 ± 18.9 18.5 ± 9.8 4.94 41 < .001
DSC  
- Affective 26.5 ± 9.8 21.1 ± 5.0 1.79 .07
- Self-devaluative 22.0 ± 6.6 17.0 ± 2.6 2.42 .02
MADRS = Montgomery-Asberg Depression Rating Scale; BDI-II = Beck Depression 
Inventory-II; EPQ-R = Eysenck Personality Questionnaire-Revised; LEIDS = Leiden 
Index of Depression Sensitivity; DSC = Depressed States Checklist. 
¹ On a scale of 1-6.     
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Significant baseline differences between the groups were found on the 
POMS depression (Z = -2.21, p = .03), POMS Fatigue (Z = -2.06, p = .04), 
POMS total (Z = -2.31, p = .02) and DSC self-devaluative (Z = -2.42, p = .02) 
subscales. Trends were found for POMS tension (Z = -1.77, p = .08) and DSC 
affective (Z = -1.79, p = .07). The recovered depressed subjects had higher 
scores on all these subscales. On the Eysenck Personality Questionnaire, 
groups differed on extraversion (F(1,41) = 5. 32, p = .03) and neuroticism 
(F(1,41) = 19.6, p < .001). The neuroticism scores of the recovered depressed 
group were above average to high, according to published norms for Dutch 
populations (Sanderman et al., 1995). The two groups also differed on most 
subscales of the Leiden Index of Depression Sensitivity. After controlling for 
depressive symptoms (BDI-II), only the following subscales remained 
significant: neuroticism (F(1,40) = 12.9, p = .001), and the Leiden Index of 
Depression Sensitivity subscales of hopelessness (F(1,40)  = 13.6, p = .001), 
control/perfectionism (F(1,40)  = 5.6, p = .02), harm avoidance (F(1,40) = 
16.5, p < .001), rumination (F(1,40) = 10.5, p = .002) and total (F(1,40) = 13.9, 
p = .001). 
Table 4. Clinical characteristics of the recovered depressed subjects
Mean                  SD
Age of onset (years) 19.9                     7.7
Number of episodes    2.0                     0.9
Antidepressant medication (past) 34.8 %
Antidepressant treatment (ever) 78.3 %
Family history (1st degree) of major 
depressive disorder 
47.8 %
Current psychotherapy 13 %
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Effect of dietary manipulations on amino acids
As shown in Table 5, plasma tryptophan concentrations and 
tryptophan/LNAA did not differ at baseline between groups. Repeated 
measures analyses with Intervention and Time as within-subjects factors and 
Group as between-subjects factors on tryptophan/LNAA revealed a 
significant effect of Intervention (F(1,29) = 84.3, p < .001). Tryptophan/ 
LNAA increased significantly by 20.9% compared to baseline after the alpha-
lactalbumin-diet and decreased by 30.0% after the casein diet. The relative rise 
of tryptophan/LNAA was 73.8% higher after alpha-lactalbumin than after 
casein. We also found significant effects of Time (F(1,29) = 7.1, p = .013) and 
of the Intervention x Time interaction (F(1,29) = 193.3, p < .001). There was 
no main effect of Group, nor any interaction effects involving Group.
Table 5. Plasma tryptophan (μmol/l) and tryptophan/LNAA ratio (Mean ± 
SD)
casein alpha-lactalbumin
morning 50.5 ± 11.2 50.8 ± 10.1Tryptophan
afternoon 57.3 ±   8.9 87.9 ± 14.5
morning .11 ± .02 .11 ± .02Tryptophan/LNAA 
afternoon .08 ± .01 .13 ± .02
Effects of stress on cortisol
Two cortisol samples were collected after the stress task, t5 (directly after 
stress) and t5.2 (10 minutes later). The highest cortisol level of these two was 
used in the analyses (tmax). Repeated measures analyses with Intervention and 
Time (before and after stress) as within-subjects factors, and Group as 
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between-subjects factor, on cortisol levels did not reveal the expected 
interaction of Intervention x Group x Time (F(1,41) = 0.1, p = .71). We did, 
however, find a significant main effect of Time (F(1,41) = 9.7, p = .003), 
reflecting an increase in cortisol levels after stress. No other main or 
interaction effects were found. Cortisol levels are shown in Table 6.  
To check for any order of intervention effects, Order, instead of group, 
was included in the analysis as a between-subjects factor. No interaction effect 
of Order x Intervention was found (F(1,41) = .01, p = .93). A trend for an 
interaction effect of Intervention x Time x Order was found (F(1,41) = 3.4, p
= .07), caused by the fact that cortisol did not rise after stress for subjects who 
had the alpha-lactalbumin diet on the second day. Alpha-lactalbumin did not 
have this protective effect for subjects who had that diet on the first day.
Although Markus et al. (1998; 2000) found cortisol responses in both 
men and women – using the same stressor – previous research with other 
stressors has shown that response may be dependent on gender, and for 
females on menstrual cycle and use of oral contraceptives (Kirschbaum et al., 
1999). We therefore divided the total group of forty-three subjects into three 
groups: men (n = 5), women taking (n = 23) and women not taking (n = 15) 
hormonal contraceptives. This analysis showed significant interaction effects of 
Intervention x Group (F(2,41)  = 4.3, p = .02), and of Time x Group (F(2,41) 
= 3.8, p = .03). Women taking contraceptives had no cortisol response to 
stress. Women not taking hormones had a small rise of cortisol on the casein 
day and not on the alpha-lactalbumin day, whereas men showed the reverse 
pattern. Because of the small groups and the opposite effects in men and 
women no further analyses were carried out.
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Effects of alpha-lactalbumin on mood
To investigate any direct effects of alpha-lactalbumin on mood, we analyzed 
the differences in mood between the morning (t-1) and the first afternoon 
rating (t3,5). On the alpha-lactalbumin day, the POMS tension (Z = -2.6; p = 
.008) and DSC self-devaluative (Z = -2.0, p = .04) ratings decreased. A trend 
was found for POMS anger (Z = -1.9; p = .06). However, on the casein day, 
POMS anger (Z = 2.9; p = .003), depression (Z = -2.8; p = .005) and fatigue (Z 
= -2.1; p = .035), as well as both DSC scores, decreased. During the alpha-
lactalbumin session, recovered patients had (almost) significantly larger 
decreases in DSC self-devaluative (Z = -2.2, p = .03) and POMS depression (Z 
= -1.9; p = .06) scores than controls. The difference in self-devaluative change 
scores between groups was also significant in the casein condition (Z = -2.2, p
= .03). No other group differences were observed. Thus, mood improved 
slightly after both interventions. Only POMS depression scores tended to 
improve more in the recovered depressed group than in the control group on 
the alpha-lactalbumin day. However, this effect was due to a floor effect in the 




Table 6. Cortisol (nmol/l) before (t4.5) and after (tmax) stress (Mean ± SD)
Casein Alpha-lactalbumin
before stress after stress before stress after stress
Healthy controls 
(n = 20)
5.1 ± 6.4 5.9 ± 6.3 5.7 ± 5.1 5.4 ± 2.8
Recovered depressed 
subjects (n = 23)
5.2 ± 3.8 7.4 ± 7.0 4.5 ± 1.8 6.4 ± 6.4
High neuroticism 
subjects (n = 27)
5.1 ± 3.7 6.8 ± 6.6 4.2 ± 2.0 5.0 ± 4.1
Low neuroticism 
subjects (n = 16)
5.4 ± 7.1 6.5 ± 7.0 6.5 ± 5.3 7.6 ± 6.1
Effects of stress on mood 
To investigate any protective effects of alpha-lactalbumin on the response to 
stress, scores on the POMS and DSC scales before and after stress were 
analysed. Mood scores are shown in Table 7. In both conditions, significant 
increases in DSC affective and self-devaluative scores were observed. In the 
alpha-lactalbumin condition, POMS anger, tension, depression and total scores 
increased, fatigue tended to increase and vigor decreased in response to stress. 
In the casein condition, similar changes were found for POMS anger, tension 
and total scores. A trend was found for depression in the casein condition. In 
the alpha-lactalbumin condition, recovered depressed subjects showed a 
significantly larger increase in self-devaluative scores compared with controls 
(Z = -2.0, p = .04). There were no differences between groups in POMS 
change scores in response to stress. To analyse the effect of Order on mood 
response to stress, Kruskal–Wallis tests were performed on mood change 
scores with order as the grouping variable. A significant effect of Order on 
vigour change score was found in both the recovered depressed group (χ² =
Chapter 3
68
5.8, p = .016) and the control group (χ² = 4.3, p = .037), but only for casein. 
The decrease of vigour was smaller if casein was given on day 2, suggesting 
that the stressful nature of the task might have been slightly reduced on the 
second day. The same effect was found for the DSC, but then only in the 
controls. No other effects of order were found. 
Results therefore showed that the stressor affected mood in both the 
alpha-lactalbumin and the casein condition. The effects were, however, much 
smaller than expected, and there were no differences between the two diets. 
To explore the reasons for these unexpected findings, we also looked 
at possible effects of past antidepressant medication use, family history of 
depression and cognitive reactivity on cortisol response and on mood. Again, 
only significant effects of time were found. Previous research (Markus et al., 
2000) using the same paradigm in a healthy population divided on the basis of  
neuroticism scores found effects of  alpha-lactalbumin on mood and cortisol 
response. Therefore, we reallocated subjects to high- and low-neuroticism 
groups (median split; see Table 6). As in the previous analyses contrasting 
previously depressed and never- depressed subjects, no between-group 
differences in cortisol response were found. A significant interaction effect of 
Intervention x Group (F(1,41) = 7.9, p = .007) and a main effect of Time 
(F(1,41) = 10.3, p = .003) were again found. Further analyses indicated that the 
low-neuroticism group had higher cortisol levels on the alpha-lactalbumin day 
than on the casein day and that both groups showed an increase in cortisol 
level after stress. 
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Table 7. Mood before and after experimental stress (Mean ± SD)   
Casein diet Alpha-lactalbumin diet
                            before stress after stress before stress after stress
Healthy controls (n = 20)
POMS
     Anger 7.2 ± 0.4 8.4 ± 1.8 7.4 ± 1.1 8.6 ± 1.8
     Tension 5.4 ± 0.7 5.9 ± 1.2 5.2 ± 0.4 6.3 ± 2.0
     Depression 8.0 ± 0.0 8.2 ± 0.5 8.0 ± 0.0 8.2 ± 0.4
     Vigor 15.5 ± 4.1 15.1 ± 4.3 15.3 ± 4.2 14.0 ± 4.1
     Fatigue 7.6 ± 2.1 7.9 ± 1.8 7.5 ± 1.5 7.9 ± 1.8
DSC Affective 15.1± 0.7 15.7 ± 1.8 15.1± 1.1 16.2 ± 2.3
DSC Self-devaluative 14.0 ± 0.0 14.6 ± 1.1 14.0 ± 0.0 14.7 ± 1.4
Recovered depressed subjects (n = 23)
POMS
    Anger 7.5 ± 1.4 8.7 ± 3.0 7.2 ± 0.5 8.3 ± 1.9
    Tension 5.4 ± 0.6 6.8 ± 2.5 5.4 ± 0.8 6.8 ± 2.8
    Depression 8.2 ± 0.5 8.5 ± 0.9 8.1 ± 0.4 8.5 ± 1.5
    Vigor 11.7 ± 5.2 10.9 ± 4.1 12.5 ± 4.6 11.0 ± 3.9
   Fatigue 8.2 ± 2.5 8.8 ± 2.4 8.5 ± 3.2 9.1 ± 3.4
DSC Affective 15.0 ± 1.0 16.4 ± 2.3 15.6 ± 2.0 17.0 ± 4.0
DSC Self-devaluative 14.0 ± 0.2 15.9 ± 3.4 14.1 ± 0.5 15.9 ± 2.4




This study used an alpha-lactalbumin-enriched diet to increase plasma 
tryptophan and tryptophan/LNAA ratio in recovered depressed subjects and 
controls. We hypothesised that alpha-lactalbumin would have a protective 
effect against stress, particularly in recovered depressed subjects. Although 
dietary alpha-lactalbumin led to the expected rises in tryptophan and 
tryptophan/LNAA, only minimal effects were found on mood and cortisol 
response to stress. The afternoon values of tryptophan/LNAA were 73.8% 
higher after the alpha-lactalbumin diet than after the casein diet, which is 
comparable to earlier findings (J.A.J. Schmitt et al., unpublished results). In 
previous studies, increasing tryptophan/LNAA by 43–48% (compared with 
casein) caused a decrease in the cortisol response to stress and reduced 
depressive feelings under stress in stress-vulnerable subjects (Markus et al., 
2000). We found rather small effects of the stressor on cortisol and mood, and 
these changes were independent of group and diet. These finding are at odds 
with the experimenters’ observations and subjects’ comments, which indicated 
that the procedure was experienced as rather stressful and unpleasant. 
However, a trend of an order effect was found: alpha-lactalbumin had the 
expected protective effect on cortisol response if taken on the second day. 
Also, the change in vigor in response to the stress task was greater on the first 
day than on the second day, when the casein diet was given. However, no 
order effects were apparent for all other measures of mood. Nonetheless, the 
stressor may have been slightly more severe during its first presentation (when 
subjects were less prepared). It would follow that the protective effects of 
alpha-lactalbumin were insufficient on the first day. Markus et al. (2000), using 
the same stressor, found a protective effect of alpha-lactalbumin on stress-
induced changes in mood and cortisol in students with high neuroticism 
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scores. There are a few possible explanations for our contradictory results. 
First, our recovered depressed subjects may have been ‘too healthy’. This 
group’s MADRS scores were below 8, they were not taking antidepressant 
medication, and they were relatively young, so few previous depressive 
episodes had occurred. Furthermore, the end of the last episode had been on 
average a little more than 2 years previously, also suggesting that our patient 
group was relatively healthy and stable. However, the expected group 
differences on personality (neuroticism) and markers of depressive 
vulnerability (cognitive reactivity) were observed, implying that the recovered 
group was, as a group, more vulnerable than the controls. The mean scores on 
these scales were above the norms for healthy subjects (Eysenck et al., 1985; 
Sanderman et al., 1995; Van der Does, 2005) but still not extremely high. 
Furthermore, this explanation is unlikely because Markus et al. found an effect 
of alpha-lactalbumin in a probably even healthier group. A second possible 
explanation is that the intervention was not strong enough. As will be reported 
separately elsewhere, alpha-lactalbumin did have an effect on cognitive 
function in both groups (Booij et al., 2006a). These findings suggest that the 
intervention did not fail, but a 1 day alpha-lactalbumin diet may be too weak 
also to affect mood and cortisol responses to stress in recovered patients. 
Future studies may investigate a higher dose or a longer duration of the diet.   
The protective effects of alpha-lactalbumin on cortisol response were also not 
observed, but this part of the study was hampered by the unexpectedly small 
effects of the experimental stressor. Previous studies using a different stressor 
– the Trier Social Stress-Task – have reported gender differences in cortisol 
response (Kirschbaum et al., 1999): men show the largest cortisol response, 
followed by women in their late luteal phase, women in the follicular phase and 
women taking oral contraceptives. The women in our sample were tested in 
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the late-follicular phase of the menstrual cycle (days 4–10) to minimise possible 
mood effects. For the purpose of measuring cortisol level, we might better 
have tested them at a later stage of the cycle. Detailed analyses of gender 
differences in cortisol response were hampered by the relatively small number 
of subjects in our sample and by the fact that only five men were included. On 
the other hand, no gender differences in cortisol response were found in 
previous studies that used the same stressor as the current study (Markus et al., 
2000; Markus et al., 2002). Another issue often raised in stress research is the 
influence of context, including the person leading the experiment. In the Trier 
Social Stress-Task, the people conducting the experiment are instructed to be 
rejecting and ‘unkind’ to the participant, adding to the level of stress that is 
meant to be induced by the task. In our study, however, we used a 
computerised stress task. The instructions were also all presented by computer. 
The possibility cannot be excluded that the experimenters in the Markus et al. 
studies were more ‘unkind’ to the subjects than in the present study, implying 
that we may have missed the social component of the stressor. If both our 
results and those of Markus et al. are replicable, this implies that neuroticism 
and a history of depression are not similar concepts in terms of 5-HT 
vulnerability. Recent studies using the acute tryptophan depletion method 
found no relationship between neuroticism and the acute tryptophan depletion 
response (Stewart et al., 2002; Booij & Van der Does, unpublished results). 
Another finding from acute tryptophan depletion research is that a depressive 
response to this manipulation of 5-HT function is mostly found in selective 
serotonin reuptake inhibitor-treated patients (Delgado et al., 1999). The same 
may be true for the effects of a tryptophan-enriched diet. Alpha-lactalbumin
possibly has a clearer effect in recovered depressed subjects taking selective 
serotonin reuptake inhibitors. In conclusion, alpha-lactalbumin increased 
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plasma tryptophan and tryptophan/LNAA in recovered depressed individuals 
and in healthy controls, but no direct or protective effects were found on 
mood or on stress-induced cortisol and mood responses. Since cognitive 
effects did occur (Booij et al., 2006a), future studies may investigate the effects 





Diet rich in alpha-lactalbumin improves 
memory in unmedicated recovered 
depressed patients and matched controls
L. Booij, W. Merens, C.R. Markus & A.J.W. Van der Does. (2006).




Depression is associated with reduced brain serotonin (5-hydroxytryptamine; 
5-HT) function and with cognitive dysfunctions. A diet rich in alpha-
lactalbumin protein has been found to increase the ratio tryptophan /large 
neutral amino acids (tryptophan/ LNAA), and to improve cognitive 
functioning in individuals with high neuroticism scores. Since cognitive 
dysfunctions sometimes persist after remission of depression, the present study 
investigated the effects of alpha-lactalbumin-enriched diet on cognition in 
recovered depressed patients. Twenty-three recovered depressed patients and 
20 healthy matched controls without a history of depression consumed meals 
rich in alpha- lactalbumin or casein protein in a double-blind crossover design. 
Mood, cognitive function and plasma amino-acids were assessed at both 
sessions before and after dietary intake. Alpha-lactalbumin protein had no 
effect on mood, but improved abstract visual memory and impaired simple 
motor performance. These effects were independent of history of depression. 
Supplements of alpha-lactalbumin may be useful for nutrition research in 
relation to age- or disease-related memory decline. The present findings should 
be further examined in different (e.g. medicated) samples. The long-term 




Depression is associated with impaired cognitive functioning (Austin et al., 
2001). Impaired spatial and verbal memory has most frequently been reported 
(Burt et al., 1995: review). However, deficits in other domains are also 
common, including psychomotor skills, attention and executive functioning 
(Austin et al., 2001). Mild deficits often persist after remission (Paradiso et al., 
1997), irrespective of residual symptoms (Weiland-Fiedler et al., 2004) or 
medication status (Paradiso et al., 1997). 
The serotonin (5-hydroxytryptamine; 5-HT) system is important in the 
regulation of mood as well as cognitive functions. Selective serotonin reuptake 
inhibitors (SSRIs) are found to relieve depressive symptoms and to enhance 
memory function in humans and rats (McEntee & Crook, 1991). Conversely, 
experimental depletion of L-tryptophan (the precursor of serotonin) induces 
depressive symptoms in depression-vulnerable individuals (see for reviews: 
Booij et al., 2003; Van der Does, 2001a) and impairs long-term memory in 
healthy volunteers (Riedel et al., 1999; Schmitt et al., 2000). The effects of 
enhanced 5-HT activity on cognitive processes have frequently been 
investigated by using low protein diets that consist almost entirely of 
carbohydrates. These diets increase the amount of plasma tryptophan as 
compared to the other large neutral amino acids (ratio tryptophan/LNAA) that 
competes with tryptophan for uptake into the brain (Fernstrom & Wurtman, 
1972). High-carbohydrate meals have been found to improve cognitive 
performance in both clinical and healthy populations, but the results are not 
consistent (see for reviews: Benton & Nabb, 2003; Dye et al., 2000; Gibson & 
Green, 2002). These inconsistent results may be related to the timing of 
intervention or the amount of carbohydrates consumed. Furthermore, 
individual differences in stress-vulnerability may be involved, as carbohydrates 
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improved mood and information processing in high stress-prone but not in 
low stress-prone healthy individuals (Markus et al., 1998). The use of 
carbohydrate-rich meals poses methodological difficulties, including lack of a 
placebo condition and expectancy effects (Dye et al., 2000; Gibson & Green, 
2002; Spring et al., 1987). Besides, a very large amount of carbohydrates, and 
consequently high-caloric meals may be needed to produce biochemical and 
behavioural changes, making implementation in a regular diet undesirable. 
A different method to enhance tryptophan availability involves using 
alpha-lactalbumin protein (Markus et al., 2000; 2002). Alpha-lactalbumin 
protein has the highest L-tryptophan concentration of all protein fractions 
(Heine et al., 1996). A diet enriched with alpha-lactalbumin increased the ratio 
plasma tryptophan/LNAA by 46–48% in healthy volunteers, as compared to 
casein (placebo). This effect is two times higher than the effect generally found 
after a carbohydrate- rich diet (Markus et al., 2000), or after 7 days of daily 
treatment with L-tryptophan (Chouinard et al., 1985). Alpha-lactalbumin 
improved mood and information processing, and attenuated stress-induced 
cortisol-responses in stress-vulnerable subjects (non-patients with high 
neuroticism scores) but not in controls (low neuroticism scores) (Markus et al., 
2000; 2002). These data suggest that enhancing 5-HT function through diet 
may be particularly beneficial for vulnerable individuals under high levels of 
stress and may improve stress coping. 
In the present study we were particularly interested in investigating the 
cognitive effects of alpha-lactalbumin in recovered depressed patients and 
matched controls. Since cognitive dysfunctions may persist after remission, we 
expected to find residual cognitive impairments at baseline in recovered 
depressed patients relative to controls. Furthermore, we expected that alpha-
lactalbumin would improve cognitive function compared to a casein diet, and 
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that the effects of alpha-lactalbumin would be more pronounced in recovered 
depressed patients than in controls. We have previously reported that alpha-
lactalbumin did not change mood or cortisol response following laboratory 
stress in recovered depressed patients or controls (Merens et al., 2005). 
However, cognitive effects in the absence of mood effects have regularly been 
reported after manipulations of neurotransmitters, e.g. tryptophan depletion 
(Booij et al., 2005a; 2005c) or a single dose of an antidepressant (Harmer et al., 
2002; 2003a). 
Methods and materials 
Participants 
Twenty-three recovered depressed patients (21 females and two males) and 20 
controls (17 females and three males) participated in the study. Some of the 
patients were former participants of a randomized psychotherapy trial, whereas 
additional patients and all controls were recruited via advertisements at Leiden 
University or in local newspapers. Inclusion criteria were: age between 18 and 
65; meeting DSM-IV criteria for history of depression (patient group only); 
free of antidepressant medication for at least 3 months; no history of 
psychiatric disorders and having no first-degree relative of major depressive 
disorder (control group only); no current psychiatric disorder; Montgomery-
Asberg Depression Rating Scale lower than eight (Montgomery & Asberg, 
1979) and a Body Mass Index (BMI in kg/m2) above 18. Exclusion criteria 
were: substance abuse within last 3 months, psychosis (lifetime), major physical 
illness, lactation, pregnancy and excessive dieting or binge eating. Diagnoses, 
demographic and clinical background variables were verified by means of the 
Structured Clinical Interview for DSM-IV (SCID-I) (First et al., 1995).
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Composition of the diet 
At each session, participants received a carbohydrate-rich breakfast and lunch. 
The energy intake per session totalled 294 kcal (1229 kJ), of which 21% was 
from fat, 75% as carbohydrates and 5% as protein. Each breakfast and lunch 
consisted of one slice of bread, 10 g butter, 15 g fruit jelly, grape juice (200 ml) 
and a chocolate drink. The two diets were identical with the exception of the 
composition of a chocolate drink in which the protein sources differed. The 
chocolate drink in the alpha-lactalbumin diet contained a whey-protein fraction 
rich in alpha-lactalbumin (containing 12.3 g/kg tryptophan; tryptophan/LNAA 
ratio of 8.7) and the chocolate drink in the control diet contained sodium 
caseinate (containing 9.5 g/kg tryptophan, tryptophan/LNAA ratio of 4.7). 
The composition and preparation of the chocolate drinks were similar in 
appearance and macronutrient composition as in Markus et al. (2000; 2002). 
Other nutrients or drinks were not allowed until the end of session, except for 
water during the whole day and one cup of coffee or tea without milk +1.25 
hours after breakfast. 
Instruments 
Mood: Changes in mood were measured using the Dutch shortened 
paper and pencil version of the Profile of Mood States questionnaire (POMS) 
(McNair et al., 1971; Wald & Mellenbergh, 1990). The POMS comprises five 
different subscales for mood. The subscale Anger (range: 0–28), Depression 
(range: 0–32), Fatigue (range: 0–24) and Tension (range: 0–24) refer to a 




Personality: Neuroticism (N) was measured with the shortened Eysenck 
Personality Questionnaire (EPQ-RSS)(Eysenck & Eysenck, 1991). The Dutch 
translation (Sanderman et al., 1995) was used, which has different norms from 
the original (about 1.5 points lower). According to the manual, the mean N 
score of the general population is around four. Norms for psychiatric patients 
are not available; however we found a mean N score of 6.4 (S.E. 0.55) in a 
recent study of 39 (partially) remitted depressed outpatients (who were in 
treatment and who had a mean of 4.4 past episodes of depression) (Van der 
Does & Booij, 2005). 
Cognition: 
Sternberg Memory Scanning Task 
The computerized Memory Scanning Task is based on the information 
processing model of Sternberg, who distinguishes scanning and non-scanning 
stages of information processing (Sternberg, 1969). The Memory Scanning 
Task consisted of three trials, corresponding to a set of two, three or six 
consonants respectively. In each trial, the set of letters is presented in the 
middle of the screen, and the participant was instructed to memorize them 
(‘memory’ set). After memorization, 90 letters in each trial are presented on the 
screen in a random order one by one for 1500 ms each at an interval range of 
500 ms. Fifty percent of the letters presented belonged to the memory set and 
50% did not. Participants were instructed to push on the ‘yes’ button if the 
letter presented belonged to the memory set of that condition and on the ‘no’ 
button when it did not. Reaction times and number of errors for each 
condition were the outcome measures of this test. 
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Abstract Patterns Recognition Task (APRT) 
The APRT modelled after Rubinsztein et al. (2001) measures (speed of) 
retrieval of non-verbal abstract information from short-term memory (STM) 
and long-term memory (LTM). Sixteen abstract patterns were presented 
consecutively for 3000 ms, with 500 ms intervals. Participants were instructed 
to memorize the patterns. After three presentations of the complete series, two 
patterns were presented simultaneously; one that had been learned and a new 
pattern. Participants had to indicate as fast as possible which one had been 
previously presented. The recognition procedure was repeated after 35 
minutes, during which verbal tasks were administered. Sensitivity measures (A’) 
were calculated for the proportion of correctly recognized patterns, corrected 
for response tendency by the formula: A’ = 1-1/4(fr/cr + (1-cr)/(1-fr)), in 
which fr = the proportion of falsely recognized patterns and cr = proportion 
of correctly recognized patterns (signal detection theory; Pollack & Norman, 
1964). 
Stroop Colour Word Task (SCWT) 
The Stroop test measures focused attention and response inhibition. Names of 
colours (red, yellow, blue, green) printed in black were presented one by one 
for a maximum of 1500 ms on a computer screen. Participants were instructed 
to read these words as fast as possible (Condition I). Next, coloured patches 
were presented (Condition II) of which the name of the colour had to be 
named. Finally, names of colours printed in an incongruent colour were 
presented and participants were instructed to name the colour of the ink 
(Condition III). Median reaction times (RTs) and errors were recorded. 
Interference was defined as the percentage of extra time needed for condition 
III relative to the average of conditions I and II. 
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Left/right choice reaction time 
This task was used to assess motor speed and response inhibition as a function 
of task difficulty. The word ‘left’ or ‘right’ was presented in randomized order 
either at the left or the right side of the screen. Participants were instructed to 
respond to the meaning of the word while ignoring its location, as fast as 
possible. The task consisted of two consecutive subtasks in which the stimulus 
interval differed (1000 ms fixed vs. 500–1500 ms variable). Correct responses 
and RTs were registered. 
Tower of London (TOL) 
The TOL modelled after Owen et al. (1995b) is a planning task consisting of 
three coloured balls (red, yellow and blue) placed on three sticks in various 
arrangements. Two arrangements were presented on the upper and lower half 
of the screen. The patient was instructed to indicate the minimal number of 
moves necessary to change the first arrangement into the second (two to five 
moves). Correct responses and RTs were registered. 
Blood plasma
A blood sample was obtained (10 ml) using EDTA tubes to determine total 
plasma tryptophan and the other large neutral amino acids (tyrosine, 
phenylalanine, isoleucine, leucine and valine). Immediately after sampling, the 
blood was centrifuged for 20 minutes at 2650 gmax and the plasma was stored 
at -20 °C. Quantitative amino acid analysis was performed by an ion-exchange 
chromatography on a Biochrom 20 automated amino acid analyser (Pharmacia) 
as described elsewhere (Merens et al., 2005). 
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Design and procedure 
The study was conducted according to a randomized double-blind crossover 
design with two experimental sessions. One week before the first experimental 
session, after receiving oral and written information about the study and 
providing written informed consent, potential participants were invited to a 
screening interview that included the Structured Clinical Interview for DSM-IV 
(SCID-I) (First et al., 1995), Montgomery-Asberg Depression Rating Scale 
(MADRS) (Montgomery & Asberg, 1979), the Beck Depression Inventory-II 
(BDI-II) (Beck et al., 1996) and a medical examination. The SCID and the 
MADRS interviews were conducted by trained clinical psychologists. In 
addition, the cognitive test battery was administered. 
During the experimental sessions, participants came to the laboratory 
at 8 or 9 am (-1h) after an overnight fast. Baseline mood was measured with 
the POMS and a first blood sample was obtained, followed by administration 
of cognitive tasks. The cognitive test battery took 45 minutes. Next, 
participants ate breakfast, including a drink containing either tryptophan-rich 
alpha-lactalbumin or casein (0 h). Lunch, at +2 h, also contained either an 
alpha-lactalbumin or casein drink. A second blood sample was taken at +3.5 h, 
followed by the POMS and cognitive tests at +3.75 h. Participants were tested 
individually, and remained in a private research room between assessments. 
The order of presentation of the alpha-lactalbumin and casein diets was 
counterbalanced. Both experimental sessions were separated by exactly four 
weeks. Pre-menopausal women not taking a contraceptive pill were tested 
during their mid-to-late follicular phase (days 4–10), whereas pre-menopausal 
women taking the contraceptive pill participated during the period in which 
they actually took the contraceptive pill. All participants were paid €80 for 
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participation. The study was approved by the Medical Ethics Committee of 
Leiden University Medical Centre.
Statistical analysis 
Prior to analysis, all variables were examined for accuracy of data-entry, 
missing values and fit between their distributions and the assumptions of the 
statistical analyses. Group differences in demographic characteristics, baseline 
mood ratings and cognitive performance were examined by means of chi-
square statistics and multivariate analyses of variance (MANOVA) by using the 
General Linear Model (GLM: SPSS 11.5 for Windows, SPSS Inc, Chicago). 
RTs of the TOL and Left/Right task were log10 transformed prior to analysis. 
POMS scores were analysed with nonparametric statistics because 
transformations were unsuccessful, as shown by visual inspection and Shapiro 
Wilk statistics (Stevens, 1996). The effects of the interventions on cognitive 
tests and biochemical outcome measures were analysed by separate repeated 
measure multivariate analyses of variance, using Intervention (alpha-
lactalbumin vs. casein) and Time (before vs. after intervention) as within-
subjects factors and Group (recovered depressed patients vs. controls) as 
between-subjects factor. Thus Intervention x Time and Intervention x Time x
Group interactions reflected the main effects of interest. Level of difficulty was 
added as a within-subjects factor for the Memory Scanning Task (three levels) 
and Tower of London (four levels); whereas the Left/Right tasks consisted of 
an additional level ‘condition’ (congruent vs. incongruent). Significant results 
revealed by these procedures were further examined by post hoc tests. 
Although we counterbalanced for order of intervention, we first conducted 
analyses with Order of intervention as a covariate. However, Order of 
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intervention did not contribute to any of the effects. All statistics were 
evaluated at a significance level of 5%. 
Results 
Data screening/drop-outs 
Of a total of 49 participants who were included, 43 (23 recovered depressed 
patients; 20 controls) completed the study. Three recovered depressed patients 
were included but decided not to participate. Three patients dropped out after 
the first session; the first case due to nausea (after alpha-lactalbumin), the 
second case dropped out because of feeling uncomfortable with venapunction 
during the first session (casein); the third one could not be contacted to 
schedule the second session on time (casein). These patients were left out of all 
analyses. Due to a computer failure, data of the cognitive tasks during the 
screening session for one control patient were lost. For one patient, data of the 
Memory Scanning task during the screening session were missing. TOL data 
during the screening session were missing for another patient. Morning 
assessments of the Left/Right task in the casein condition were unavailable for 
one patient. Twenty-two of the 172 blood samples (13%) were missing because 
of difficulties with the venapunction. Cases with missing data were omitted 
separately by analysis. 
Participants, baseline cognitive performance 
Clinical and demographic characteristics are shown in Table 1. Recovered 
depressed patients (‘recovered MDD’) did not differ from the participants with 
no history of depression (‘controls’) in terms of gender distribution, age and 
education level, indicating that matching was successful. BDI-II scores were 
higher in the patient group than in controls (F(1,41) = 7.31; p = .01); however, 
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BDI-II scores are low and well within the normal range in both groups. There 
were no group differences on any of the cognitive tasks conducted during the 
screening session or in the morning sessions of both conditions. Controlling 
data for group differences in BDI-II scores did not change these results. 
Dietary effects on amino acids 
Repeated measures analyses for tryptophan/LNAA with Intervention and 
Time as within-subjects factors and Group as between-subjects factors 
revealed a main effect of Intervention (F(1,29) = 84.39; p < .001), Time 
(F(1,29) = 7.08; p = .01) and a significant interaction between Intervention and 
Time (F(1,29) = 193.28; p < .001). Tryptophan/ LNAA increased significantly 
by 20.9% compared to baseline after the alpha-lactalbumin-diet and decreased 
by 30.0% after the casein diet. After alpha-lactalbumin, the tryptophan/LNAA 
ratio was 71.5% higher than after casein. After alpha-lactalbumin, tryptophan 
levels increased 77.5% relative to baseline and were 54.0% higher than after 
casein (p < 0.001). There were no group or baseline differences in plasma 
tryptophan or ratio tryptophan/LNAA. Repeated measures analyses for 
tyrosine/LNAA revealed a main effect of Intervention (F(1,29) = 22.51; p < 
.001), Time (F(1,29) = 8.14; p = .01) and a significant interaction between 
Intervention and Time (F(1,29) = 123.59; p < .001). Compared to baseline 
levels, tyrosine/ LNAA decreased 11.5% in the alpha-lactalbumin condition 
and increased 28.1 % in the casein condition. After casein, the tyrosine/LNAA 
ratio was 35.8% higher than after alpha-lactalbumin. 
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Table 1. Characteristics of the investigated sample 
Recovered MDD
(n  = 23)
Controls
(n  = 20)
Mean age in years ± SD 29.96 ± 9.7 26.95 ± 10.1
Female n = 21 n = 17
Body Mass Index (BMI) 
(kg/m2 ± SD)
22.84 ± 2.5 21.69 ± 2.1
Eduction level
High1 / Medium2 / Low 3
1 / 14 / 7 1 / 12 / 7
MADRS 1.30 ± 1.6 0.80 ± 1.6
BDI-II 4.43 ± 4.5 1.45 ± 2.2
Number of previous episodes
- Single episode
- Multiple episodes
















1 Higher vocational education, university; 2 Secondary education, medium and higher 
level or senior secondary vocational education; 3 Primary education, secondary 
education lower level. MADRS = Montgomery Asberg Depression Rating Scale; BDI-





POMS depression scores (mean ± SE) in the alpha-lactalbumin session 
changed from 0.74 ± 0.29 to 0.17 ± 0.14 for the recovered MDD group. The 
mean ± SE for the control group in the alpha-lactalbumin session on that scale 
was 0.00 ± 0.00 both before and after intervention. POMS depression scores 
in the casein condition changed from 1.00 ± 0.47 to 0.17 ± 0.10 for the 
recovered MDD group and from 0.30 ± 0.16 to 0.00 ± 0.00 for the control 
group. Non-parametric tests did not reveal a significant Group or Intervention 
effect on any POMS subscale. 
Cognition 
Multivariate analysis of variance revealed an intervention x time interaction for 
the outcome measures of the APRT (F(4,38) = 3.06; p = .03). Further 
univariate tests revealed significant Intervention x Time interactions for the 
STM measures A’ (F(1,41) = 5.99; p = .02) and RT (F(1,41) = 4.07; p = .05) 
and also for LTM–RT (F(1,41) = 4.49; p = .04), but not for LTM–A’ (F(1,41) 
= 0.08; p = .78) (Figures 1 and 2). Alpha-lactalbumin diet improved the 
number of correctly recognized abstract pictures and improved speed of 
recognition from STM and LTM, but there were no group differences, as 
shown by nonsignificant Intervention x Time x Group interactions for STM–
A’ (F(1,41) = 2.04; p = .16), STM–RT (F(1,41) = 0.53; p = .47) and LTM–RT 
(F(1,41) = 2.26; p = .14). The interaction for LTM–A’ was statistically a trend 
(F(1,41) = 3.08; p = .09). To further explore the effects as shown in Figures 1 
and 2, separate analyses were conducted for the recovered MDD and control 
group. These should be interpreted with caution however because of an 
absence of an interaction with group in the primary analyses of interest. In the 
recovered MDD group, significant Intervention x Time interactions were 
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found for STM–A’ (F(1,22) = 9.09; p = .006), LTM–RT (F(1,22) = 4.64; p = 
.04), and a trend for LTM–A’ (F(1,22) = 2.89; p = .10). The Intervention x 
Time interaction for STM–RT was not significant (F(1,22) = 0.70; p = .41), 
whereas this interaction was the only significant interaction in the control 
group (F(1,19) = 5.07; p = .04). 
For the Left/Right task, there was a multivariate significant 
Intervention x Time x Group effect (F(2,39) = 4.12; p = .02), due to a group 
difference in the subtask with variable stimulus intervals (F(1,40) = 7.78; p = 
.01). Separate analysis for the recovered MDD group and the control group 
showed that controls became faster after alpha-lactalbumin condition relative 
to casein condition, whereas the reverse pattern occurred in the recovered 
MDD group. Using a similar double multivariate repeated measures design, the 
number of errors increased in the alpha-lactalbumin condition relative to 
casein condition, as shown by an Intervention x Time interaction effect 
(F(2,39) = 3.47; p = .02). Univariate tests showed that this was true for the 
fixed interval subtask (F(1,40) = 6.87; p = .01). There were no higher order 
interactions with group. 
On the Memory Scanning Task, there was an overall multivariate main 
effect of memory set on total reaction time (F(2,40) = 81.34; p < .001) and 
number of errors (F(2,40) = 18.33; p < .001), indicating that the time to 
respond and the number of errors increased when the memory set becomes 
larger. A similar pattern was found for the TOL, with slower responses 
(F(3,36) = 173.53; p < .001) and a higher number of errors (F(3,36) = 43.85; p 
< .001) as the task became more difficult. 
There were no Intervention x Time, Intervention x Time x Group on 
the Memory Scanning Task, Stroop Task and TOL (Table 2).
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Figures 1 and 2. Mean change (SE) in percentage of correctly recognized 
patterns (Figure 1, above) and median RT (ms) for correctly recognized 
patterns (Figure 2, below) for the Abstract Patterns Recognition Task as a 
function of group and intervention. Scores are changes relative to baseline 
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Table 2. The means (SE) of the cognitive tasks as a function of group, time 
and intervention
Recovered MDD (n = 23) Controls (n = 20)
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α -lac = alpha-lactalbumin condition; SCWT = Stroop Colour Word Task; TOL = 




The aim of this study was to investigate whether increased tryptophan 
availability after alpha-lactalbumin diet affects cognitive function, particularly in 
recovered depressed patients. The alpha-lactalbumin diet increased plasma 
tryptophan/LNAA ratio (21% increase from morning to afternoon; afternoon 
ratio 71.5% higher than in the placebo condition). Memory performance after 
alpha-lactalbumin improved in both groups, and no other reliable effects were 
found. 
Baseline cognitive performance in recovered depressed patients vs. controls
Unexpectedly, no baseline differences in cognitive performance were found 
between recovered depressed patients and controls. Using the same cognitive 
tests, our previous study in remitted depressed patients showed impaired 
abstract long-term visual memory at baseline relative to controls (Booij et al., 
2005a). This result is also in contrast with other studies that found residual 
cognitive impairments in short-term memory, attention and executive 
functioning in recovered depressed patients (e.g. Paradiso et al., 1997). One 
likely explanation for this difference might be that the recovered MDD group 
in the present study was much younger (30.0 years) than in our previous study 
(48.7 years) or in Paradiso et al. (55.9 years), with about one third of the 
individuals having experienced a single episode during late adolescence rather 
than multiple episodes. Cognitive impairments in the recovered phase may be 
more severe in patients with recurrent episodes than in those with a single 
episode (Kessing, 1998). 
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Dietary effects on cognitive performance 
The alpha-lactalbumin diet improved abstract visual memory in both recovered 
depressed patients and controls. More specifically, alpha-lactalbumin improved 
recognition and speed of retrieval from short- and long-term abstract visual 
memory. Overall, there was no interaction with group. There were no effects 
on the TOL, Memory Scanning Task and Stroop Task, indicating that alpha-
lactalbumin did not change the encoding phase, working memory, perception 
or general motor speed. Thus, alpha-lactalbumin may specifically affect 
memory consolidation in an early phase. 
This effect mirrors the consolidation deficit that was found after 
lowering 5-HT function by tryptophan depletion in healthy volunteers (Riedel 
et al., 1999; Rubinsztein et al., 2001) and is in line with improved memory after 
a single dose of citalopram in healthy volunteers (Harmer et al., 2002). Alpha-
lactalbumin also improved abstract visual memory in females with 
premenstrual symptoms (Schmitt et al., 2005). However, it is important to 
mention that the latter study did not include a control group. Hence, the 
present study showed that the beneficial effects on memory are not limited to 
individuals vulnerable to 5-HT related mental disorders. This is of interest 
because of the fact that the mean age of the participants in the present study 
was 28.5 years, while cognitive processes usually start to decline around 45–50 
years (Hedden & Gabrieli, 2004: review). Thus abstract visual memory 
improved even though performance was uncompromised by aging or 
psychiatric symptoms.
Results might also be (partly) explained by impaired memory in the 
casein condition. Without a non-intervention control group, these possibilities 
cannot be separated. Nevertheless, the change of tryptophan/LNAA ratio in 
the casein condition was comparable to what is usually observed after a 
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balanced meal (Fischer et al., 2003; Spring et al., 1987), which justifies the use 
of casein as a placebo procedure (Schmitt et al., 2005). 
Alpha-lactalbumin impaired motor performance, as shown by an 
increased number of errors in the fixed interval condition of the Left/Right 
task, irrespective of group. These results are consistent with previous studies 
finding decreased performance on simple RT tasks after 5-HT stimulation in 
patients and in healthy volunteers (Riedel et al., 2002; Sobczak et al., 2003). As 
intervention had no effect on the number of errors in the more difficult 
versions of the Left/Right task (variable time intervals) or on working memory 
tasks (Tower of London/Memory Scanning Task), this suggests that alpha-
lactalbumin impaired cognitive performance when the task was relatively easy 
and monotonous, possibly due to the sleep-inducing properties of alpha-
lactalbumin (Markus et al., 2005; Minet-Ringuet et al., 2004). 
Complex interactions were found on the variable time interval 
condition of the Left/Right task. RTs improved in the control group after 
alpha-lactalbumin and remained unchanged after casein. Conversely, in the 
recovered MDD group, RTs improved after casein but did not change after 
alpha-lactalbumin. We have no clear explanation for this finding. In the 
Left/Right task, both task uncertainty (incongruent vs. congruent trials) and 
time uncertainty (fixed vs. variable stimulus time intervals) were manipulated. 
Alpha-lactalbumin had no differential effect on the congruent and incongruent 
trials, a finding consistent with the lack of effect on interference levels on the 
Stroop Colour Word Task in the present study. Thus, 5-HT did not affect 
performance in conditions of task uncertainty. No previous studies 
investigated the effects of 5-HT and/or depression on motor speed as a 
function of time uncertainty. 
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The lack of effect on the Memory Scanning Task found in the present 
study contrasts with the results of Markus et al. (1998; 2002), who reported 
improved information processing in individuals with high neuroticism scores. 
Life events and neuroticism are risk factors for major depression, and 
individuals with high neuroticism have a greater risk of major depression in 
response to a stressful life event (Kendler et al., 2004). Individuals with high 
neuroticism may benefit more from an alpha-lactalbumin diet because a high 
amount of 5-HT activity is required to cope with stress, thereby increasing the 
risk of a shortage in brain 5-HT concentrations, which increases the risk of 
depression (Markus et al., 2002). However, about 60% of the individuals with 
high neuroticism scores actually became depressed (Ormel et al., 2001). In 
addition, neuroticism has been shown to be stable over time in adulthood 
(Kendler et al., 2004). In the present study, most recovered depressed patients 
had been treated. They may also have coping mechanisms developed through 
effective treatment, which may reduce the detrimental effects of stress. The 
neuroticism (N) scores of the recovered depressed group in the present study 
were above average to high (mean ± SD: 5.64 ± 2.3, range: 2–10), while the 
control group had low-average scores (mean ± SD: 2.60 ± 2.0, range 0–8). 
These group differences are statistically and clinically significant but seem 
smaller than in Markus et al. (2002), who used a different measure and selected 
students with N scores in the lowest and highest quartile of a large subject 
pool. The results of the present study suggest that high neuroticism and history 
of depression are different concepts in terms of 5-HT vulnerability. 
Mood remained unaffected, which is consistent with the finding that 
single administration of SSRIs ameliorated emotional processing in healthy 
volunteers, without changing mood (e.g. Harmer et al., 2003a). These findings 
support our suggestion that cognitive markers may be more sensitive makers 
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for changes in 5- HT function than mood or symptom scales (Booij et al., 
2005a). 
Effect of diet on plasma amino acids and serotonin 
The increases in tryptophan and ratio tryptophan/LNAA were within similar 
range as in Schmitt et al. (2005) and Markus et al. (2000; 2002). However, the 
composition of breakfast and lunch used in Markus et al. (2000; 2002) and 
Schmitt et al. (2005) contained about three times more calories and two times 
more carbohydrates than in the present study, whereas the composition of the 
alpha-lactalbumin or sodium caseinate containing chocolate drink were 
identical. Thus, the present study demonstrated that alpha-lactalbumin is able 
to raise tryptophan levels without necessarily ingesting an excessive amount of 
carbohydrates, suggesting that alpha-lactalbumin might be relatively easy to 
implement within a regular diet. A study, reporting an increase of 16% relative 
to baseline using an amount of 12g alpha-lactalbumin combined with a regular 
meal, supports this notion (Beulens et al., 2004). 
However, as we assessed total tryptophan concentration and not free 
tryptophan, it must be acknowledged that we do not know how much 
tryptophan following alpha-lactalbumin actually reaches the brain. Plasma 
tryptophan, however, circulates in two forms: either bound to plasma albumin 
proteins (80–90%) or free (10–20%). It has been argued that only free-
circulating tryptophan controls the uptake of plasma tryptophan into the brain, 
whereas others have suggested that total tryptophan (plasma free and bound 
levels) is the most decisive factor. Separate studies have shown that both 
increases in total plasma tryptophan (initiated, for instance, by immobilization 
stress or carbohydrate consumption) and increases in free tryptophan (initiated, 
for instance, by physical stress or fasting) may lead to an increase in brain 
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tryptophan and serotonin activity (Chaouloff, 1993). Moreover, total- and free 
tryptophan are very closely related, also following an alpha-lactalbumin diet 
(Attenburrow et al., 2003). In animals, administration of alpha-lactalbumin 
increased baseline extracellular 5-HT in the hypothalamus, indicating that 
alpha-lactalbumin not only enhance 5-HT synthesis but also its release (Orosco 
et al., 2004). In humans, increases of 20–40% in ratio tryptophan/LNAA led 
to significant increases in peripheral markers of 5-HT activity, including 
cortisol and prolactin (Anderson et al., 1990b; Kaye et al., 1988; Markus et al., 
2000). 
Changes in mood and cognitive performance might also be related to 
raised plasma tyrosine levels, as catecholamines are involved in mood and 
cognitive processes as well (Booij et al., 2003: review). The effects on 
catecholamine precursor levels in the alpha-lactalbumin condition are probably 
negligible – in fact, the tyrosine/LNAA ratio decreased slightly. The rise in the 
casein condition was higher, which is not surprising as this diet contained less 
tryptophan and twice the amount of tyrosine (Markus et al., 2000; Markus et 
al., 2002). No other alpha-lactalbumin experiments have reported 
tyrosine/LNAA ratios. In healthy samples, tyrosine administration improved 
Stroop performance and working memory (Deijen & Orlebeke, 1994), 
however we found no intervention effect on working memory tasks. Similarly, 
a memory consolidation deficit was induced by ATD and not by Acute 
Phenylalanine Tyrosine Depletion (APTD), whereas a working memory deficit 
was induced by APTD and not by ATD (Harrison et al., 2004). High-dose 
ATD (100 g) markedly decreases tryptophan levels and 5-hydroxyindoleacetic 
acid (5-HIAA), but also induces an increase (50%) of tyrosine/LNAA levels –
however, homovanillic acid (HVA) remains unaffected, measured either in 
cerebrospinal fluid (Carpenter et al., 1998) or plasma (Van der Does & Booij, 
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2005). Nevertheless, it is recommended to investigate the biochemical 
specificity further by combining alpha-lactalbumin- enriched diets with 
monoaminergic depletion paradigms and to develop alternative placebo 
procedures. 
In conclusion, diet enriched with alpha-lactalbumin enhanced memory, 
irrespective of history of depression. Mood and other cognitive functions 
remained unaffected. As 5-HT activity is reported to decline with aging 
(McEntee & Crook, 1991), the present findings could be further examined in 
older samples. The long-term effects of alpha-lactalbumin should also be 
investigated. 
5
The effects of experimentally lowered 
serotonin function on emotional 
information processing and memory in 
remitted depressed patients
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It has been well documented that acute tryptophan depletion (ATD) induces 
symptoms in remitted depressed patients treated with an SSRI. ATD also has 
effects on cognition, both in patients and in healthy samples. The exact nature 
of ATD-induced cognitive changes in depression remains unclear. It is also 
unclear whether cognitive effects can be induced through partial (‘low-dose’) 
depletion. The aim of this study is to investigate the differential effects of low-
dose and high-dose ATD on emotional information processing and mood in 
remitted depressed patients. Eighteen remitted depressed patients received 
high-dose and a low-dose ATD in a randomized, double-blind, within-subjects 
crossover design. Mood was assessed before and after administration of the 
depletion drink. Five hours after administration, patients conducted tests 
measuring neutral and emotional information processing. High-dose ATD 
increased depressive symptoms and induced a temporary depressive ‘relapse’ in 
half of the patients. High-dose ATD also decreased the recognition of fear and 
impaired learning and memory retrieval. The impaired learning occurred only 
in mood-responders. Low-dose ATD had no effects on mood but speeded the 
recognition of facial expressions of disgust. Accurate recognition of sad faces 
at baseline was associated with mood response to ATD. High-dose ATD leads 
to changes in memory and in the recognition of negative facial expressions in 
SSRI-treated remitted depressed patients. The effect of low-dose ATD on 
mood and cognition seems to be quite limited. Emotional information 




Acute tryptophan depletion (ATD) is a useful tool to investigate the effects of 
lowered serotonin function in humans (Young et al., 1985). With this 
procedure plasma tryptophan is temporarily reduced by 70-90%. Central 
serotonin function is also affected (Carpenter et al., 1998; Nishizawa et al., 
1997). ATD results in a temporary depressive ‘relapse’ in 50-60% of remitted 
depressed patients taking serotonergic antidepressants (Van der Does, 2001a). 
In healthy individuals only small mood effects are found in subjects with a 
family history of affective disorders (Benkelfat et al., 1994; Klaassen et al., 
2002). 
ATD also has cognitive effects. In healthy volunteers, ATD selectively 
impairs learning (Park et al., 1994), memory retrieval and consolidation 
(Klaassen et al., 2002; Park et al., 1994; Riedel et al., 1999) and ATD improves 
attention in healthy samples (Schmitt et al., 2000) and patients (Booij et al., 
2005a). Recently, interest has been paid to the effects of ATD on emotional 
information processing. ATD impaired the recognition of facial expressions of 
fear in female healthy volunteers, but not in males (Harmer et al., 2003c). 
Three studies investigated the effects of ‘low-dose ATD’, which 
involves administering fewer and/or smaller amounts of amino acids 
compared to ‘high-dose ATD’.  In both healthy and recovered depressed 
individuals, an increased negative attentional bias was found following low-
dose ATD, in absence of any effects on mood (Hayward et al., 2005). Also, in 
recovered depressed patients low-dose ATD reduced the recognition of 
happiness, increased startle response, impaired initial memory of neutral words 
(Hayward et al., 2005), and increased processing of social threat cues (Munafò 
et al., 2006). Booij et al. (2005a), however, found only minor effects of low-
dose ATD on cognition in remitted depressed patients. In that study, selective 
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attention for neutral stimuli improved following high-dose and low-dose ATD 
in a dose-dependent manner, and the processing of positive information was 
impaired only following high-dose ATD (Booij et al., 2005a). A limitation of 
this study is that the cognitive test battery consisted mainly of neutral stimuli, 
which may explain the differences with Hayward et al. (2005) and Munafò et al. 
(2006). It is also possible, however, that differences in the low-dose procedures 
are responsible. The traditional (high-dose) ATD procedure consists of 15 
amino acids; amounting to 102.5g. Booij et al. used the Krahn et al. (1996) 
procedure as their low-dose condition, which consists of a 25% amount of the 
same 15 amino acids (25.7 g). Although developed as a placebo, this procedure 
reduces plasma tryptophan levels by 40-50% (Van der Does, 2001a).  Hayward 
et al. and Munafò et al. however, used 8 of these 15 amino acids in 
approximately 50% amount (a total of 31.2 g). Another difference is that in 
Booij et al. (2005a) patients kept a low-tryptophan diet the day before the ATD 
sessions. Calculations using the data provided by Hayward et al. reveal that 
their low-dose mixture resulted in an 87% decrease in the ratio of tryptophan 
to large neutral amino acids (LNAA). This effect is similar to the decrease 
found following high-dose depletion in other studies. The low-dose mixture in 
Booij et al. (2005a) resulted in a decrease of only 42% in the 
tryptophan/LNAA ratio. Hence, it may be doubted whether the studies by 
Hayward et al. and Munafò et al. may be viewed as low-dose ATD studies 
(Merens & Van der Does, 2007).
The present study is the first to investigate the effects of low-dose vs. high-
dose ATD on emotional information processing, and aims to answer three 
questions:
1. Do low-dose and high-dose ATD have differential effects on emotional 
information processing and memory in remitted depressed patients?
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2. Does ATD exert a specific effect on (a certain form of) emotional 
information processing or is the effect generalized over different aspects of 
emotional information processing?
3. Is there a relationship between emotional information processing and 
changes in mood?
To investigate this, different cognitive tests were used to assess neutral 
(memory) as well as emotional information processing (negative attentional 
bias, facial expression recognition, implicit attitudes) in remitted depressed 
patients. Two different ATD dosages were used to investigate a possible dose-
response relationship. This study extends on previous work by combining two 
ATD dosages to test the effects on emotional information processing and 
memory in remitted depressed patients and by investigating the link between 
emotional information processing and changes in mood. Based on previous 
research we hypothesized that high-dose ATD would increase symptoms in a 
subgroup of patients, but no mood effects of low-dose were expected (Booij et 
al., 2005a). We also hypothesized that both high-dose and low-dose ATD 
would affect attentional bias and facial expression recognition (Harmer et al., 
2003c; Hayward et al., 2005; Munafò et al., 2006) and that the cognitive effects 
of low-dose ATD would be strongest in participants with a depressive 
response to high-dose ATD. 
Methods
Participants   
Participants were outpatients of the Mood Disorders clinic of a psychiatric 
hospital. Inclusion criteria were 18 to 65 years; primary DSM-IV diagnosis of 
major depressive disorder; no longer fulfilling DSM-IV criteria for depression; 
Hamilton Rating Scale for Depression (HAM-D-17) scores below 16; ongoing 
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treatment with a Selective Serotonin Reuptake Inhibitor (SSRI) or a Selective 
Serotonin-Noradrenalin Reuptake Inhibitor (SSNRI) for at least four weeks; no 
psychosis (lifetime); no substance abuse in the past 3 months (DSM-IV 
criteria); (above-) normal weight (BMI > 18 kg/m2); free of neuro-endocrine 
and neurological disease; no pregnancy or lactation.
Design
The study was conducted according to a double-blind, randomized crossover 
design. 
Composition of the Amino-Acid (AA) mixtures
The high-dose AA mixture consisted of fifteen amino acids (102.5 g) (Delgado 
et al., 1990). The low-dose mixture consisted of the same amino acids but at 
one quarter strength (25.7 g) (Krahn et al., 1996). The amino acids were given 
in drink form by mixing the amino acid powders with water to a final volume 
of 300 ml. To compensate for the unpleasant taste of the mixture, chocolate 
syrup was added and the mixtures were served chilled. 
Materials
Symptoms
Symptoms were assessed using the Montgomery Asberg Depression Rating 
Scale (MADRS) (Montgomery & Asberg, 1979) and the Brief Anxiety Scale 
(BAS) (Tyrer et al., 1984). A self-rating list of physical symptoms was 
administered, consisting of 48 items rated on a five-point scale. State versions 
of all questionnaires were used during the depletion sessions. Because changes 
in weight or sleep do not occur during the course of an ATD session, these 




Facial Expression Recognition Test: This task, adapted from Harmer et al. 
(2003c), features examples of five basic emotions—happiness, sadness, fear, 
anger, and disgust (Ekman & Friesen, 1976). Emotional expression intensity 
was morphed between neutral (0%) and emotional standard (100%) in 10% 
steps, providing a range of emotional intensities. Each emotion-intensity was 
presented twice (one male and one female face) in random order on a 
computer screen for 500 ms. and immediately replaced by a blank screen. 
Participants responded by pressing a labelled key, after which the next face 
appeared. They were instructed to respond as quickly and accurately as 
possible. Accuracy and speed of recognition were recorded.
Word Learning Test (Saan & Deelman, 1986): A list of 15 unrelated, 
neutral words was presented from a tape (e.g. flower, store). Immediate recall 
was tested after each of five consecutive presentations. After the fifth trial, 
subjects continued with a non-verbal task. Fifteen minutes later delayed recall 
was tested. Different versions were used at each session in a randomized order. 
Immediate recall performance was defined as the total of correct words 
remembered over the five trials. Retrieval was defined as the number of correct 
words produced at delayed recall. Incorrect responses were also registered. 
Consolidation was defined as the number of correct words at delayed recall 
compared to the fifth trial.
Verbal fluency: Participants were instructed to produce as many correct 
four letter words with the same initial letter as possible within one minute. The 
starting letters were H, M, R or L (Schmitt et al., 2000) and the order of these 
letters was randomized over the assessments. The total number of correct and 
incorrect words was calculated.
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Dot probe test: This task measures attentional bias to emotional stimuli 
(MacLeod et al., 1986). Word pairs were presented on a computer screen for 
500 ms, one in the upper part of the screen and one below. Following the 
termination of that display, a dot appeared on the location of either word. 
Participants had to indicate the location of the dot by pressing a key. All word 
pairs were preceded by a white fixation cross for 500 ms. Subjects were first 
run through six practice trials. The main experiment consisted of trials of 
neutral words paired with threat-related words and trials of depression-related 
words paired with positive words. The neutral and threat-related words were 
taken from Lavy et al. (1993) and the depression and positive words from 
McCabe et al. (2000). To control for possible outliers, median latencies for 
correct responses were used in the analyses; incorrect responses and responses 
on practice trials were excluded. Attentional bias was calculated by subtracting 
the RT for positive (neutral) words from the RT for depressive (threatening) 
words. Attentional bias is associated with faster reaction times if the dot 
replaces the negative word compared to trials where the dot replaces the 
neutral or positive word. 
Implicit Association Test: The IAT is a sorting task that assesses implicit 
associations on the basis of reaction times (Egloff & Schmukle, 2002; 
Greenwald et al., 1998). This test is extensively used in social psychological 
research to assess stereotypes (Greenwald & Banaji, 1995). Participants are 
asked to sort stimuli representing four categories by pressing the appropriate 
key (each response key was assigned to two categories). If two categories are 
strongly related, the sorting task will be easier (: faster RTs) when the 
categories share the same response key than when they share different 
response keys. We used an emotional and a neutral version of this task. In the 
neutral version, negative and positive words were presented, which were paired 
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with flower- and insect words. RTs to congruent (e.g. flower words paired with 
positive words) and incongruent (e.g. insect words paired with positive words) 
trials were calculated. The emotional version was identical to the neutral 
version except for the stimuli: self-related words were paired with negative 
words and other-related words with positive words and vice versa. The 
negative and positive words were taken from McCabe et al. (2000); the neutral 
words were selected by Lavy et al. (1993) and the self and other words were 
taken from Egloff & Schmukle (2002) and were previously used by De Jong 
(2002). To control for possible outliers, median latencies for correct responses 
were included in the analyses; incorrect responses were excluded. Reaction 
times to congruent (e.g. self and positive words) and incongruent stimuli (e.g. 
self and negative word pairs) were calculated.
The Dysfunctional Attitudes Scale (DAS) (Weissman, 1979) is a self-rating 
scale and assesses the level of dysfunctional attitudes, which is a measure of 
cognitive reactivity. Two comprised 11-item versions, based on the original 
form A, were used in randomized order. 
Biochemical measures
To determine total plasma tryptophan concentrations and the ratio total 
tryptophan/ large neutral amino acids (LNAA), venous blood was obtained 
(10ml) in ethylene-diamine-tetra-acetic-acid tubes. After sampling, the blood 
was centrifuged for 20 minutes at 2650gmax. Plasma was stored at – 65°C until 
quantitative amino acid analysis by high-performance liquid chromatography 




After showing interest in taking part, all volunteers were given oral and written 
information about the study. Written informed consent was obtained and 
participants who seemed to meet inclusion criteria were invited for a screening 
session. During the screening session, the Structured Clinical Interview for 
DSM-IV (First et al., 1995), HAM-D17 and MADRS were administered. 
Participants filled out the personality questionnaires. A clinical psychologist or 
a trained research assistant conducted the interviews. At screening the 
cognitive tasks were done for the first time. The day before each ATD session, 
participants kept a low-protein diet (Booij et al., 2005a). Participants arrived at 
9 am at the laboratory after fasting overnight. They were instructed not to 
drink alcohol 24 hours prior to the sessions and to arrive well rested. After 
arrival, baseline symptom measures were taken, followed by a blood sample. 
Next, participants ingested the AA mixture within half an hour. Participants 
remained in the research room until 5 pm. Neutral music and magazines were 
available. Participants were not allowed to sleep. Water, (de)caffeinated coffee 
and (herb) tea were allowed in standard amounts. Three hours after ingestion 
of the AA mixture, participants were served a protein-poor lunch (Booij et al., 
2005a; Riedel et al., 1999). At t4.5 the cognitive tasks were administered, which 
took approximately 50 minutes. Next, a blood sample was obtained and 
symptoms and side-effects were assessed (t6.5). Before the participants went 
home at 5 pm, they received a snack to speed up normalization of tryptophan 
levels. The procedure was repeated approximately seven days later; participants 
who had first received the 100% strength mixture now received the 25% 
strength mixture and vice versa. The morning after each session, patients 
returned to the lab where symptoms were assessed and a blood sample was 
obtained. The day after the second ATD session, participants performed the 
Chapter 5
  111
cognitive tests a final time (post-intervention session). The study was approved 
by an independent medical ethics committee (METIGG, Utrecht). Participants 
were tested individually. Participants were paid €115 for participation. 
Statistical analysis
The effects of ATD on symptoms and cognitive performance were analyzed 
separately using General Linear Models (GLM) for repeated measures. 
Symptom ratings were analyzed with Intervention (low-dose vs. high-dose) and 
Time (pre-depletion vs. post-depletion vs. the next day) as within-subject 
factors. Cognitive performance was analyzed with Intervention (baseline vs. 
low dose vs. high-dose) as within-subject factor. In those instances in which 
the assumption of homogeneity of covariance in repeated measured analysis 
was violated, as assessed with Mauchly’s Test of Sphericity, Huynh-Feldt 
corrected p-values were used (Field, 2005). Main effects were compared using 
Bonferroni corrections to adjust for multiple comparisons. Results are reported 
as means and standard deviations.
Results
Data screening
All data were screened for accuracy of data-entry, missing values and the 
assumptions of multivariate data-analysis. Data were missing for one patient at 
the post-intervention session following the second day, due to an emotional 
reaction to the high-dose depletion drink. After having contacted the patient 
by telephone the next morning, she reported to be less emotional but she was 
still very tired and did not want to come to the lab. For the MADRS and BAS, 
data for this patient were replaced by the outcome of a regression equation 
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based on her mood in the afternoon, because we knew her symptoms had not 
returned to baseline the next morning (when X = mood in the afternoon, A = 
constant, b = unstandardized coefficient and Y = mood the next morning: Y = 
A + b . X). The missing biochemical measures were replaced by the sample 
mean. The MADRS, BAS and side-effect data were log transformed due to 
non-normal distributions. All transformations were successful. 
Participants
Twenty patients were included. One patient withdrew after the screening 
session due to family problems. One patient dropped out after the first day 
(high-dose depletion) due to physical and mood complaints following that 
session. These complaints had disappeared the day after, however she decided 
to withdraw participation. These patients were excluded from analyses, leaving 
a total of eighteen participants. Five participants vomited after high-dose ATD; 
one of them also vomited after low-dose ATD. One patient could only finish 
75% of the drink on both days. All these cases were retained. Clinical and 
demographical characteristics of the patients are shown in Table 1.
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Table 1. Clinical and demographical characteristics (n = 18) 
Mean (SD)
M / F 2 / 16
Age (years) 44.4  (13.3)
Type of medication
- SSRI 1 n = 12
- SSNRI 2 n = 6
Type of remission
- partial remission n = 7
- full remission n = 11
Duration of remission, partial or full (months) 13.4 (22.9)
Age of onset of first depressive episode 26.5 (15.6)
Number of previous episodes (incl. latest) 4.8 (4.2) [range 1-15]
Single / recurrent 2 / 16
Family History of Depression (1st degree) n = 12
BMI 25.5 (3.4)
HDRS (at screening) 7.8 (3.7)
SSRI = Selective Serotonin Reuptake Inhibitor; SSNRI = Selective Serotonin and 
Noradrenalin Reuptake Inhibitor; 1 citalopram 20-60 mg, fluoxetine 40 mg, paroxetine 
10-40 mg , sertraline 100 mg; 2 venlafaxine 150 mg- 375 mg; BMI = Body Mass Index; 
HDRS = Hamilton Depression Rating Scale 
Effects on plasma tryptophan levels
In the low-dose condition, mean plasma tryptophan levels decreased with 
60.3% ± 13.3 from 42.8 ± 5.1 μmol/l to 17.3 ± 6.9 μmol/l. In the high-dose 
condition, plasma tryptophan levels decreased with 84.0% ± 11.0 from 41.9 ± 
7.1 μmol/l to 6.7 ± 4.4 μmol/l. The plasma tryptophan/LNAA ratio decreased 
with 58.5% ± 15.9 in the low-dose condition (from 10.4 ±1.6 to 4.3 ± 1.6) and 
with 91.4% ± 8.7 in the high-dose condition (from 10.0 ± 1.6 to .82 ± .80). 
Repeated measures analysis on the tryptophan/LNAA ratio revealed 
significant effects of Intervention (F(1,17) = 59.7, p < .001), Time 
(F(1.64,27.81) = 266.0, p < .001) and Intervention x Time (F(2,34) = 28.9, p < 
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.001). Both interventions resulted in a significant decrease in plasma 
tryptophan and the tryptophan/LNAA ratio and the decrease was larger after 
high-dose than after low-dose ATD. Since a sizable number of patients had 
vomited following the high-dose AA mixture, all analyses were run twice, both 
with and without those five patients. All effects regarding the plasma 
tryptophan and tryptophan/LNAA ratio remained significant with 13 patients.
Side effects
Physical complaints increased in the high-dose but not in the low-dose 
condition and levels were back to normal the next morning (Intervention 
F(1,16) = 5.0, p = .039; Time F(2,32) = 17.0, p < .001; Intervention x Time 
(F(2,32) = 5.7, p = .008). The main effects remained significant for n = 13, 
however the interaction effect became a trend (F(2,22) = 2.9, p = .079). 
Significant Intervention x Time interactions were found for individual items 
indicating a decreased appetite (F(1.28,20.41) = 8.1, p = .006), increased nausea 
(F(2,32) = 14.4, p < .001), and sweaty hands (F(2,32) = 4.1, p = .027). 
Symptoms were back to baseline the next morning. 
Effects on symptoms
Depressive symptoms increased significantly in the high-dose condition from 
5.3 ± 5.4 to 10.8 ± 8.1, but not in the low-dose condition (from 3.7 ± 4.0 to 
3.6 ± 4.2). All scores were back to baseline the next morning (Intervention 
F(1,17) = 17.3, p = .001; Time F(2,34) = 4.6, p = .018; Intervention x Time 
F(2,34) = 3.9, p = .030). High-dose ATD induced a brief ‘depressive relapse’, 
defined as an increase in MADRS score of 6 points or more (Booij et al., 
2005a) in nine patients. Relapses occurred in four of twelve SSRI users and five 
of six SSNRI users, indicating mood response to be equally distributed over 
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SSNRI and SSRI users. These patients will be referred to as mood-responders. 
When relevant, analyses were re-run including Mood-response as a between-
subject factor. Anxiety symptoms also increased following high-dose ATD but 
not following low-dose ATD (Intervention F(1,17) = 2.9, p = .105, Time 
F(2,34) = 3.2, p = .053, Intervention x Time: F(2,34) = 4.6, p = .017). The 
effects of ATD on symptoms remained the same when the mood data were re-
analysed, excluding the five patients who vomited. Of the five patients who 
vomited, two were mood-responders. 
Learning effects, baseline measures and order effects
To detect possible learning effects, screening and post-intervention 
assessments were compared for all cognitive tests. No learning effects were 
found on the Dot-probe and Word Learning Test. On the VF, patients 
produced more correct words post-intervention compared to screening (t(16) 
= -4.5, p < .001). On the IAT neutral, patients were faster to respond to 
congruent (t(16) = 2.6, p = .021) as well as incongruent stimuli (t(16) = 4.8, p < 
.001) at post-intervention compared to screening. This was also true for the 
IAT emotional (congruent stimuli t(16) = 4.1, p = .001; incongruent stimuli 
t(16) = 2.8, p = .012). Patients were better at recognizing sadness (t(16) = 2.8, p
= .012), anger (t(16) = 4.3, p = .001), disgust (t(16) = 2.4, p = .029) and fear 
(t(16) = 3.4, p = .004) at the post-intervention session compared to screening. 
Patients were also faster in recognizing the different emotions at post-
intervention compared to screening (p values ranging from .000 to .051). To 
control for these effects, a baseline cognitive performance score was calculated 
by taking the mean score of the screening session and the post-intervention 
session (the day after the second depletion session). This procedure is in lieu of 
a baseline measure at the morning of each ATD session (cf. Booij et al., 
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2005a).  Repeated measures analyses were done with Intervention (baseline vs. 
low dose vs. high-dose) as within-subject factor.
Effects of Order of administration (low-dose ATD first vs. high-dose 
ATD first) were investigated by including Order as a between subjects factor in 
the analyses. Only on the IAT emotional, an interaction effect of Intervention 
x Order was found for incongruent stimuli (F(2,32) = 5.7, p = .007) indicating 
that patients who received the low-dose first, became faster to respond to 
incongruent stimuli following both low-dose and high-dose. Patients who 
received the high-dose first became slower to respond to incongruent stimuli 
following high-dose ATD.
Effects on neutral information processing
Word Learning Task
Immediate recall: An Intervention effect was found for the number of 
correct (F(2,34) =  4.1, p = .026) and incorrect (F(1.24,21.07) = 6.0, p = .018) 
responses. Post-hoc contrast tests indicated fewer correct responses after high-
dose depletion compared to baseline (F(1,17) = 4,9, p = .040) and low-dose 
depletion (F(1,17) = 5.4, p = .033). Also, more incorrect responses were given 
following high-dose depletion compared to baseline (main effect of 
Intervention F(1,17) = 8.2, p = .033) and low-dose ATD (a trend for an 
Intervention effect: F(1,17) = 3.9, p = .066). 
Retrieval: An Intervention effect was found for the number of correct 
(F(1.45,25.58) = 9.8, p = .002) and incorrect (F(1.56,26.58) = 4.2, p = .035) 
words at +15 min. Contrast tests revealed that the number of correct words 
decreased after high-dose ATD compared to baseline (F(1,17) = 14.5, p = 
.001) and low-dose depletion (F(1,17) = 8.4, p = .010). The number of 
incorrect responses increased following high-dose compared to baseline (effect 
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of Intervention F(1,17) = 5.6, p = .031) and low-dose (a trend of an 
Intervention effect F(1,17) = 4.3, p = .055). 
Consolidation: Main effects of Intervention (F(1.29,21.99) = 6.7, p = 
.012) and Time (F(1,17) = 21.2, p < .001) were found. The interaction effect of 
Time x Intervention was not significant (p > .1). Subjects recalled fewer words 
at delayed recall compared to immediate recall (5th trial), but there were no 
differences between the conditions. When data were re-analysed with n = 13, 
results were equal.
Verbal Fluency: The number of correct and incorrect words were 
analysed separately with Intervention as a within-subjects factor. No effects of 
high-dose and low-dose depletion were found on any of the verbal fluency 
measures (p >.10).
Effects on emotional information processing
Facial Emotion Recognition Test 
Accuracy: Overall accuracy data were analyzed with Intervention and 
Emotion as within-subject factors. Subjects were better at recognizing certain 
emotions compared to others (main effect of Emotion F(4,68) = 24.1, p < 
.001) and they performed differently over the interventions (main effect of 
Intervention F(2,34) = 4.1, p = .026) (see Figure 1). When re-analysed with n
=13, the Intervention effect became a trend (F(2,24) = 3.0, p = .071) but the 
effect of Emotion remained significant (p < .001). Separate analyses were done 
for each emotion with Intervention and Intensity (in five 20% blocks) as 
within-subject factors. Decreased fear recognition was found following high-
dose ATD (Intervention F(2,34) = 4.1, p = .025; Intensity F(3.12,52.96) = 
233.1, p < .001; Intervention x Intensity F(8,136) = 2.0, p = .052) as compared 
to low-dose (F(1,17) = 6.2, p = .023) and baseline (F(1,17) = 6.3, p = .023). 
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The Intervention effect was significant for the 30-40% (F(1.53,25.99) = 3.9, p
= .044) and 70-80% (F(2,34) = 4.5, p = .018) intensity levels. The higher the 
intensity of the emotion, the better it was recognized. No difference in fear 
recognition between low-dose depletion and baseline was found (see Figure 2). 
Repeating the analysis with 13 patients, the Intervention effect was no longer 
significant for the 30-40% intensity level (F(1.4,16.5) = 1.6, p = .230) but 
remained significant for the 70-80% intensity level (F(2,24) = 3.7, p = .039).  
No effects of ATD on the recognition of the other emotions were found. 
Speed: Analyses for the reaction times were done with Intervention and 
Emotion as within-subject factors. Main effects of Intervention (F(2,34) = 7.2, 
p = .002) and Emotion (F(2.38,40.44) = 8.4, p < .001) revealed that ATD 
affected speed of recognition and that subjects were faster in recognizing 
certain emotions compared to others. Separate analyses per emotion showed 
that subjects became faster at recognizing disgust following ATD (main effect 
of Intervention F(1.36,23.07) = 4.0, p = .048). Contrast tests showed that low-
dose ATD speeded the recognition of disgust compared to baseline (F(1,17) = 
10.4, p = .005). High-dose also speeded the recognition of disgust compared to 
baseline, although this was a trend (F(1,17) = 4.2, p = .056). When data were 
re-analysed with n = 13, the overall Intervention effect disappeared (F(1.3,15.9) 
= 2.3, p = .146), however the difference between low-dose ATD and baseline 
remained significant (F(1,12) = 6.9, p = .022). 
The results of the other cognitive tests are shown in Table 2.
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Figure 1. Facial expression recognition
Facial expression recognition at baseline (dark bars), following low-dose 
depletion (grey bars) and high-dose depletion (white bars). Values represent 
means ± 1 SEM. Asteriks represent statistical significance of the comparisons, 


















Figure 2. Fear accuracy
Fear accuracy (number of correctly recognized faces) per 20% intensity block at 
baseline, following low-dose depletion and high-dose depletion. Values represent 






















Dot-probe Task: Attentional bias scores were calculated for depressive 
and threatening stimuli. One patient appeared to be an outlier, due to 
extremely slow responses. Analyses on the attentional bias score, with 
Intervention as a within-subjects factor, were therefore performed with and 
without this patient. No effects of low-dose and high dose ATD on attentional 
bias were found (p > .10). 
Implicit Association Test
Neutral: Median latencies for congruent and incongruent word pairs 
were calculated (e.g. flower and positive vs. insect and positive). One outlier 
was found due to a large number of incorrect responses; analyses were 
performed with and without this subject. Analysis with Intervention and 
Stimulus-type (congruent vs. incongruent) was performed on the reaction time 
data. The IAT-effect (Greenwald et al., 1998) was found, indicating that 
subjects were faster to respond to congruent stimuli compared to incongruent 
stimuli (main effect of Stimulus-type F(1,17) = 87.9, p < .001). This effects was 
also significant for n = 13. No effect of ATD on the IAT effect was observed. 
Emotional: Two outliers were found; one made a large number of errors, 
the other was extremely slow to respond. Analyses were performed on median 
response latencies, with and without the outliers, using Intervention and 
Stimulus-type as within-subjects factors. Latencies for congruent and 
incongruent stimuli were calculated. No IAT effect was found indicating that 
subjects were equally fast to respond to congruent (self and positive) and 
incongruent (self and negative) stimuli. No effect of low-dose or high-dose 
depletion was found (p > .10).
Dysfunctional Attitudes Scale: DAS scores were analysed with Intervention 
as a within-subjects factor. No effect of low-dose or high-dose depletion on 
DAS scores was found.
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Table 2. Cognitive tests
Baseline Low-
dose
High-dose F df p
Dot-probe¹




526.5 (81.8) 0.6 16 .569




528.4 (88.3) 0.1 16 .874




523.2 (82.8) 0.3 16 .752




533.2 (84.5) 0.3 16 .727
AB depressive-
positive
-4.7 (13.3) 5.2 (25.7) 3.3 (20.7) 1.0 16 .384




47.9 (11.6) 47.7 (9.7) 43.0 (11.7) 4.1 17 .026*
immediate recall 
false 
1.0 (1.3) 2.0 (2.2) 4.3 (4.8) 6.0 17 .018*
delayed recall 
correct
10.7 (2.8) 10.4 (3.4) 8.3 (3.7) 9.8 17 <.001**
delayed recall false 0.3 (0.5) 0.3 (0.5) 1.0 (1.2) 4.2 17 .035*
Verbal Fluency
# correct responses 10.9 (3.2) 9.8 (4.0) 10.3 (4.6) 1.4 17 .271
# false responses 0.5 (0.8) 0.3 (0.6) 0.3 (0.6) 0.3 17 .732
IAT Neutral































DAS-11 38.9 (8.8) 35.7 (7.6) 36.5 (9.4) 2.9 34 .069
Values represent means with SD in parentheses. AB = attentional bias, RT = reaction 
time, IAT = Implicit Attitudes Test, * p < .05, ** p < .01, ¹ Dot-probe data are 
reported for n = 17, excluding one outlier, ² total of trial 1-5  
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Differences between mood-responders and non-responders
At screening, mood-responders had a higher level of depressive symptoms 
compared to non-responders (MADRS score 12.3 ± 4.6 vs. 5.7 ± 5.0, t(16) = 
3.0, p = .009). Furthermore, mood-responders were better at recognizing 
sadness than non-responders (main effect of Mood-response F(1,16) = 6.6, p
= .021). When corrected for residual depressive symptoms, the effect of 
Mood-response became a trend (F(1,15) = 3.6, p = .077). The increased 
accuracy was not at the expense of the speed of recognition: an overall 
interaction effect of Emotion x Mood-response was found for speed of facial 
expression recognition (F(5,80) = 4.0, p = .003): mood-responders were faster 
at recognizing sadness (main effect of Mood-response F(1,16) = 4.8, p = .043) 
and tended to be faster at recognizing fear (F(1,16) = 3.5, p = .080). However, 
when corrected for baseline depressive symptoms, these effects disappeared 
(F(1,15) = 0.9, p = .338; F(1,15) = 0.5, p = .479). A trend for an interaction 
effect of Intervention x Mood-response was found for the number of correct 
responses at immediate recall (F(2,32) = 3.2, p = .056); mood-responders 
recalled more correct words at baseline compared to non-responders (52.1 ± 
12.8 vs. 43.8 ± 9.1) but this difference was not significant (main effect Mood-
response F(1,17) = 2.5, p = .132). Separate analyses for mood-responders and 
non-responders revealed that immediate recall performance decreased after 
high-dose ATD in mood-responders (main effect of Intervention F(2,16) = 
6.1, p = .011) but not in non-responders (main effect of Intervention F(2,16) = 
0.1, p = .911). Analyses with n =13 revealed equal results.
Effects of type of antidepressant medication
Twelve patients were taking an SSRI at the time of study: citalopram 20-60 mg 
(n = 5); paroxetine 10-40 mg (n = 5); sertraline 100 mg (n =1); fluoxetine 40 
Chapter 5
124
mg (n = 1). Six patients were taking the SSNRI venlafaxine, 150-375 mg. The 
effect of type of medication (SSRI vs. SSNRI) on the different outcome 
measures was investigated by including type of medication as a between-
subjects factor in the repeated measures analyses. Differences were found 
between patients taking an SSRI and patients taking an SSNRI  in that the 
latter group experienced more physical symptoms (main effect of Medication 
F(1,15) = 5.0, p = .041), more depressive symptoms ( main effect of 
Medication F(1,16) = 5.7, p = .029) and more anxiety symptoms (main effect 
of Medication F(1,16) = 8.5, p = .010). However these effects were 
independent of ATD.
A considerable overlap was found between SSNRI use and mood-response: 
the majority of patients taking an SSNRI were mood-responders (five out of 
six), compared to one third of the patients taking an SSRI (four out of twelve).
Discussion
This study confirms that the effects of ATD on psychiatric symptoms depend 
on the extent of depletion. High-dose ATD led to a marked increase of 
symptoms, whereas low-dose ATD did not (91% vs. 59% reduction of plasma 
tryptophan/LNAA ratio). Although 59% reduction of tryptophan is thought 
to be sufficient to decrease brain serotonin synthesis (Biggio et al., 1974; 
Young et al., 1989), low-dose ATD may still be used as a placebo procedure, if 
the study focuses on symptoms. Furthermore, this study showed that ATD 
affects memory and facial expression recognition, as had previously been 
found in healthy subjects. Another new finding is that baseline emotional 
information processing, in particular the recognition of facial expressions of 
sadness, predicts mood-response to ATD. A number of other information 
processing measures have recently been found to predict depressive response 
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to ATD: cognitive reactivity (Booij & Van der Does, 2007); emotional Stroop 
interference (Booij et al., 2005a) and low heart rate variability, which is 
associated with impaired prefrontal functioning (Booij et al., 2006b).
Differential effect of low-dose and high-dose ATD 
We observed few effects of low-dose ATD, since only the speed of disgust 
recognition was affected. While two recent studies presented stronger effects 
of low-dose ATD (Hayward et al., 2005; Munafò et al., 2006), the low-dose 
mixtures in these two studies resulted in larger decreases of tryptophan and the 
tryptophan/LNAA ratio and may therefore not be comparable to our low-
dose mixture (Merens & Van der Does, 2007). Furthermore, these studies 
compared ‘low-dose’ ATD to a tryptophan containing mixture which increased 
tryptophan and tryptophan/LNAA ratio (by 48% and 27% respectively). This 
active control mixture may have increased the probability of finding an 
interaction effect. In the current study, low-dose ATD resulted in a 58.5% 
decrease of tryptophan/LNAA.
Several studies have now reported that ATD increases emotional 
Stroop interference (attentional bias) in healthy subjects and in recovered 
depressed patients (Booij et al., 2005a; Evers et al., 2006; Hayward et al., 2005; 
Munafò et al., 2006). However, the current study failed to find an effect of 
ATD on attentional bias as measured with the dot-probe test. This difference 
may be due to the different tests to measure attentional bias: the dot-probe test 
is a measure of spatial attention, whereas performance on the Stroop test 
reflects several other processes. Another reason may be that we did not use the 
optimal stimulus presentation times. Studies using the dot-probe test have 
found attentional biases in depression using relatively long stimulus 
presentations (1 sec or more) (Mogg et al., 1995). When stimuli are presented 
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for shorter durations, results are mixed (Bradley et al., 1997; Mathews et al., 
1996). In the current study stimuli were presented for only 500 ms., which is 
the most often used procedure, but which in retrospect may explain the lack of 
effect on this measure. However, the dot-probe has advantages in that it 
circumvents the possibility of response bias interpretations, since it requires a 
response to a neutral stimulus (dot). Also, it allows for an investigation of both 
a facilitating and a possible impairing effect of the emotional stimulus on the 
detection of the dot, depending on the position of the emotional word relative 
to the dot (MacLeod et al., 1986).
Specific or generalized effect of ATD on information processing
High-dose ATD decreased the recognition of facial expressions of fear, which 
was not accompanied by faster or slower responses to fear. The recognition of 
facial expressions of disgust was speeded following both low-dose and high-
dose ATD. This unexpected effect may represent a mood-congruent effect of 
ATD, which may be related to the unpalatable taste of the AA mixtures, but 
also to the self-declarative nature of depressive cognition.
The effect on fear recognition is in line with Harmer et al. (2003c) who 
found a similar effect in healthy females, but not in males. Since our sample 
included only two males, it is unclear whether this gender effect was replicated. 
Even though these effects are consistent, they are in contrast to the expected 
effects of lowered serotonin function and the symptomatic effects of ATD. 
Studies investigating the acute effects of other serotonin manipulations have also 
found effects on emotion recognition. In healthy subjects, both citalopram and 
tryptophan increased the recognition of fear (Attenburrow et al., 2003; Harmer et 
al., 2003a). However, in remitted depressed patients elevated fear recognition was 
normalized following citalopram administration (Bhagwagar et al., 2004). 
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Subchronic treatment with citalopram or tryptophan decreased the recognition 
of negative facial expressions in healthy volunteers (Harmer et al., 2004; Murphy 
et al., 2006). Both the direction of the effect of ATD on facial expression 
recognition and the differential effects of SSRI administration on fear 
recognition in different samples remain to be fully explained.
In contrast with our previous findings, ATD had no effect on verbal 
fluency, which measures retrieval from semantic memory (Booij et al., 2005a). 
Effects of ATD on learning, memory retrieval and consolidation have been 
observed in healthy individuals (Park et al., 1994; Riedel et al., 1999; Schmitt et 
al., 2000). In remitted depressed patients, ATD was found to decrease memory 
for positive words (Booij et al., 2005c). ATD also impaired short-term memory, 
in recovered but not in healthy subjects, and without affecting learning or long-
term memory consolidation (Hayward et al., 2005). In the present study high-
dose ATD impaired learning and retrieval in remitted depressed patients, which 
is in line with results in healthy subjects. However, the impaired learning 
following high-dose ATD occurred mainly in mood-responders. In contrast to 
previous studies, memory consolidation was not affected. 
Our results give no indication for a general effect of ATD on emotional 
information processing. Only facial expression recognition was affected by ATD; 
attentional bias and implicit attitudes were unaffected.  Future research should 
direct attention to the effects of ATD on different aspects of emotional 
information processing to clarify whether effects are specific for certain aspects 
of emotional information processing. Although the patients in the current study 
were repeatedly exposed to emotional stimuli, habituation to these stimuli does 
not seem to be an explanation for the absence of any effects on the IAT and dot-
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probe test. The observed effects of ATD on the recognition of fearful facial 
expression do not support this explanation.  Also, we compared the effects of 
ATD to a baseline measure that was based on the mean of the screening and 
final (post-intervention) session. If learning or habituation effects occur, the 
average of these sessions would be the best estimate of the baseline (the 2nd and 
3rd sessions were low- and high-dose ATD in randomized order).
Relationship between emotional information processing and serotonergic vulnerability
Mood response to ATD was related to faster and more accurate recognition of 
sadness and faster recognition of fear, although when corrected for residual 
depressive symptoms only the effect on the accuracy of sadness recognition 
remained, and became statistically a trend. The sample of the current study was 
too small to correct for clinical and demographic factors that might mediate 
the relationship between cognitive processing and mood response to ATD. 
However, the relation between recognition of sadness and mood response to 
ATD was not entirely related to the level of residual depressive symptoms 
since the effect became a trend and did not disappear when corrected for 
residual depressive symptoms. These results are in line with research in 
symptomatic and remitted depressed patients, which showed that a bias 
towards the perception of negative faces is a vulnerability factor for depressive 
relapse and that negative mood increases this negative perceptual bias 
(Bouhuys et al., 1999; Gur et al., 1992). 
Differential results were found for SSNRI and SSRI users; however 
these were mostly independent of ATD. These differences may be due to an 




Suggestions for future research 
Facial expression recognition has been found to be related to serotonin 
function. However, more research on the direction of this association is 
needed. Since our study failed to find an effect of ATD on attentional bias, 
ATD studies comparing different tests to measure attentional bias may shed 
light on the link between serotonin and attentional bias in depression. Also, 
more studies on the effects of ATD on the different aspects of memory in 
remitted depressed patients are needed since evidence in this field mainly 
involves healthy subjects.
Limitations 
The small sample size of the current study is a limitation. Furthermore, the 
relatively large number of patients who vomited following the depletion 
mixture warrants replication of the results in a larger sample. We carried out all 
analyses twice (with and without the five patients who vomited in response to 
the AA mixture), and found only a few minor differences in results. The 
biochemical data, when analysed for all patients, showed a significant decrease 
in tryptophan levels, supporting the view that despite the vomiting, the amino-
acids were well absorbed. We also compared the decreases in plasma 
tryptophan and tryptophan/LNAA ratio of the five patients who vomited to 
the patients who did not. No significant differences were observed (p values > 
.08); therefore we decided to include the patients who vomited in the overall 
analyses. Since the present study was a continuation of our previous 
experiments, using the same batch of amino acids, and the same design, 
procedures, recruitment and setting, it is unclear what has caused the 
differences in tolerability. Another limitation is the absence of a placebo 
condition. However, a true placebo does not exist. Studies have used mixtures 
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containing between 2.3g and 5g tryptophan. This procedure leads to increases 
in tryptophan and the tyrptophan/LNAA ratio which in turn may affect 
cognitive performance and symptoms (Markus et al., 1998; Markus et al., 
2002). Including such a placebo mixture may thus lead to overestimations of 
the effects of ATD. A possible solution for future studies would be to use the 
novel ATD method of administrating a natural collagen mixture  with low-
tryptophan content (Lieben et al., 2004), since the placebo condition of this 
method seems to have no effect on tryptophan concentrations in humans 
(Evers et al., 2005). 
6
Plasma tryptophan levels following low-
dose and high-dose 
tryptophan depletion
Part of this chapter is published: 
W. Merens & A.J.W. Van der Does. (2007). Biological Psychiatry, 62, 542-543
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ATD has been found to markedly decrease plasma tryptophan levels and the 
ratio tryptophan/LNAA, depending on the amount and composition of the 
amino acid mixture, whether it is combined with a low-tryptophan diet and on 
the time at which plasma samples are taken. In this chapter, different ‘low-
dose’ ATD methods are discussed. Also, the inter-individual variations in 
plasma tryptophan levels following high-dose and low-dose ATD are reported.
Low-dose tryptophan depletion
Acute tryptophan depletion (ATD) is a popular method to investigate the 
effects of lowered serotonin function in humans. Acute tryptophan depletion 
induces a temporary depressive ‘relapse’ in 50-60% of remitted depressed 
patients treated with serotonergic antidepressants. In healthy individuals, ATD 
has no or minor mood effects, but cognitive effects have been found in both 
healthy and recovered depressed individuals (Booij et al., 2003).
The magnitude of the reduction of plasma tryptophan concentrations 
following ATD depends on the amount and composition of the amino acid 
mixture (Young et al., 1989) and whether or not a pre-test low tryptophan diet 
is included. It has been suggested that a threshold exists that needs to be 
exceeded before any behavioural effects occur, since studies in which the 
plasma tryptophan reduction was lower than 70% generally do not find any 
symptomatic effects (Van der Does, 2001b). However, depression-congruent 
effects on sleep architecture have been observed at moderate tryptophan 
reductions (Bhatti et al., 1998). The placebo procedure developed by Krahn et 
al. (1996) may be suitable as a low-dose ATD procedure (Van der Does, 
2001a). Since this procedure reduces plasma tryptophan concentrations by 40-
50%, and has been found not to affect mood (Booij et al., 2005a), it allows for 
the investigation of possible dose-response effects.  
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Booij et al. (2005a), using the Krahn et al. method as low-dose ATD, 
found that ATD had a dose-dependent effect on selective attention (Stroop 
colour-word interference) in remitted depressed patients, but no other 
cognitive effects of low-dose ATD were observed. Merens et al. (in press) 
observed no effects of low-dose ATD on attention, memory, and accuracy of 
emotion recognition in remitted depressed patients (Merens et al., in press).  
Two recent papers have reported much stronger effects of low-dose ATD. 
Hayward et al. (2005) found that low-dose ATD had no effects on mood 
ratings in unmedicated recovered depressed subjects, but that it increased the 
emotion-potentiated startle reflex, impaired  recognition of happy faces and 
initial recall memory and increased emotional Stroop interference. Some 
cognitive effects were also observed in healthy controls. Munafò et al. (2006) 
reported that low-dose ATD slightly increased self-rated depressive symptoms 
in medicated recovered depressed patients and also increased Stroop 
interference for social threat words. 
The low-dose mixture used by Hayward et al. (2005) and Munafò et al. 
(2006) consisted of eight amino-acids (31.2g), whereas the Krahn et al. (1996) 
procedure consists of 15 amino-acids (25.7g). We calculated the plasma 
tryptophan reductions obtained by Hayward et al. (2005), and found that low-
dose ATD decreased plasma tryptophan levels by 73.9% in recovered 
depressed patients. The tryptophan/large neutral amino acids (LNAA) ratio 
decreased by 86.9%. This suggests that Hayward et al. (2005) studied high-dose
ATD rather than low-dose. The reductions cannot be calculated from the 
report by Munafò et al. (2006), but this study used the same procedure and 
partly the same sample. Viewing these studies as high-dose ATD studies 
resolves the inconsistencies with the studies by Booij et al. (2005a) and Merens 
et al. (in press). It also explains the symptomatic effects in the Munafò et al. 
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study. However, high-dose ATD would be expected to have increased 
symptoms in Hayward et al.’s paper. This may be explained by the fact that 
patients in this study had a relatively low number of previous episodes, which 
predicts a weaker response to ATD (Booij et al., 2002).
There is no generally accepted definition of high-dose or low-dose 
ATD. Hayward et al. (2005) presented their study as a low-dose ATD study on 
the basis of the amount of amino acids used. However, peripheral biochemical 
measures indicate that this study may be considered a high-dose ATD study. In 
our view, the term low-dose should reflect the decrease of plasma tryptophan 
concentrations and not the amount and content of the ATD mixture. Future 
research should carefully consider which terminology is used to prevent 
misinterpretation and biochemical data should be reported in detail.
Inter-individual variations in plasma tryptophan levels following ATD
The regularly used ATD mixture containing fifteen amino acids, weighing 
approximately 100g (also called ‘high-dose’ ATD) usually results in a temporary 
decrease in plasma tryptophan levels of 70-90%. Peak reductions in plasma 
levels are found 5 to 7 hours after ingestion of the amino-acid mixture 
(Delgado et al., 1990; Young et al., 1985). This decrease in plasma tryptophan 
levels following ATD is thought to be sufficient to significantly decrease brain 
serotonin synthesis (Biggio et al., 1974; Young et al., 1989). Since tryptophan 
competes with the other large neutral amino acids (LNAA) at the blood-brain 
barrier, the ratio of tryptophan/LNAA is suggested to be an important index 
of serotonin turnover (Biggio et al., 1974; Fernstrom & Wurtman, 1972).
In our ATD study, which is reported in Chapter 5 and 7, high-dose 
ATD led to a 91% reduction of plasma tryptophan/LNAA ratio, compared to 
a 59% reduction following low-dose ATD (: a mixture of fifteen amino acids at 
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a quarter strength of the regular 100g mixture). Since a sizable number of 
patients had vomited or not finished the AA mixture, we inspected the 
individual decreases in plasma tryptophan and the tryptophan/LNAA ratio 
following both low-dose and high-dose ATD (see Table 1). Especially the low-
dose mixture resulted in a large variability in the reductions in the 
tryptophan/LNAA ratio: three patients showed a large decrease (79% - 86%) 
in the plasma tryptophan/LNAA ratio, equivalent to the decreases found in 
the high-dose condition. Three other patients showed a relatively small 
decrease in the tryptophan/LNAA ratio following low-dose ATD (33% -
37%). These six patients all deviated from the mean decrease following low-
dose (59% ± 16) with more than one standard deviation.
Following high-dose ATD, three patients showed a smaller decrease 
than expected in plasma tryptophan/LNAA ratio (71% - 81%). For two of 
these patients, this may be attributed to the fact that they vomited following 
the high-dose mixture. However, three other patients that vomited following 
the high-dose mixture did not show a smaller than expected decrease in plasma 
levels.
The inter-individual variations in the decreases of plasma 
tryptophan/LNAA ratio were larger than in previous studies (Booij et al., 
2005a; Booij et al., 2006b). Unfortunately, studies usually do not report 
individual decreases in plasma tryptophan levels, so not much is known about 
their variations or the origin of these variations. One factor that could play a 
role in inter-individual differences in tryptophan levels following ATD is 
gender. Men have a higher rate of serotonin synthesis compared to women and 
the biochemical effects of ATD are greater in women compared to men 
(Nishizawa et al., 1997). The two men that were included in our study did 
show relatively small decreases in tryptophan/LNAA ratio following low-dose 
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ATD, but the biochemical response to high-dose ATD in men was similar to 
women’s.
The large variations in tryptophan levels may be partly explained by the 
fact that several participants vomited. Five out of eighteen patients that were 
included in our study, vomited in response to high-dose ATD, one of whom 
also vomited in response to low-dose ATD.  Four of these patients were able 
to complete the study. One patient dropped out after the high-dose ATD 
session (which was the second session for her) because of an emotional 
reaction to the depletion drink. One patient was excluded from the analyses 
because she dropped out after the first session (high-dose ATD) due to 
physical and mood complaints following that session (she also vomited in 
response to the high-dose mixture).
Since the present study was a continuation of previous experiments, 
using the same batch of amino acids, and the same design, procedures, 
recruitment and setting, it is not certain what has caused the differences in 
tolerability. However, ATD mixtures are consistently reported to be highly 
unpalatable and nauseating (Reilly et al., 1997). There are rather large 
differences in the reported tolerability of ATD in the literature. Some studies 
do not report any somatic side-effects, other studies may report side effects 
following both the tryptophan depletion drink and the control mixture (e.g. 
Rubinsztein et al., 2001; Schmitt et al., 2000; Spillman et al., 2001); other 
studies report low, but varying numbers of patients that vomited following the 
ATD mixture (e.g. Anderson et al., 2003; Booij et al., 2005a; Riedel et al., 1999; 
Spillman et al., 2001).
Despite a clear overall difference between low-dose and high-dose 
ATD in the present study, in one third of the patients the biochemical effects 
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were out-of-range following low-dose, and in three out of eighteen patients 
following high-dose. 
Table 1. Individual decreases in tryptophan/LNAA ratio following low-dose 
and high-dose ATD (%)
_____________________________________________________________
Patient                        low-dose  high-dose
___________________________________________________________________
1   -37.41   -88.19
2 -32.73   -93.57
3   -50.81   -96.14
4 -72.75   -97.72a
5 -59.36   -94.63
6 -67.11   -97.59b
7 -71.93   -98.65
8 -60.98   -96.11
9   -85.98  -98.81
10   -49.35   -80.79
11   -50.84   -97.25
12   -48.89   -96.19
13   -79.94   -96.91
14 -79.22  -87.42c
15   -33.83   -96.12
16   -47.87   -86.43
17 -67.52d  -70.55e
18 -55.72   -72.91f
___________________________________________________________________
a: vomited five hours after ingestion of the high-dose mixture
b: vomited within 15 minutes after ingestion of the high-dose mixture
c: vomited one hour after ingestion of the high-dose mixture
d: vomited one and a half hour after ingestion of the low-dose mixture
e: vomited ten minutes after ingestion of the high-dose mixture
f: vomited one and a half hour after ingestion of the high-dose mixture
We underlined the values that differed from the mean decrease in plasma 
tryptophan/LNAA by more than one standard deviation: low-dose: M = 58.5% 




The effects of acute tryptophan depletion 
on heart rate variability in remitted 
depressed patients




Low heart rate variability (HRV) has been found to be associated with 
depressive disorder. Recent findings indicate that experimentally lowering 
serotonin function leads to reduced HRV and increased impulsivity in remitted 
depressed patients with a history of suicidal ideation (Booij et al., 2006b). Also, 
symptom effects of ATD correlated with low HRV at baseline. These findings 
suggest that low HRV may be mediated by serotonin function in a specific 
group of depression vulnerable patients. Fourteen remitted depressed patients 
received high-dose and a low-dose ATD in a randomized, double-blind, 
within-subjects crossover design. Mood was assessed before and after 
administration of the depletion drink. Five hours after administration, 
attentional bias was measured. HRV was measured during rest and during the 
attentional test. ATD led to the expected decreases in plasma tryptophan 
levels. High-dose ATD increased depressive and anxiety symptoms in half of 
the patients. High-dose ATD increased heart rate compared to baseline, but no 
statistically significant effects on HRV were found. At baseline, patients with 
low HRV had higher attentional bias scores for threat-related stimuli compared 
to patients with high HRV. Also, mood response to ATD was higher in 
patients who showed a decrease in HRV following ATD. Unfortunately, a 
replication of the differential effects in patients with and without a history of 
suicidal ideation could not be performed, due to unequal sample sizes. The 
direction of effects of ATD on HRV in patients with a history of suicidal 
ideation was the same as in a previous study. More research is needed on the 
role serotonin plays in HRV in depressive disorder. Especially the specific role 
of impulsivity and suicidal ideation should be further investigated. Our findings 
do suggest that low HRV may be related to mood and poor affective 




Heart rate variability (HRV) is a measure of autonomic regulation of the heart 
(Krantz & McCeney, 2002). HRV reflects the capacity of the autonomic 
nervous system to vary the intervals between consecutive heart beats (Grippo 
& Johnson, 2002). Reductions in HRV are related to depression (Agelink et al., 
2002; Rechlin et al., 1994), however, negative results have also been found 
(Gehi et al., 2005). Low HRV is also associated with generalized anxiety 
disorder (Thayer & Lane, 2000), impulse control disorders such as ADHD 
(Beauchaine et al., 2001), and alcoholism (Ingjaldsson et al., 2003).  
Depression has been found to be an independent risk factor for 
cardiovascular disease (CVD) (see for a review Rugulies, 2002). Cardiovascular 
disease is the leading cause of death in the United States (American Heart 
Association, 2006). Depression after a myocardial infarction also predicts 
mortality (Anda et al., 1993). Decreased HRV is a risk factor for CVD (Stein & 
Kleiger, 1999) and has also been associated with depression and may thus 
underlie the increased risk of cardiovascular disease in depression (Gorman & 
Sloan, 2000; Grippo & Johnson, 2002; Musselman et al., 1998). 
Serotonin dysfunction is suggested to play an etiological role in both 
depression and cardiac dysfunction (Grippo & Johnson, 2002), and may thus 
underlie the association between HRV and depression. This has been 
supported by several studies. Kellett et al. showed changes in cardiac function 
following serotonin depletion in rats (2005). In a study with depressed patients, 
resting heart rate and systolic blood pressure decreased following 21 days of 
treatment with the selective serotonin reuptake inhibitor (SSRI) nefazodone, 
but no effects on HRV were found (Agelink et al., 2001). Glassman et al. 
concluded that treatment with the SSRIs paroxetine, fluoxetine and sertraline 
either had no effects or was beneficial for depressed patients with heart disease 
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(Glassman et al., 1998). SSRIs may also have a beneficial effect on cardiac 
function and improve HRV in patients with panic disorder (Gorman & Sloan, 
2000). The evidence described above indicates that HRV is a risk factor for 
cardiovascular disease. Depression is linked to cardiovascular disease and is 
associated with lowered HRV. Serotonin is implicated in depression and may 
also play a role in HRV. Therefore, manipulating serotonin function (through 
SSRI administration or by another means) may affect HRV. 
Acute tryptophan depletion (ATD) is a useful tool to investigate the 
effects of lowered serotonin function in humans. ATD leads to a rapid 
lowering of plasma tryptophan levels. ATD results in a temporary depressive 
‘relapse’ in 50-60 % of recovered depressed patients treated with an SSRI (Van 
der Does, 2001a). In healthy subjects, mood effects of ATD are only found in 
subjects with a family history of depression (Klaassen et al., 2002). Cognitive 
effects of ATD have been found in both healthy subjects and in recovered 
depressed subjects. ATD selectively impairs learning (Park et al., 1994), 
memory retrieval and consolidation (Klaassen et al., 2002; Park et al., 1994; 
Riedel et al., 1999) in healthy volunteers and ATD improves attention in 
healthy samples (Schmitt et al., 2000) and patients (Booij et al., 2005a; Evers et 
al., 2006).  Also, ATD may increase emotional Stroop interference (Booij et al., 
2005a; Evers et al., 2006; Hayward, 1995) in recovered depressed patients. 
Besides the link between serotonin and cognitive processing, 
autonomic nervous system regulation as manifested in cardiac variability may 
be related to both attentional regulation and affective processing, since 
decreased HRV is a marker for low parasympathetic activation and prefrontal 
hypoactivity (Thayer & Brosschot, 2005). HRV in particular has been shown to 
be related to attentional control and to emotional regulation, low HRV being 
related to poor affective processing (Thayer & Lane, 2000). Further evidence 
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indicates that HRV is related to cognitive flexibility (Johnsen et al., 2003). The 
prefrontal cortex is necessary for many tasks involving executive function. The 
level of resting HRV seems to be related to executive functioning. Subjects 
with high HRV were found to perform better on executive tasks and working 
memory tasks compared to subjects with low HRV (Hansen et al., 2003; 
Hansen et al., 2004).
Since serotonin may underlie the link between HRV and depression, 
and HRV may in turn be related to cognitive processing, it would be 
interesting to investigate the effects of lowered serotonin function on HRV 
and cognitive performance in depression.
Recently, the effects of ATD on HRV were investigated in a sample of 
remitted depressed patients (Booij et al., 2006b). Selective effects were found 
in remitted depressed patients with a history of suicidal ideation; high-dose 
ATD reduced HRV during rest, increased impulsivity (as measured by the 
Continuous Performance test) and increased anxiety symptoms in this 
subgroup of patients. Also, symptom effects of ATD correlated with low HRV 
at baseline (Booij et al., 2006b). The authors suggested that reduced HRV in 
depression may thus be limited to patients who are prone to display impulsive 
or aggressive behaviour. 
The first objective of the current study is to replicate these findings 
using a different test of attention, to investigate whether the effects of ATD 
are mainly linked to impulsivity or to attention and anxiety. If serotonin is 
indeed implicated in HRV, lowering serotonin function may affect (: decrease) 
HRV. It is interesting to investigate whether the effects on HRV will be limited 
to those patients who experience a mood response following ATD or if the 
effect will be generalized to all patients. We evaluated the effects of ATD on 
mood, cardiac function and attentional bias to depressive and threatening 
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information in medicated remitted depressed patients with and without a 
history of suicidal ideation. ATD affects attentional bias, as measured with the 
Stroop task (Booij et al., 2005a; Evers et al., 2006; Hayward et al., 2005; 
Munafò et al., 2006). However, since the Stroop task is used as an experimental 
stressor in cardiac activity research (Renaud & Blondin, 1997), we chose 
another measure of attentional bias; the Dot-probe test (MacLeod et al., 1986) 
to investigate how mental workload may affect the influence of ATD on HRV. 
Since mental effort is known to lower HRV measures (Johnsen et al., 2003; 
Van Roon et al., 2004), the workload task may strengthen the lowering effect 
of ATD on HRV. We hypothesized that ATD would increase symptoms in a 
subgroup of patients. Furthermore, we expected low HRV to be related to the 
symptomatic effect of ATD and to a decreased attentional function following 
ATD. We hypothesized that the effects of ATD on attentional bias would be 
strongest in patients with a history of suicidal ideation.
Research has identified several predictors of response to ATD in 
remitted depressed patients, such as chronicity of depression (Booij et al., 
2002) and cognitive reactivity (Booij & Van der Does, 2007). The study of 
Booij et al. (2006b) showed that low HRV predicted a stronger response to 
ATD in SSRI treated remitted depressed patients. The second aim of the 
current study is therefore to find support for the predictive role of low HRV in 
mood response to ATD.
Methods 
Participants
Participants were outpatients of the Mood Disorders clinic of a psychiatric 
hospital. Inclusion criteria were age between 18 to 65 years; primary DSM-IV 
diagnosis of major depressive disorder; no longer fulfilling DSM-IV criteria for 
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depression; Hamilton-17 scores below 16; ongoing treatment with an SSRI or 
selective serotonergic and noradrenergic reuptake inhibitor (SSNRI) for at least 
four weeks; no psychotic disorder (lifetime); no substance abuse in the past 3 
months (DSM-IV criteria); BMI above 18 kg/m2; free of neuro-endocrine or 
neurological disease; no pregnancy or lactation.
Design
The study was conducted according to a double-blind, randomized crossover 
design. 
Composition of the amino-acid mixtures
The high-dose amino-acid (AA) mixture consisted of fifteen amino acids 
(102.5 g) (Young et al., 1985). The low-dose mixture consisted of the same 
amino acids but at one quarter strength (25.7 g) (Krahn et al., 1996). The 
amino acids were given in drink form by mixing the amino acid powders with 
water to a final volume of 300 ml. To compensate for the unpleasant taste of 
the mixture, chocolate syrup was added and the mixtures were served chilled. 
Instruments
Symptoms
The Hamilton depression rating Scale (HDRS) (Hamilton, 1967) and the 
Montgomery Asberg Depression Rating Scale (MADRS) (Montgomery & 
Asberg, 1979) were administered at screening. Symptoms were assessed during 
the test sessions using the Comprehensive Psychopathological Rating Scale 
(CPRS) (Goekoop et al., 1991),  an observer-rating scale that includes the 
MADRS and the Brief Anxiety Scale (BAS) (Tyrer et al., 1984). Because 
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changes in weight or sleep do not occur during the course of an ATD session, 
these items were omitted.
Attentional bias
The Dot-probe task measures attentional bias (MacLeod et al., 1986). Word 
pairs were presented one by one on a computer screen for 500 ms, one in the 
upper part of the screen and one below. Following the termination of that 
display, a dot appeared on the location of either word. Participants had to 
indicate at which location the dot was placed by pressing a key. The duration 
of the presentation of the dot on the screen was variable since the dot 
disappeared and a new screen appeared as soon as a response was given. Each 
trial started with a white fixation cross for 500 ms. Subjects were first run 
through six practice trials. The main experiment consisted of trials of neutral 
words paired with threat-related words and trials of depression-related words 
paired with positive words. Only median latencies for correct responses were 
included in the analyses to reduce the influence of possible outliers. Attentional 
bias was associated with faster reaction times if the dot replaces the negative 
word compared to trials where the dot replaces the neutral or positive word. 
Attentional bias is calculated as the mean reaction time for depressive (or 
threat related) words minus the mean reaction time for positive (or neutral) 
words.
Biochemical analyses
To determine total plasma tryptophan concentrations and the ratio total 
tryptophan/ large neutral amino acids (LNAA), venous blood was obtained 
(10ml) in EDTA tubes. After sampling, the blood was centrifuged for 20 
minutes at 2650gmax. Plasma was stored at – 65°C until quantitative amino acid 
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analysis by high-performance liquid chromatography took place (as described 
by Fekkes et al., 1995). 
Cardiac activity
Heart rate and HRV were measured by the VU-AMS device (version 4.6. TD-
FPP, Vrije Universiteit, Amsterdam, the Netherlands). This device has been 
used extensively and details of its characteristics have been published elsewhere
(AMS; Klaver et al., 1994).   In the present study the electrocardiogram signal 
was recorded using disposable pre-gelled Ag-AgCL electrodes (ConMed, New 
York, USA) that were placed at the jugular notch of the sternum, 4 cm under 
the left nipple and at the lateral right side. The device detects the R-wave of the 
electrocardiogram and records the time in milliseconds (with one millisecond 
resolution). Using this three electrode configuration inter-beat intervals were 
generated from which HRV was computed using software from the Leiden 
University Medical Center (Bootsma et al., 1994). Apart from heart rate (HR), 
different time domain measures of HRV were taken: the standard deviation of 
the inter-beat interval (SD), the coefficient of variation, CVr (SD/ inter-beat 
interval), the square root of the mean squared differences of successive inter-
beat intervals (RMSSD) and the percentage of successive normal interval 
differences greater than 50 ms (PNN50). Frequency domain measures included 
low frequency power (LF: 0.07-0.14 Hz) which is associated with both 
parasympathetic and sympathetic modulation and high frequency power (HF: 
0.14-0.40 Hz) which is a measure of centrally mediated cardiac vagal control 
(Berntson et al., 1997). HF variations are variations in HR related to the 
respiratory frequency (also called respiratory sinus arrhythmia: RSA). Also, the 
LF/HF ratio was calculated, which is thought to reflect the relative balance of 
sympathovagal influences on the heart (Bootsma et al., 1994). We chose to 
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include both time and frequency domain measures of HRV since studies on 
depression and HRV usually investigate both (e.g. Rechlin et al., 1994; Van der 
Kooy et al., 2006), although studies on the effect of workload or mental stress 
on HRV focus mostly on frequency measures (Hjortskov et al., 2004; Van 
Roon et al., 2004). 
Procedure
After showing interest in taking part, all volunteers were given oral and written 
information about the study. Participants who seemed to meet inclusion 
criteria were invited to a screening session during which informed consent was 
obtained. During the screening session, the SCID-IV interview (First et al., 
1995), HDRS and MADRS were administered. A clinical psychologist or a 
trained research assistant conducted the interviews. At screening the cognitive 
tasks were done for the first time. The day before each ATD session, 
participants kept a low-tryptophan diet (Booij et al., 2005a). 
The scheme of the test sessions is presented in Table 1. Participants 
arrived at 9.00 am at the laboratory after fasting overnight. They were 
instructed not to use alcohol 24 hours prior to the sessions and to arrive well 
rested. After arrival (t-1), blood pressure was assessed; baseline mood measures 
were taken, followed by a blood sample. Next, participants ingested the AA 
mixture within half an hour (t0). Participants remained in the research room 
until 5.00 pm. Neutral music and magazines were available. Participants were 
not allowed to sleep. Water, (de)caffeinated coffee and (herb) tea were allowed 
in standard amounts. Three hours after ingestion of the AA mixture,
participants were served a protein-poor lunch (Booij et al., 2005a; Riedel et al., 
1999).  During the hour preceding the cognitive and cardiac measures, patients 
were not allowed to smoke or to drink caffeinated coffee or tea. At around 
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2.15 pm, the electrodes were placed and the AMS device was connected to the 
computer. Also, blood-pressure was assessed. Patients performed a neutral 
distraction task for 5 minutes (‘resting’ period): they were given a Swedish text 
and were instructed to cross each letter a. It was explained that this was 
intended as a simple baseline task and that there were no demands concerning 
time or accuracy. At 2.30 pm (t4.5) the cognitive tasks were performed which 
lasted about 50 minutes. Thereafter, the electrodes were removed, a blood 
sample was obtained and the symptom interview and questionnaires were 
administered (t6.5). Before the participants went home, again the blood-
pressure was assessed and they received a snack to speed up normalization of 
tryptophan levels. The procedure was repeated approximately seven days later; 
participants who had first received the 100% strength mixture now received 
the 25% strength mixture and vice versa. The morning after each session, 
patients returned to the lab where symptoms were assessed as well as blood 
pressure and a blood sample was obtained. The day after the second ATD 
session, cardiac activity was assessed while participants again performed the 
cognitive tests (post-intervention session). This study was approved by an 
independent medical ethics committee (METIGG, Utrecht). Participants were 
tested individually and were paid € 115,-. 
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Table 1. Scheme of the sessions
Time Assessment
 9.00 am Arrival, CPRS, blood pressure                                         (t-1)                
 9.50 Blood sample
10.00 Ingestion AA mixture                                                      (t0)
1.00  pm Lunch
2.30 Cardiac assessment, blood pressure & cognitive tests      (t4,5)                                
4.00 Blood sample
4.30 CPRS, blood pressure                                                      (t6,5)                                                                     
5.00 End of session
AA = amino acid; CPRS = Comprehensive Psychopathological Rating Scale
Statistical analysis:
The effects of tryptophan depletion on symptoms and Dot-probe performance 
were analyzed separately using General Linear Models (GLM) repeated 
measures analyses. Symptom ratings were analyzed with Intervention (low-
dose vs. high-dose) and Time (pre-depletion vs. post-depletion vs. the next 
day) as within-subject factors. Dot-probe performance was analyzed with 
Intervention (baseline vs. low-dose vs. high-dose) as within-subject factor. 
Baseline cognitive performance was calculated by taking the mean score of the 
screening session and the post-intervention session (the day after the second 
depletion session). This procedure is in lieu of a baseline measure at the 
morning of each ATD session and corrects for any learning effects that may 
occur over the course of four assessments (Booij et al., 2005a). The post-
intervention HRV assessment was taken as a baseline for cardiac activity. 
Cardiac activity measures were analyzed separately using Intervention (baseline, 
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low-dose, high-dose ATD) and Period (resting vs. Dot-probe) as within-
subject factors. Since cardiac activity may be influenced by age, gender and 
smoking, the effect of these variables were checked separately. The effect of 
order of administration on cardiac activity and Dot-probe performance was 
also analyzed. In those instances in which the assumption of homogeneity of 
covariance in repeated measured analysis was violated, as assessed with 
Mauchly’s Test of Sphericity, Huynh-Feldt corrected p-values were used (Field, 
2005). Bonferroni corrections were used to adjust for multiple comparisons. 
Results
Data screening
All data were screened for accuracy of data-entry, missing values and the 
assumptions of multivariate data-analysis. The MADRS and BAS data were not 
normally distributed; hence a logarithmic transformation was performed. 
PNN50, LF, HF and LF/HF ratio were log10 transformed because of skewed 
distributions. All transformations were successful. 
Participants 
Twenty patients were included. One patient withdrew after the screening 
session due to family problems. One patient dropped out after the first day 
(high-dose depletion) due to physical and mood complaints following that 
session. These complaints had disappeared the day after, however she decided 
to withdraw participation. One patient was excluded from analyses due to a 
possible lack of sinus rhythm. Data were missing for one patient at the post-
intervention session following the second day, due to an emotional reaction to 
the high-dose depletion drink. After having contacted the patient by telephone 
the next morning, she reported to be less emotional but she was still very tired 
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and did not want to come to the lab. For two patients cardiac data were 
missing due to technical problems. Analyses were therefore performed on 
fourteen patients. Four patients vomited after high-dose ATD; one patient also 
vomited after low-dose ATD. One patient could only finish 75% of the drink 
on both days. All these cases were retained. Analyses with and without those 
patients did not show any differences in results. Clinical and demographical 
characteristics of the subjects are shown in Table 2.




Number of smokers 8
Type of medication: SSRI/SSNRI 9 / 5
Number of previous episodes 5.4 (4.7)
Duration of remission (months) 15.3 (25.7)
Single/recurrent episodes 2 / 12
Partial/ full remission 5 / 9
SI+/ SI- 11 / 3
MADRS 9.1 (5.8)
HDRS 7.4 (3.8)
SSRI: selective serotonin reuptake inhibitor, SSNRI: selective serotonin noradrenalin 
reuptake inhibitor, SI: history of suicidal ideation, MADRS = Montgomery-Asberg 
Depression Rating Scale, HDRS = Hamilton Depression Rating Scale
Effects on amino-acid levels
In the low-dose condition, mean plasma tryptophan concentrations decreased 
by 58.3% from 43.0 ± 5.1 μmol/l to 18.1 ± 5.7 μmol/l. In the high-dose 
condition plasma tryptophan levels decreased by 82.2% from 41.4 ± 6.9 
μmol/l to 7.3 ± 4.7 μmol/l. The plasma tryptophan/LNAA ratio decreased by 
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56.2% in the low-dose condition (from 10.2 ± 1.5 to 4.4 ± 1.4) and by 89.9% 
in the high-dose condition (from 9.9 ± 1.6 to 1.0 ± 0.9). Significant effects of 
Intervention (F(1,13) = 30.8, p < .001), Time (F(2,26) = 225.9, p < .001) and 
Time x Intervention (F(2,26) = 34.0, p < .001) were found for the 
tryptophan/LNAA ratio. Both interventions resulted in a significant decrease 
in plasma tryptophan and the tryptophan/LNAA ratio and the decrease was 
larger after high-dose than after low-dose ATD. 
Symptoms
Depressive symptoms increased significantly in the high-dose condition from 
4.1 ± 3.5 to 10.0 ± 6.8, but not in the low-dose condition (from 4.4 ± 4.1 to 
3.1 ± 4.1). All scores were back to baseline the next morning (Intervention 
F(1,13) = 13.9, p = .003; Time F(2,26) = 4.0, p = .030; Intervention x Time 
F(2,26) = 6.7, p = .004). High-dose ATD induced a depressive relapse (defined 
as an increase in MADRS score of 6 points or more) in seven of fourteen 
patients. These patients will be referred to as mood-responders. Anxiety 
symptoms also increased following high-dose ATD but not following low-dose 
ATD (Time x Intervention: F(2,26 ) = 8.1, p = .002). Side-effects of the 
tryptophan depletion drinks are reported elsewhere (Merens et al., in press).
The effect of ATD on cardiac activity
Analyses with Intervention (low-dose vs. high-dose) and Time (morning (t-1) 
vs. beginning of the afternoon (t4,5) vs. end of the afternoon (t6,5) vs. next 
morning (t+24h)) on blood pressure revealed no effects of ATD on blood 
pressure. Only a Time effect was found for the diastolic blood pressure 
(F(3,39) = 4.1, p = .012) indicating a decrease in diastolic BP from morning to 
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the beginning of the afternoon (F(1,13) = 14.2, p = .002) during both 
interventions. 
Analyses with Intervention and Period (rest vs. Dot –probe) revealed 
effects of Intervention (F(2,26) = 4.3, p = .025) and Period (F(1,13) = 14.2, p = 
.002) on heart rate. Heart rate increased following high-dose ATD compared 
to baseline (F(1,13) = 7.9, p = .015) and low-dose (F(1,13) = 7.4, p = .018). 
Heart rate was higher during rest than during the Dot-probe (M ± SEM: 78.2 
± 2.2 vs. 76.0 ± 2.1). No significant effect of ATD on any of the HRV 
measures was found. 
Eleven patients reported to have suffered from suicidal ideation (SI+) 
in the past, while three patients did not (SI-). Due to these unequal sample 
sizes, analyses using suicidal ideation as a between subjects factor could not be 
performed. Hence, analyses on HR and HRV measures were done for the 
eleven SI+ patients only. Again significant effects of Intervention (F(2,20) = 
6.9, p = .005) and Period (F(1,10) = 8.6, p = .015) were found on HR.  HR 
increased following high-dose ATD compared to baseline and was higher 
during rest than during Dot-probe. Also an interaction effect of Intervention x 
Period (F(2,20) = 6,9, p = .005) was found. Post-hoc contrast tests showed that 
low-dose ATD decreased HR slightly during rest, but increased HR during the 
Dot-probe (F(1,10) = 7.9, p = .018). HR increased following high-dose 
compared to baseline during both periods (F(1,10) = 6.5, p = .029). 
For RMSSD, also an interaction effect of Intervention x Period was 
found (F(2,20) = 5.4, p = .013). Post hoc tests indicated that following low-
dose ATD, RMSSD decreased during the Dot-probe but increased during rest 
(F(1,10) = 6.2, p = .032). RMSSD and PNN50 both decreased following high-
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dose ATD compared to baseline; however these changes were not significant. 
See Table 3 for the cardiac measures per intervention for the SI+ group.
Analyses on HR and HRV were rerun to check for possible influences 
of smoking, order of administration and age. The effect of gender could not be 
investigated since only one male was included in the sample. Regarding HR, 
the Intervention effect was no longer significant when age was included as a 
covariate, (F(2,24) = 0.1, p = .907), and the effect of Period became a trend 
(F(1,12) = 4.2, p = .062); however no main effect of age was present (F(1,12) = 
0.7, p = 431). Order did not have an effect on HR (F(1,12) = 0.02, p = .904), 
neither did smoking (F(1,12) = 0.8, p = .388). Also, no effects were found of 
order or smoking on any of the HRV measures. When age was included as a 
covariate in the repeated measures of LF, a main effect of age was found 
(F(1,12) = 9.2, p = .010), indicating that LF was lower for older patients. For 
RMSSD, an effect of Period (F(1,12) = 5.8, p = .033) and an interaction effect 
for Period x Age (F(1,12) = 5.9, p = .032) were found when age was included 
as a covariate; RMSSD was lower during rest than during the Dot-probe. The 
same effects were found for PNN50 (Period F(1,12) = 5.1, p = .044; Period x 
Age F(1,12) = 5.1, p = .043); PNN50 was lower during rest than during the 
Dot-probe when age was included as a covariate.
Attentional bias
Attentional bias scores were calculated for depression- and threat-related 
stimuli. One patient appeared to be an outlier, due to extremely slow 
responses. Analyses were therefore performed with and without this patient. 
Using repeated measures with Intervention as within-subject factor, no effects 
of low-dose and high dose ATD on attentional bias were found (p > .10). 
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Order of administration (low-dose first vs. high-dose first) did not have an 
effect on Dot-probe performance.
Relationship between HRV and Dot-probe performance
Patients with low HRV levels during rest at baseline (median split) had higher 
attentional bias scores for threat-related words at baseline than patients with 
high HRV. The difference was significant for the ratio LF/HF (-18.1 vs. 7.4 
ms; t(12) = -3.1, p = .009). Statistical trends were found for SD (-14.6 vs. 4.0 
ms: t(12) = -2.0, p = .075), PNN50 (-17.7 vs. 1.6 ms; t(12)= -1.9, p = .078), and 
CVr (-14.6 vs. 4.0 ms: t(12) = -2.0, p = .075). 
Relationship between HRV and clinical variables
The change in HRV (Δ) from baseline to high-dose ATD was calculated (for 
RMSSD, PNN50, SD, CVr, LF, HF, and ratio LF/HF separately). Scores were 
divided into groups of patients that showed either an increase or a decrease in 
HRV following high-dose ATD. The degrees of freedom for the different tests 
may vary because patients whose HRV levels remained unchanged (Δ = 0) 
following ATD were left out of the analyses. Mood-response was higher in 
patients who showed a decrease in HRV following ATD. This was significant 
for LF (t(12) = 2.2, p = .050) and a trend for RMSSD (t(11) = -2.1, p = .061). 
Patients with a decrease in HRV following ATD were older compared to 
patients showing an increased HRV. This was significant for RMSSD (t(11) = -
2.5, p = .030) and PNN50 (t(9) = -2.3, p = .048). 
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Table 3. Means (SD) of the cardiac measures per intervention for patients
with a history of suicidal ideation (SI+) (n = 11)
Baseline Low-dose High-dose F p
HR (beats/min) 6.9 .005**
- rest 73.9 (7.5) 71.9 (6.0) 80.1 (9.6)
- dot-probe 71.5 (7.9) 72.8(7.4) 76.8 (8.0)
SD IBI (ms) 1.1 .338
- rest 32.1 (8.7) 35.5 (12.9) 31.4 (7.7)
- dot-probe 33.3 (11.5) 35.1 (11.6) 31.0 (9.3)
CVr (%) 0.4 .647
- rest 3.9 (1.1) 4.2 (1.3) 4.2 (1.0)
- dot-probe 3.9 (1.3) 4.3 (1.5) 4.0 (1.3)
RMSSD (ms) 1.7 .209
- rest 18.9 (7.5) 20.7 (8.5) 15.4 (4.5)
- dot-probe 20.4( 9.6) 18.2 (8.6) 16.6 (4.7)
PNN50 2.1 .143
- rest 2.6 (4.2) 3.6 (5.9) 0.8 (1.5)
- dot-probe 4.0 (5.7) 2.7 (4.3) 1.1 (1.8)
LF (ms2) 0.2 .816
- rest 319.6 (181.3) 410.2 (388.9) 409.7 (244.6)
- dot-probe 347.9 (181.1) 335.4 (257.1) 375.9 (254.2)
HF (ms2) 0.2 .829
- rest 288.7 (182.4) 417.9 (374.6) 285.4 (177.1)
- dot-probe 316.1 (220.0) 307.3 (210.0) 241.3 (162.6)
LF/HF ratio 0.6 .558
- rest 1.9 (2.5) 1.1 (0.9) 2.0 (2.4)
- dot-probe 1.7 (2.1) 1.3 (0.6) 1.6 (1.2)
The original data are reported. Analyses on the PNN50, LF, HF, LF/HF ratio were 
done using log transformed variables. ** p < .01
F = main effect of Intervention in the repeated measures analysis, df = (2,20)
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Relationship between baseline HRV and mood response to ATD
A trend was found for the correlation between baseline PNN50 during rest 
and the change in MADRS following high-dose ATD; r = .497, p = .070. No 
other correlations were found between baseline HRV and mood response to 
ATD. Patients with relatively low (below median) HRV levels did not have a 
depressive response to ATD more often compared to patients with high HRV 
levels.
Discussion
As reported elsewhere (Merens et al., in press),  the current findings confirm 
that high-dose ATD affects mood in remitted depressed patients, whereas low-
dose does not affect mood (Booij et al., 2005a; Spillman et al., 2001). Half of 
the patients were mood-responders in response to high-dose ATD. The 
reported decreases in plasma tryptophan levels and the ratio 
tryptophan/LNAA following ATD are also in line with expectations. Previous 
research using low-dose and high-dose ATD found similar changes in 
tryptophan levels (Booij et al., 2005a). 
High-dose ATD increased heart rate both during rest and during the 
Dot-probe test. This is in line with previous findings that also showed an effect 
of ATD on HR (Booij et al., 2006b). The finding that HR was higher during 
rest than during the Dot-probe test is in line with the finding that HR 
decreases during tests that require sustained attention (Swenne et al., 1995), 
although HR has been found to increase during the Stroop task (Renaud & 
Blondin, 1997). In that study however, the Stroop task was suggested to act as 
an experimental stressor.
However, although the effects of ATD on the HRV measures in the 
SI+ group were in the same direction as in our previous study, none of these 
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changes was statistically significant. Unfortunately, a replication of the 
differential effects in patients with and without a history of suicidal ideation 
was not possible due to a low number of patients without such a history. 
At baseline, low HRV was related to a higher attentional bias for 
threat-related words. This is in line with previous research that found a higher 
attentional bias for threat-related words in low HRV patients with dental 
anxiety compared to high HRV patients (Johnsen et al., 2003). Our results also 
follow the findings that low HRV is related to poor affective information 
processing (Thayer & Lane, 2000).
In the total group of remitted depressed patients, a decreased HRV 
following high-dose ATD was related to a stronger mood-response compared 
to an increased HRV. This suggests that patients who are sensitive to changes 
in serotonin in the sense that they show a mood response following ATD, may 
also respond to ATD with a lowered HRV. 
In contrast to expectations, low PNN50 at baseline was not related to 
an increased mood response to ATD (Booij et al., 2006b) but to a decreased 
mood response. This correlation however did not reach significance. 
Limitations and suggestions for future research:
The current findings are limited by the small number of patients. Replication in 
larger samples is therefore warranted. Also, we did not select for a history of 
suicidal ideation when recruiting patients for this study. 
We assessed HRV during rest and during a Dot-probe test. The choice 
of the cognitive tests was based on the possible link between serotonin 
function and attentional bias. Other tests that may be more specifically linked 
to cardiac function, such as the Stroop test or other tests of executive function, 
should also be investigated in future studies. A strength of the Dot-probe test 
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should also be mentioned. The inter-stimulus-intervals of the task were 
variable between and within individuals due to variable response times (a new 
stimulus was presented as soon as a response was given). The HF component 
of HRV is sensitive to task-induced signal repetition, but by using this version 
of the Dot-probe no task related peak in HF was formed and the HF 
component of HRV was not influenced (Mulder, 1992). 
In addition to the effects of acute tryptophan depletion, it would also 
be interesting to investigate the effects of other serotonin manipulations on 
heart rate variability, to clarify the exact mechanisms underlying the link 
between serotonin and cardiac variability. Previous studies have found effects 
of SSRI treatment on cardiac activity in depressed patients (Agelink et al., 2001; 
Bär et al., 2004; Glassman et al., 1998) however not much is known about the 
acute effects of SSRI administration on HR and HRV in depression vulnerable 
subjects. Kemp et al. investigated the effects of acute SSRI administration in 
healthy subjects (Kemp et al., 2004). Compared to placebo, citalopram 
suppressed differences in heart rate associated with the viewing of pleasant and 
unpleasant images. Also, the electrophysiological activation to unpleasant 
images was attenuated following citalopram, while the activation to pleasant 
images was potentiated. 
In summary, the present study could not establish a link between 
serotonin function, HRV and impulsivity. However our findings do indicate 
that low HRV may be related to mood and poor affective processing through 
changes in serotonin function.
8
The effects of serotonin manipulations on 
emotional information processing 
and mood
W. Merens, A. J. W. Van der Does, P. Spinhoven. (2007).




Serotonin is implicated in both mood and cognition.  It has recently been 
shown that antidepressant treatment has immediate effects on emotional 
information processing, which is much faster than any clinically significant 
effects. This review aims to investigate whether the effects on emotional 
information processing are reliable, and whether these effects are related to 
eventual clinical outcome. Treatment-efficiency may be greatly improved if 
early changes in emotional information processing are found to predict clinical 
outcome following antidepressant treatment. This is a review of studies 
investigating the short-term effects of serotonin manipulations (including 
medication) on the processing of emotional information, using PubMed and 
PsycInfo databases. Twenty-five studies were identified. Serotonin 
manipulations were found to affect attentional bias, facial emotion recognition, 
emotional memory, dysfunctional attitudes and decision making. The 
sequential link between changes in emotional processing and mood remains to 
be further investigated. The number of studies on serotonin manipulations and 
emotional information processing in currently depressed subjects is small. No 
studies yet have directly tested the link between emotional information 
processing and clinical outcome during the course of antidepressant treatment. 
Serotonin function is related to several aspects of emotional information 
processing, but it is unknown whether these changes predict or have any 





Major depressive disorder is one of the most disabling diseases in the world 
(Üstün et al., 2004). Of the people who have been treated for a depressive 
episode, 50% will get depressed again. This percentage increases to a 90% 
chance of a future depression, having experienced three depressive episodes in 
the past (Judd, 1997). The most effective treatments for depression are 
antidepressant medication, structured forms of psychotherapy (eg. cognitive 
behavioural therapy), or a combination.  Selective serotonin reuptake inhibitors 
(SSRIs) form the most widely used pharmacological treatment for depression 
(Petersen et al., 2002). The monoamine theory of depression states that 
monoamine levels, such as serotonin, are low in the brain during untreated 
depressive episodes, but no explanation had been found for how monoamine 
loss occurs (Maes & Meltzer, 1995). Recently, Meyer et al. (2006) found 
evidence that  elevated monoamine oxidase (MAO-A) density may be the 
primary monoamine-lowering process during depression. 
Serotonergic antidepressants increase brain serotonin function by 
inhibiting the re-uptake of the neurotransmitter serotonin (5- hydroxy-
triptamine; 5-HT) (Blier & de Montigny, 1994). Research has indicated that 
80% occupancy of the serotonin transporter (5-HTT) may be necessary for the 
therapeutic effect of SSRIs to occur (Meyer et al., 2004). One puzzling factor 
in the treatment with SSRIs is the delay in onset of action. A recent meta-
analysis (Taylor et al., 2006) suggests that treatment with SSRIs may lead to
clinical improvement as early as the end of the first week. Although this is 
faster than is commonly assumed, there is still a considerable delay between the 
biochemical effects of SSRI administration and symptomatic improvement. 
One possible explanation for this delay in onset is a process called ‘receptor 
desensitization’. All SSRIs enhance the activity of the 5-HT1a autoreceptor via 
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the blockade of the 5-HT transporter in the raphe nuclei (Blier & de Montigny, 
1998).  After two to three weeks, 5-HT transmission is increased in the brain 
because of a normalized firing rate in the presence of sustained 5-HT reuptake 
blockade and because the terminal 5-HT autoreceptor is desensitised. The 
autoreceptors normally have an inhibitory effect on the amount of serotonin 
that is released per impulse. After long-term administration of an SSRI, this 
inhibitory effect is lifted (Blier & de Montigny, 1998).
Evidence for this receptor desensitisation-hypothesis comes from 
studies investigating the effects of the 5-HT1a/β-adrenoreceptor antagonist 
pindolol in combination with SSRI treatment. Pindolol blocks the 5-HT1a 
autoreceptor on the cell body of 5-HT neurons to prevent the initial decrease 
in firing activity of these neurons at the start of SSRI treatment. This process 
mimics the desensitisation of the 5-HT1a autoreceptor, which occurs after 
about 2 weeks of SSRI treatment. Pindolol has been found to accelerate the 
therapeutic effect of SSRIs (Ballesteros & Callado, 2004; Perez et al., 1997) 
although results have been conflicting (Berman et al., 1997; Moreno et al., 
1997). 
Cognitive effects of antidepressant treatment
A recently proposed alternative explanation for the delay in therapeutic 
response following treatment with antidepressants is that cognitive changes, 
which may occur within hours after administration, mediate the antidepressant 
response (Amado-Boccara et al., 1995; Harmer et al., 2003b). Very brief (one 
day or one week) treatment with a serotonergic antidepressant caused selective 
changes in emotional information processing, in particular changes in the 
recognition of facial expressions of emotions (Bhagwagar et al., 2004; Harmer 
et al., 2004). It may take a number of days or weeks for these changes to build 
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up to a clinical (mood) effect (Harmer et al., 2003a). This hypothesis receives 
indirect support from research showing that experimental lowering of 
serotonin may also lead to cognitive changes in the absence of changes in 
mood (Hayward et al., 2005; Murphy et al., 2002; Park et al., 1994). 
In the psychological treatment of depression the emphasis lies on 
reducing negative cognitions and information processing biases. The research 
on the immediate cognitive effects of antidepressant treatment suggests that 
similar effects may occur in pharmacotherapy (Harmer et al., 2003b). This idea 
remains speculative but is the basis for recent studies on the acute cognitive 
effects of antidepressants and hypotheses about their relation to a clinical 
response (Bhagwagar et al., 2004; Harmer et al., 2002; Harmer et al., 2003a; 
Harmer et al., 2003b). To test this idea, cognitive functions should be 
measured in patients before starting on an SSRI and for the first few weeks of 
treatment, to investigate whether any changes in emotional information 
processing are related to subsequent mood response. If clinical outcome can be 
predicted on the basis of short-term changes in emotional processing, earlier 
switching to another antidepressant may become feasible. However, such a 
study seems premature considering how little is known of the relation between 
cognitive and mood effects following SSRI treatment.
SSRIs may regulate emotional information processing by activating 
plasticity processes via brain-derived neuroptrophic factor (BDNF) in neural 
networks associated with mood regulation. Serum BDNF is suggested to 
influence plasticity. Structural alterations in neuronal plasticity occur in patients 
with mood disorders (Sheline et al., 1999). Supporting this notion are findings 
that indicate baseline levels of serum BDNF in depressed patients were 
significantly lower than those of controls (Gonul et al., 2005). However, after 
eight weeks of SSRI treatment serum BDNF levels had increased significantly 
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and differed no longer from those of controls. The exact timeline of the 
changes in BDNF is of yet unknown but seems to resemble that of clinical 
response and may thus be slower than the process of receptor desensitisation. 
Also a post-mortem study found increased BDNF expression in hippocampal 
regions at the time of death in patients treated with antidepressants compared 
to untreated patients (Chen et al., 2001). It was therefore concluded that 
antidepressants may normalize hippocampal levels of this important 
neuroprotective factor. Animal studies showed that chronic stress and chronic 
antidepressant treatment are associated with long-lasting changes in BDNF 
gene expression in the hippocampus (Tsankova et al., 2006). Since the 
hippocampus contributes to altered mood in depression and to cognitive 
function (Duman, 2004), a possible link between SSRIs, emotional processing 
and plasticity is suggested. 
The aim of the present paper is to review the available evidence 
concerning the hypothesis that cognitive changes mediate the effects of 
antidepressant treatment. This hypothesis is based on three assumptions. The 
first assumption is that serotonin manipulations (in particular the 
administration of antidepressants) have reliable effects on emotional 
information processing. The second is that these effects are also observed in 
currently depressed patients starting antidepressant treatment. The third 
assumption is that the cognitive effects of antidepressants predict clinical 
outcome.  No studies have yet addressed the third assumption. We will 
therefore focus our review on the first two assumptions, and summarize the 
studies that measured short-term effects of serotonin manipulations on 
emotional information processing and mood and the effects of 
pharmacotherapy on emotional information processing and mood in 
depression. We will first briefly summarize the cognitive dysfunctions that are 
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associated with depression, which is necessary to assess whether any cognitive 
changes induced by serotonin manipulations are clinically relevant. In addition, 
different aspects of emotional information processing related to depression will 
be discussed.
Neutral and emotional information processing in depression
Cognitive dysfunctions (eg. dysfunctions in the processing of neutral as 
opposed to emotional information) associated with depressive disorders have 
been subject of many studies (Deuschle et al., 2004; Elliott, 1998; Paradiso et 
al., 1997).  Clear conclusions on the exact cognitive dysfunctions are difficult to 
draw because of the large differences among studies in subject samples, 
methods and design. Also, most tests are linked to a number of different 
cognitive domains, making it difficult to clarify the primary deficit when 
performance is impaired (Austin et al., 2001). Cognitive dysfunctions that are 
often impaired in depression include memory, learning, attentional set-shifting, 
psychomotor speed, sustained attention, and complex problem solving (Austin 
et al., 2001; Weiland-Fiedler et al., 2004). Effortful executive tasks, which are 
related to the functioning of the prefrontal cortex, are most often impaired 
(Elliott, 1998). Cognitive impairments are also found in recovered depressed 
patients; however these effects are usually statistically non-significant after 
controlling for residual depressive symptoms, except for attentional deficits 
(Paelecke-Habermann et al., 2005; Weiland-Fiedler et al., 2004).
Apart from dysfunctions in the processing of neutral information, 
dysfunctions in emotional information processing have also been studied 
extensively. The earliest studies investigated a mood-congruent memory bias: 
depressed patients have a better memory for disorder-related information 
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(Blaney, 1986; Bower, 1981; Teasdale, 1983), and impaired memory for 
positive information (Matt et al., 1992).
Depressed patients also have difficulties in retrieving specific 
autobiographical memories (Brittlebank et al., 1993; Kuyken & Dalgleish, 1995; 
Williams & Scott, 1988). This deficit may even persist into the euthymic phase 
(Peeters et al., 2002) and predicts depressed mood after a stressful life event 
(Van Minnen et al., 2005). 
Compared to healthy volunteers, depressed patients are impaired in the 
recognition of facial expressions of emotions. Both a general deficit in the 
recognition of emotions as well as emotion-specific impairments have been 
found (Bouhuys et al., 1999; Gur et al., 1992; Persad & Polivy, 1993; Rubinow 
& Post, 1992). A recent study showed subtle impairments in discrimination 
accuracy as well as a bias away from the identification of happy faces 
(Surguladze et al., 2004). 
Murphy et al. (2001) investigated decision making in manic and 
depressed patients and healthy controls using a gambling task. Both patient 
groups showed delayed deliberation times and altered betting strategies, 
however only the manic patients were impaired in the quality of their decisions. 
In the depressed and the control group, the subjects who were slowest were 
also the ones that made suboptimal decisions.
Depressed patients have been found to show an attentional bias for 
negative stimuli. This bias is thought to be not only a symptom of depression, 
but also to be important in the development and maintenance of depressive 
disorders (Williams et al., 1996). The literature on attentional bias in depression 
is contradictory, which may be explained by the fact that different measures of 
attentional bias (e.g. the Stroop and the dot-probe test) are not necessarily 
inter-correlated and may even assess different constructs (Gotlib et al., 2004). 
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Higher-order cognitive processes in depression are also distorted: 
depressed patients hold negative schemas about oneself, the world and the 
future (Beck, 1976). These dysfunctional cognitions can be assessed with the 
Dysfunctional Attitudes Scale (DAS) (Beck, 1976; Weissman, 1979). In acutely 
depressed patients, DAS scores are significantly increased compared to healthy 
controls; however they normalize following clinical recovery. When negative
mood increases, the level of dysfunctional attitudes has been found to increase 
more in recovered depressed patients than in healthy controls (Ingram et al., 
1998). This increase in DAS scores in response to relatively small 
deteriorations of mood has been labelled cognitive reactivity (CR). Higher CR 
scores have been associated with an increased risk of relapse in recovered 
depressed subjects (Segal et al., 2006). 
Overall, depressed patients show impairments in several cognitive 
domains, such as memory, learning, attentional set-shifting, psychomotor 
speed, sustained attention, planning, inhibitory control and problem solving. 
Impairments in emotional information processing include the recognition of 
facial expressions of emotions, attentional bias toward negative material, an 
over-general autobiographical memory, an increased level of dysfunctional 
attitudes and impaired decision making. Only some of these impairments are 
detectable in remitted depressed patients.
As noted above, the framework of this review is the hypothesis that 
cognitive changes mediate the antidepressant response. Because of a lack of 
studies directly testing this hypothesis, we will review studies 1) on the short-
term effects of serotonin manipulations on emotional information processing 
and mood in healthy and depression-vulnerable individuals and depressed 
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patients, and 2) on the changes in emotional information processing and mood 
in depressed patients starting antidepressant treatment. 
Methods
A literature search was performed with PubMed and PsycInfo databases (1966-
2006) using the following key words: serotonin, depression, emotional 
information processing, cognition, SSRI, and tryptophan.  We also searched 
reference lists of papers that seemed suitable to review. Twenty-five studies 
were identified through this combined search strategy to be eligible for 
inclusion in this review. The first study was published in 1994 and the most 
recent studies were published in 2006. Studies were divided into four classes on 
the basis of the manipulation that was used: 
- four studies on short-term effects of administration of a serotonergic 
antidepressant (SSRI)  
- two studies using a serotonin-receptor agonist or antagonist
- three studies using dietary manipulations (e.g. tryptophan loading) 
- sixteen studies using acute tryptophan depletion (ATD)
Results
All studies including their subject sample, methods, outcome measures and 
results are shown in Table 1.
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Table 1. Effects of serotonin manipulations on emotional information processing and mood




n = 25 healthy 
women
Citalopram (10 mg) 
vs. saline (5 ml); 
single, intravenous 
administration          
- Facial expression recognition 
task
- VAS scales, BFS
A better and faster recognition of 
fear and happiness was found after 




n = 20 unmedicated 
euthymic women 
with a history of 
MDD  
n = 20 healthy 
women
Citalopram (10 mg) 
vs. saline; single, 
intravenous 
administration                 
- Facial expression recognition 
task
- VAS scales    
Citalopram decreased recognition 
of fear in recovered depressed 
subjects and increased fear 
recognition in healthy subjects; 
citalopram increased subjective 








reboxetine (8 mg/day) 
vs. placebo; 7 days, 
oral administration
- Facial expression recognition 
task
- Emotional categorization 
task
- Emotional memory
- Emotion potentiated startle 
- STAI, BDHI, BDI, PANAS, 
SASES, BFS
Citalopram and reboxetine 
reduced recognition of anger and 
fear and increased recall of positive 
material. Citalopram abolished the 
emotional startle response to 
negative stimuli. Reboxetine 
decreased subjective feelings of 
hostility and increased energy.
172 Table 1. (continued)
Authors Sample Intervention Outcome measures Results
Harmer et 
al. (2006a)
n = 24 healthy 
volunteers
citalopram (20 
mg/day) vs. placebo; 7 
days, oral 
administration
- Masked facial expression 
recognition task
- Facial expression recognition 
task
- STAI, BDHI, BDI, BFS, 
VAS scales
Citalopram attenuated the neural
response to fear, decreased the 
recognition of fearful facial 
expressions and reduced subjective 
hostility.
5-HT receptor agonist / antagonist studies
Meyer et al. 
(2003)
1) n = 29 healthy 
volunteers
2) n = 22 
unmedicated 
depressed subjects; 
n = 18 subjects 
with a history of 
self-harm; n = 29 
healthy volunteers
d-fenfluramine (0.3 
mg/kg) vs. clonidine 
(1.4 μg/kg) ; single 
intravenous 
administration    
- Dysfunctional attitudes scale 
- VAS scales 
- Dysfunctional attitudes scale 
- cortex 5-HT2 receptor
binding potential using 
[18F]setoperone PET
- HAM-D
DAS scores decreased after 
administration of d-fenfluramine 
compared to placebo.
Depressed subjects with high DAS 
scores had higher 5-HT2 BP 
compared to healthy subjects.
Harmer et 
al. (2006b) 
n = 24 healthy 
volunteers
Ondansetron (12 mg) 
vs. lactose; single, oral 
administration
- Facial expression recognition 
task
- Emotional categorization 
task
- Emotional memory
- Emotion potentiated startle 
- STAI, VAS scales
Ondansetron diminished the 
emotion potentiated startle. No 
effects were found on mood, facial 













- Digit span/ spatial spana
- Letter cancellation task
- Spatial working memory 
- Affective working memory
- Verbal fluency
- Finger tapping test
- Grooved pegboard test
- PANAS
Both tryptophan loading and ATD 
decreased positive affect. ATD 
increased motor performance. 
Tryptophan decreased motor 
coordination and verbal and 
affective working memory (only 




n = 38 healthy 
volunteers
Tryptophan (1 g 
3x/day) vs. placebo; 
14 days, oral 
administration
- Facial expression recognition 
task
- Emotion potentiated startle 
- Attentional probe task
- Emotional categorization
- Emotional memory
- Dysfunctional attitudes scale 
- PANAS, STAI, BDHI, BDI, 
BFS
Tryptophan increased the 
recognition of happiness, 
decreased the recognition of 
disgust in females, reduced 
attentional vigilance to negative 
words and decreased baseline 
emotional startle response. No 
effects on mood or dysfunctional 
attitudes were found.
174 Table 1. (continued)
Authors Sample Intervention Outcome measures
ATD studies
Park et al. 
(1994)
n = 12 healthy men ATD vs. placebo - Spatial working memory test
- Tower of London
- Visual discrimination test 
(attentional set shifting)
- Paired associated learning
- Pattern and spatial 
recognition test
- Rapid visual information 
processing
- Autobiographical memory 
test
- VAS scales
ATD selectively impaired learning 
and retrieval. No effects on mood 
were found.
Coull et al. 
(1995) 
n = 12 healthy 
volunteers
ATD vs. placebob - Emotional selective attention 
task 
ATD reduced reaction times to 
incompatible stimuli, but not to 
compatible stimuli. (independent 
of emotional valence). No effects 
on focused attention were found.
Rogers et al. 
(1999a) 
n = 31 healthy 
volunteersc
ATD vs. placebo - Decision making task ATD impaired decision making: 
the tendency to choose the least 




Authors Sample Intervention Outcome measures Results
Rubinsztein 
et al. (2001)
n = 30 healthy 
volunteers
ATD vs. placebo - Affective go/no-go task
- Visual pattern recognition 
task
- POMS, VAS scales
ATD impaired ‘maintenance of 
set’ and visual delayed recognition. 
No effect on mood was found.
Klaassen et 
al. (2002)
n = 16 healthy 
volunteers (FH+)1
n = 11 healthy 
volunteers (FH-)
ATD vs. placebo - Visual verbal learning test 
(positive and neutral words)
- POMS
ATD lowered mood in FH+ 
subjects and impaired delayed 
recall of neutral and positive words 




n = 12 healthy 
women
ATD vs. placebo - Probability reversal task
- Affective go/no-go task
- Tower of London
- HAM-D, VAS scales
ATD slowed the processing of 
happy material and slowed 
responding in a visual 
discrimination and reversal 
learning task. No effects on 
planning or mood were found.
Anderson et 
al. (2003) 
n = 28  healthy 
volunteers




n = 38 healthy 
volunteers
ATD  vs. placebo  - Facial expression recognition 
task
- PANAS
ATD impaired recognition of fear 
only in women. No effects on 
reaction times or mood were 
found.
176 Table 1. (continued)
Authors Sample Intervention Outcome measures Results
Rogers et al. 
(2003)
n = 18 healthy 
volunteers
ATD vs. placebo - Decision making task ATD impaired decision making.
Booij et al 
(2005c)





- Self-referent adjectives 
encoding and recall task
- MADRS, BAS, CPRS, BDI-
II, PANAS
High-dose ATD decreased the 
consistency of positive trait ratings 
and decreased immediate recall of 
positive words in mood-
responders.
Booij et al. 
(2005a)





- Tower of London
- Stroop task (neutral and 
emotional)
- Abstract patterns recognition 
task
- Letter fluency
- Left/right choice reaction 
time
- MADRS
High-dose ATD impaired the 
processing of positive information, 
independent of mood change. 
ATD improved attention for 
neutral information in a dose-
dependent manner. High-dose 
ATD increased depressive 
symptoms in a subgroup of 
patients.
Evers et al. 
(2005)
n = 15 healthy 
volunteers
ATD vs. placebo - Probabilistic reversal 
learning task
- Visual verbal learning test 
(positive and neutral words)
- Abstract pattern learning 
task 
- VAS version of POMS
ATD increased reaction times for 
delayed recognition on verbal 




Authors Sample Intervention Outcome measures Results
Hayward et 
al. (2005)
n = 24 unmedicated 
recovered 
depressed patients
n = 24 healthy 
volunteers
Low-dose ATD vs. 
placebo
- Stroop task (neutral and 
emotional)
- Emotional memory task 
- Auditory verbal learning task
- Emotion potentiated startle
- Facial expression recognition 
task
- BDI, POMS, VAS scales, 
HAM-D
Low-dose ATD did not affect 
mood. ATD produced an elevation 
of the startle response, impaired 
recognition of happiness, impaired 
initial recall memory and increased 
emotional interference in the 
recovered depressed group. In 
healthy subjects, ATD enhanced 
recognition of happiness and 
increased emotional interference.
Talbot et al. 
(2006)
n = 32 healthy 
volunteers
ATD vs. placebo - Decision making task
- ID/ED attentional set-
shifting task
- VAS scale
ATD improved decision-making. 
No effects on risk taking, speed of 
decision making, set-shifting, 
reversal learning or mood were 
found.
Evers et al. 
(2006) 
n = 15 healthy 
women
ATD vs. placebo - Stroop task (neutral and 
emotional)
- POMS
ATD increased interference for 
negative words and decreased 
interference on the neutral Stroop. 
No effect on mood was found.
178 Table 1. (continued)
Authors Sample Intervention Outcome measures Results
Munafò et 
al. (2006)  
n = 24 medicated 
recovered 
depressed patients
n = 24 unmedicated 
recovered 
depressed patients
n = 24 healthy 
volunteers
Low-dose ATD vs. 
placebo
- Stroop  task (emotional) 
- BDI, POMS, VAS scales, 
HAM-D
ATD increased the processing of 
social threat cues and self-rated 
depression only in medicated 
recovered depressed patients.
BAS = Brief Anxiety Scale, BDI = Beck Depression Inventory, BDHI = Buss-Durkee Hostility Inventory, BFS = Befindlichkeits 
Scale, CPRS= Comprehensive Psychopathological Rating Scale, HAM-D = Hamilton Rating Scale for Depression, MADRS = 
Montgomery-Asberg Rating Scale for Depression, MDD = Major Depressive Disorder, PANAS = Positive and Negative Affect 
Scale, POMS = Profile of Mood States, SASES = Social Adaption Self Evaluation Scale, STAI = State-Trait Anxiety Inventory, 
VAS = Visual analogue scale, 1 FH = Family history of major affective disorder, 
a Neuroendocrine measures were also taken but are not reported here, b The effects of clonidine, diazepam and haloperidol were 
also studied but are not reported here, c Amphetamine users, opiate users, frontal subjects and ORB-PFC patients were also 
included but these results are not reported here. 
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Selective serotonin reuptake inhibitor studies
It has long been known that antidepressant medications have effects on 
cognitive function. For instance, a review by Thompson (1991) shows a wide 
range of effects of antidepressants on memory. The effects varied from 
improvement to no effect to impairment, and there was limited evidence for 
specific effects of different antidepressants. In patients with memory 
impairments, SSRIs possibly had a positive effect on memory (Thompson, 
1991). Amado-Boccara et al. (1995) also reviewed the effects of antidepressants 
on –neutral- cognitive performance. They concluded that serotonergic 
antidepressants either had no effect on reaction time tasks and psychomotor 
functioning or caused small improvements. The authors noted that the acute 
effects differed from the effects on the middle and long- term. For most 
antidepressants a tolerance effect occurs after a week or two. In depressed
individuals who often suffer from impairments in memory and concentration, 
a normalization of cognitive function accompanies mood improvement 
following long-term administration of an SSRI. 
More recent research has focused on the acute effects of SSRIs on the 
processing of emotional, in contrast to neutral, information (Bhagwagar et al., 
2004; Harmer et al., 2003a). This seems to yield more consistent findings. 
Harmer et al. (2003a) investigated the effects of intravenous administration 
(over 30 minutes) of 10 mg citalopram or saline (placebo) on mood and 
information processing in healthy women. Participants completed the 
assessments 30 minutes after the end of the infusion. Compared to placebo, 
participants were better and faster at recognizing facial expressions of 
happiness following citalopram. Contrary to expectation, the recognition of 
fearful facial expressions also improved. No immediate effects of citalopram 
on mood were observed. Bhagwagar et al. (2004) compared the effects of 
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citalopram on facial expression recognition in women with and without a 
history of depressive episodes. A single dose of citalopram or placebo was 
administered intravenously and effects were measured 30 minutes after the 
infusion. The women with a history of depression showed a better recognition 
of fear at baseline compared to healthy women, which was normalized 
following administration of citalopram. This effect was opposite to the effect 
seen in the healthy women, in whom the recognition of fear increased 
following citalopram. Subjective anxiety levels were increased after citalopram 
in both groups, although this effect tended to be stronger in the participants 
with a history of depression. These results suggest that a negative cognitive 
bias may persist into the euthymic phase and that this cognitive vulnerability is 
sensitive to antidepressant administration. The authors suggested that the 
effect of the antidepressant on the processing of fear (increasing vs. 
decreasing) may be dependent on baseline levels of fear processing. This 
however was not tested and no other studies have reported baseline levels of 
facial emotion recognition to be of influence on the response to serotonergic 
modulation. 
Harmer et al. (2003a) suggest that changes in the processing of 
emotional information may occur independently of changes in mood. Also, 
there appear to be significant differences between the acute effects of SSRI 
administration and the effects of repeated (‘sub-chronic’) SSRI administration. 
A seven-day administration of citalopram (20 mg/day) or the selective 
norepinephrine reuptake inhibitor (SNRI) reboxetine (8 mg/day) in healthy 
volunteers resulted in a decreased recognition of anger and fear, and an 
increased memory for positive material (Harmer et al., 2004). Citalopram also 
abolished the increased startle response to negative stimuli. Mood and anxiety 
were not significantly affected. Another study also found decreased recognition 
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of fear after a seven-day administration of citalopram (20 mg/day) compared 
to placebo, which was accomplished by a reduced neural response to fear 
measured by functional Magnetic Resonance Imaging (fMRI). Citalopram also 
reduced subjective hostility (Harmer et al., 2006a). A single dose of an SSRI 
however resulted in increased levels of fear recognition in healthy subjects 
(Harmer et al., 2003a). These effects of SSRIs on the processing of fearful 
facial expressions are mirrored in the initial increase of symptoms of anxiety 
during the early phase of SSRI treatment before these and other symptoms 
eventually decrease (Bagdy et al., 2001; Humble & Wistedt, 1992). However, a 
single dose of an SSRI not only increased fear recognition but also the 
recognition of happiness (Harmer et al., 2003a). This might indicate that 
serotonin manipulations have a general effect on perception rather than a 
specific effect on the recognition of certain –positive or negative- emotions. 
The fact that serotonin affects a positive and negative emotion in the same 
direction, may also indicate that there are two separate processes. On the one 
hand an effect of SSRIs on fear recognition, which reverses from acute to 
repeated administration. On the other hand there is a positive effect of SSRIs 
on affective processing (i.e. on the recognition of happy facial expressions, 
emotional memory and attentional bias) which is seen very early with 
antidepressant drug administration and is still observed after 1 week of 
treatment. It remains to be seen which of these effects is related to clinical 
improvement, if any. 
Conclusion
Short-term administration of an SSRI increases the processing of fear 
and happiness in healthy individuals and decreases the processing of fear in 
recovered depressed women. Sub-chronic administration of an SSRI in healthy 
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subjects results in opposite effects compared to acute administration, e.g. a 
decreased recognition of anger and fear. Mood is affected by SSRI 
administration but only in recovered depressed patients and independent of 
emotional information processing. 
Serotonin receptor agonist / antagonist studies
Challenge procedures using 5-HT receptor agonists and antagonists have been 
widely used. Apart from neuro-endocrine effects, cognitive effects have also 
been investigated, but rarely. Riedel et al. (2002) found that the 5-HT2c agonist 
metachlorophenylpiperazine (m-CPP), but not the 5-HT1a agonist ipsapirone 
selectively increased depression and tension in depressed patients. Ipsapirone 
however impaired immediate recall in controls but improved immediate recall 
in depressed patients. m-CPP impaired signal detection efficiency in controls 
but not in patients in a visual search task and impaired reaction times in both 
groups on a choice reaction time task. These results support the hypothesis 
that depression is associated with 5-HT1a receptor desensitisation and 5-HT2c
receptor sensitisation. 
Meyer et al. (2003) investigated the effects of d-fenfluramine vs. 
clonidine (an α2 receptor agonist, as a placebo) on dysfunctional attitudes 
(measured with the DAS) and 5-HT2 receptor binding potential (BP) in the 
cortex. Three different groups were studied: unmedicated depressed patients, 
patients with a history of self-injurious behaviour outside of a depressive 
episode (all with an Axis II diagnosis of Borderline Personality Disorder) and 
healthy controls. The rationale for this study was based on the finding that 
suicide victims with and without major depressive episodes have elevated levels 
of 5-HT2 receptor density in the prefrontal cortex (Arango et al., 1990; Hrdina 
et al., 1993). Since higher levels of dysfunctional attitudes are found in 
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depressed patients with and without suicidal tendencies, the authors 
hypothesized that 5-HT2 BP and dysfunctional attitudes may be related. 
Results showed that dysfunctional attitudes improved significantly more after 
d-fenfluramine compared to clonidine in healthy subjects. No effects on 
subjective mood were found. In a second experiment, dysfunctional attitudes 
were found to be strongly related to 5-HT2 BP in all cortex brain regions in 
depressed patients. This was not true for patients with a history of self-harm 
and healthy controls. A subgroup of depressed patients with high DAS scores 
had greater 5-HT2 BP in all investigated brain regions compared to healthy 
controls. These results indicate a relationship between serotonin and the level 
of dysfunctional attitudes. Also, depressed patients with high levels of 
dysfunctional attitudes showed low levels of 5-HT agonism and higher 5-HT2
BP compared to healthy subjects. In the patients with self-injurious behaviour, 
cortex 5-HT2 BP was unrelated to the levels of dysfunctional attitudes. The 
authors concluded that a deregulated neuromodulation of serotonin seems to 
play an important role in the pathophysiology of dysfunctional attitudes. This 
might indicate that SSRI-treatment affects the same cognitive processes which 
are also the focus of cognitive therapy. Simons et al. (1984) have found that 
antidepressant therapy and cognitive therapy resulted in similar changes on 
various measures, including dysfunctional attitudes. Again, the results of this 
study suggest that cognitive processes are sensitive to changes in serotonin 
function. Recently, more evidence was found to support the link between 5-
HT receptor BP and dysfunctional attitudes (Bhagwagar et al., 2006). 
Recovered depressed patients demonstrated elevated cortical 5-HT2A receptor 
BP compared to healthy volunteers and 5-HT2A BP correlated positively with 
DAS scores only in recovered depressed patients. However, future research is 
needed since no other studies have looked at the acute reactivity of 
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dysfunctional attitudes following manipulations of serotonin function, e.g. 
soon after initiating SSRI treatment.  Also, the link between 5-HT2 BP and 
dysfunctional attitudes was only significant in a small subgroup of depressed 
patients (those with a high level of dysfunctional attitudes). No link between 
cortex 5-HT2 BP and DAS scores in patients with chronic self-harm behaviour 
was found. The authors suggested that the extreme psychological factors 
playing a role in borderline personality disorder may obscure the relationship 
between dysfunctional attitudes and serotonin. Also, other serotonin 
abnormalities that do not influence 5-HT2 BP may play a role. 
One study investigated the effects of a serotonin receptor antagonist 
on emotional processing (Harmer et al., 2006b). Healthy volunteers were given 
either 12 mg ondansetron (a 5HT3 antagonist) or placebo orally. The effects on 
facial emotion recognition, emotional categorization and memory and emotion 
potentiated startle were assessed as well as mood. Results indicated that 
ondanstron reduced the emotion potentiated startle, especially in response to
negative pictures. Contrary to the effects of acute SSRI administration, no 
effects were found on facial emotion recognition. Also no effects were found 
of ondansetron on mood or emotional memory. These results suggest a role 
for 5HT3 receptors in some elements of fear processing. However other 
measures of emotional processing, for example the recognition of fearful facial 
expressions, may depend on different mechanisms; for example more 
interpretative strategies than the emotion potentiated startle, which is a more 
automatic process (Harmer et al., 2006b).
Conclusion
Increasing serotonin function by administration of d-fenfluramine, 
results in decreased levels of dysfunctional attitudes in healthy subjects. Also, 
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high serotonin receptor binding potential is associated with more dysfunctional 
attitudes in depressed individuals, but not in healthy subjects and borderline 
patients with a history of self-harm. These results are not confounded by any 
effects on mood. A study on the effects of ondansetron suggests a role for 
5HT3 receptors in other, more automatic aspects of fear processing. 5HT2 and 
5HT3 receptors may thus play separate roles in the effects of serotonergic 
manipulations on mood and cognition.
Tryptophan augmentation studies
Increasing serotonin function by raising plasma levels of its precursor 
tryptophan can be achieved with different methods. Tryptophan loading 
studies mostly administer L-tryptophan intravenously or orally. Plasma 
tryptophan levels can also be elevated through administration of alpha-
lactalbumin, a milk whey rich in tryptophan (Heine et al., 1996). Both methods 
have proven to be effective in raising plasma tryptophan levels and the ratio of 
tryptophan to the large neutral amino acids (LNAAs). Compared to casein 
(placebo), a diet rich in alpha-lactalbumin was found to increase the plasma 
tryptophan/LNAA ratio by 73.8% (Merens et al., 2005). Alpha-lactalbumin 
improved memory scanning in healthy, stress-vulnerable subjects compared to 
placebo (Markus et al., 2002) and improved abstract visual memory and slowed 
simple motor performance, without affecting mood in both recovered 
depressed patients and healthy controls (Booij et al., 2006a). Attenburrow et al. 
(2003) investigated the effects of an 80% tryptophan powder derived from 
milk whey (approximately 1.8 g tryptophan) on facial expression recognition in 
healthy females. This resulted in enhanced recognition of fear and happiness 
compared to placebo. These results are similar to the effects of acute SSRI 
administration on recognition of fear and happiness (Harmer et al., 2003a). 
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The results are also in line with the effects of a fourteen days intervention with 
tryptophan in healthy volunteers by Murphy et al. (2006) who found that the 
recognition of happiness was increased and the recognition of disgust was 
decreased, but only in females. Tryptophan administration also decreased 
attentional vigilance toward negative stimuli as well as baseline emotional 
startle response. Mood was not affected, neither was the level of dysfunctional 
attitudes (Murphy et al., 2006). 
Luciana et al. (2001) compared the effects of tryptophan loading with 
the effects of tryptophan depletion on cognitive functioning, mood and 
neuroendocrine measures (prolactin and cortisol) in healthy participants. 
Tryptophan loading impaired working memory performance of negative 
stimuli and fine motor coordination and improved immediate vigilant 
attention. Both tryptophan loading and depletion resulted in a slight decrease 
of positive affect, leading the authors to conclude that the observed changes in 
cognitive function were not related to any changes in mood. However, because 
of a lack of a placebo condition, the results of this study may be inflated. 
Conclusion
In healthy subjects enhancement of the serotonin precursor may lead 
to impaired affective working memory but also to enhanced attention and 
recognition of fear and happiness. Sub-chronic effects include an increased 
recognition of happiness and a decreased recognition of disgust as well as a 
decreased processing of negative stimuli. These cognitive changes seem to be 
unrelated to changes in mood. Tryptophan loading seems to have a broader 
range of effects on cognitive performance compared to the effects of receptor-
agonist and -antagonist administration. 
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Acute tryptophan depletion studies
Experimental depletion of the serotonin precursor tryptophan has been found 
to decrease plasma tryptophan levels by 70-90% in 5-6 hours (Young et al., 
1989). Acute tryptophan depletion (ATD) is therefore a useful tool to 
investigate the effects of lowered serotonin function in humans. ATD results 
in a temporary depressive relapse in 50-60% of recovered depressed patients 
taking serotonergic antidepressants (Delgado et al., 1990; Van der Does, 
2001a). In healthy subjects, only small mood effects are found and particularly 
in subjects with a family history of affective disorders (Ellenbogen et al., 1999; 
Klaassen et al., 2002). In acutely depressed patients, ATD did not worsen 
symptoms on the test day, however a delayed effect was observed the next 
morning in a minority of patients (improvement and worsening) (Delgado et 
al., 1994). A delayed mood improvement was also found in depressed patients 
treated with venlafaxine (Booij et al., 2005b). The effects of ATD on mood are 
congruent with the expected effects of lowered serotonin function. One 
question we aim to answer in this paper is whether the same is true for the 
cognitive effects following ATD.
Tryptophan and cognitive performance are associated in a complex 
manner: differential results are observed across cognitive functions and subject 
groups. Experimental manipulations of tryptophan seem to affect temporal 
and frontal cognitive functions (memory consolidation and working memory 
for example) in opposite ways. ATD affects the processing of neutral 
information in healthy subjects; it especially impairs memory consolidation and 
improves focussed attention (Harrison et al., 2004; Riedel et al., 1999; Schmitt 
et al., 2000). These effects have been repeatedly reported and support a specific 
role for serotonin in memory and learning and not in executive (frontal-lobe) 
functions. However, because of the variation in cognitive tests used, drawing 
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strong conclusions on the effects of ATD on cognitive function remains 
problematic.
Effects of ATD in healthy subjects
A wide range of studies have been done on the cognitive effects of 
ATD in healthy participants but only a few reported effects of ATD that were 
dependent of the emotional valence of the stimuli. Murphy et al. (2002) found 
slowed responses to happy but not sad target words in the affective go/no-go 
task following ATD in healthy female volunteers. ATD also slowed responding 
in a visual discrimination and reversal learning task, in absence of a change in 
mood. These findings were in line with an earlier study that found increased 
reaction times for happy but not sad targets in depressed patients compared to 
healthy controls (Murphy et al., 1999). Rubinsztein et al. however did not find 
a differential effect of ATD on target valence using the same affective go/no-
go task (Rubinsztein et al., 2001).
Harmer et al. (2003c) used a facial expression recognition task to test 
the effects of ATD in healthy subjects. Two competing hypotheses were 
formulated by the authors. The first stated that since administration of an SSRI 
resulted in increased fear recognition, ATD should result in decreased fear 
recognition (Harmer et al., 2003a). However, since acute administration of an 
SSRI can have the paradoxical effect of decreasing synaptic serotonin levels 
through activation of auto-receptors, ATD may also result in increased
recognition of fear. Results showed that, ATD decreased the recognition of 
fear, but only in females. The speed of recognition of fear was slowed in all 
subjects. No effects on mood were found. These results are in line with the 
finding that increased serotonin function increases the processing of fear. As a 
possible explanation for the specific effects in women, the authors noted that 
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the effects of ATD on mood are also greater in women, possibly resulting 
from greater reductions in serotonin synthesis following ATD in women 
compared to men (Ellenbogen et al., 1996; Nishizawa et al., 1997). One 
methodological remark should be made regarding this study.  The effects of 
ATD on the accuracy of facial emotion recognition may have been even more 
complex. The interaction effect of emotion x drink in females was not 
significant (p = 0.1). However, separate analyses per emotion revealed a 
significant effect of ATD on fear recognition. In males the interaction effect of 
Emotion x Drink was also not significant (p = 0.13). However, no separate 
analyses were performed in this group, suggesting that a significant effect of 
ATD on one of the emotions in males may have been overlooked. Looking at
the graphic display of the accuracy data, ATD may have increased the 
recognition of anger and surprise in males. 
Park et al. used a variety of neutral tests and found that ATD 
selectively impaired learning and retrieval in healthy male volunteers. However, 
no effect was found on the specificity of autobiographical memory (Park et al., 
1994). Coull et al. (1995) found that, using an emotional selective attention 
task, ATD reduced reaction times to incompatible stimuli but this effect was 
independent of the emotional valence of the distractor words. Evers et al. 
found that speed of delayed recognition on a verbal learning task was slowed 
following ATD, but again no differential effect was found for word valence 
(Evers et al., 2005). In another study ATD improved performance on a neutral 
Stroop task but increased the interference for negative words in an emotional 
Stroop task (Evers et al., 2006). Hayward et al. also found an increased negative 
attentional bias in healthy subjects in response to ATD, together with an 
enhanced recognition of happiness (Hayward et al., 2005). These results are in 
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line with result from studies in depressed patients, showing an emotional 
processing bias towards negative stimuli (e.g. Murphy et al., 1999).
Effects of ATD on decision making
Rogers et al. (1999a) used a gambling task to investigate the effect of 
ATD on decision making in healthy subjects. Results showed that tryptophan 
depleted subjects had an increased tendency to choose the least probable 
outcome and a trend toward increased deliberation times compared to the 
placebo group. These impairments partly resembled the performance of 
amphetamine abusers and patients suffering from damage to the orbitofrontal-
prefrontal cortex. Results from animal and human studies indicate that the 
difficulty with decision making in chronic amphetamine abusers may result 
from altered serotonergic modulation of the ventral PFC and its connected 
structures (Groenewegen et al., 1997; Hotchkiss & Gibb, 1980). 
In a recent study on decision making by Rogers et al. (2003), a novel 
version of the gambling task was used that allows for an examination of 
separate mechanisms that play a role in decision making: the magnitude of 
expected gains and losses and the probability to which these outcomes are 
delivered. ATD resulted in an impaired capacity to discriminate between 
magnitudes of expected gains, associated with different choices. ATD was not 
associated with altered discrimination between the magnitudes of expected 
losses, or altered discrimination with the relative probability with which these 
positive or negative outcomes occurred. Risk-averse and risk-seeking bias were 
also unaffected by ATD. The authors concluded that decreased serotonin 
function leads to altered modulation of cortical and subcortical regions that 
mediate important aspects of associative learning. They suggested that decision 
making may be influenced by monoaminergic systems, possibly involving 
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changes in the modulation of the prefrontal cortex and the limbic-striatal 
circuit.
Another study investigated the effect of ATD on decision making, 
using the same gambling task as Rogers et al. and ID/ED attentional set 
shifting in healthy subjects (Talbot et al., 2006). Contrary to previous results, 
ATD improved decision making (subjects chose the more likely outcome more 
often following ATD compared to placebo). There was no effect of ATD on 
set-shifting, reversal learning, risk taking, impulsivity or mood. The 
contradiction between these results and the results of the Rogers et al studies 
(1999a; 2003) was suggested to be due to possible influences of trait 
characteristics of the individuals tested, such as aggression and genetic factors 
associated with a family history of alcoholism. Also, genetically determined 
variations in the effects of ATD on ventral PFC function (e.g. decision 
making) caused by, for example, serotonergic polymorphisms were suggested 
to play a role. Finally, there were differences between the studies in the 
exclusion of hormonal contraception, the permission of smoking and small 
differences in age and IQ (Talbot et al., 2006).
 Anderson et al. (2003) studied the effects of ATD on an imaginary 
gambling task in healthy subjects. No effects of ATD were found on the 
performance on this task, but the imaginary nature of the gambling task raises 
the question of whether this test is comparable to computerized gambling 
tests. 
These studies emphasize the need for further investigations of the role 
of serotonin in decision making. Other factors possibly confounding the 
contradictory results should also be investigated: e.g. characteristics of the 
subject sample such as age and gender; differences in design –between- or 
within-subjects- and task difficulty. 
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In healthy volunteers with and without a family history of affective 
disorders (FH+ and FH-) the effect of ATD on memory bias and mood was 
investigated (Klaassen et al., 2002). ATD led to a significant lowering of mood 
(at 6 hours after ingestion of the drink), especially in the FH+ subjects. ATD 
impaired the recall of neutral words (6 hours after ingestion of the ATD drink) 
and positive words (at +24 hours), but not of negative words in all subjects. 
There was no association between mood and affective memory bias. However, 
ATD did impair delayed recall for neutral words more in mood-responders (all 
FH+ subjects) than in non-mood responders. The authors suggested that 
depressed mood did not seem to mediate the cognitive disturbance. Also, since 
only delayed recall was affected, ATD seems to selectively influence 
consolidation and not retrieval.
Effects of ATD in remitted and recovered depressed subjects
Booij et al. (2005a) investigated the effects of a full strength tryptophan 
depletion drink compared to a quarter strength mixture (high-dose vs. low-
dose) on mood and cognitive function in medicated remitted depressed 
patients. The low-dose tryptophan depletion mixture consists of the same 
amino acids as the high-dose mixture, but at quarter strength following the 
method of Krahn et al. (1996). Most studies included in this review use a 
tryptophan containing amino acid mixture as a placebo (Murphy et al., 2002; 
Park et al., 1994; Rubinsztein et al., 2001) which causes a marked but highly 
variable increase of tryptophan levels. This means that most studies use an 
active condition rather than a neutral control condition, which is important 
when investigating subtle effects. A low-dose tryptophan mixture is also not a 
neutral procedure but results in a predictable moderate reduction of the 
tryptophan/LNAA ratio. Since the low-dose mixture has been found not to 
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affect mood (Booij et al., 2005a), it allows for an investigation of the dose-
response effects of lowered serotonin function and thus is a better control 
condition for some research questions.
Following high-dose ATD, a subgroup of patients experienced a 
temporary depressive ‘relapse’ (: responders) (Booij et al., 2005a). The 
processing of positive material was impaired independent of mood change, 
whereas in another study in healthy subjects ATD impaired attention for 
negative words (Evers et al., 2006). Attention for neutral stimuli improved in a 
dose-dependent manner in all patients, which is in line with the effects of ATD 
in healthy subjects (Evers et al., 2006). The authors suggested that ATD may 
affect mood and cognition through different pathways; one implicated in 
mood and the processing of emotional information and one implicated in the 
processing of neutral information. In another study, high-dose ATD decreased 
immediate recall of positive words in responders but not in non-responders. 
Also, high-dose ATD tended to decrease the consistency of positive trait 
ratings compared to low-dose ATD, but again only in responders (Booij et al., 
2005c). Another study investigated the effects of ATD in unmedicated 
recovered depressed patients and healthy controls (Hayward et al., 2005).  The 
recovered depressed subjects showed an elevated startle response, impaired 
short-term memory, increased negative attentional bias and impaired 
recognition of happy facial expressions. Independent of the effects of ATD, 
the recovered depressed subjects showed enhanced recognition of disgust 
compared to healthy controls and a lack of a positive bias in the recall of 
emotionally valenced words. No changes in mood were found following the 
low-dose tryptophan depletion.
Munafò et al. (2006) studied the effects of ATD on the processing of 
social threat cues in medicated and unmedicated recovered depressed subjects 
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and healthy controls. Compared to a control drink, the tryptophan depletion 
mixture increased the processing of social threat cues on an Emotional Stroop 
Task in the medicated recovered depressed subjects, as shown by an increased 
interference. In this group, also a small but significant increase in self-rated 
depression scores was found. The tryptophan depletion mix did not affect 
mood and emotional processing in healthy volunteers and unmedicated 
depressed subjects. The authors explained the effects by suggesting that ATD 
may remove the neurochemical support of continued medication usage among 
this group. Also, the two recovered depressed groups may differ in their 
underlying vulnerability to decreases in serotonin function. Important to note 
is that the medicated patient group in this study was not selectively treated with 
SSRIs but with different kinds of serotonergic antidepressants (eg. also tricyclic 
antidepressants); however patients taking selective noradrenergic medication 
were not included.
Conclusion
ATD affects a broad range of cognitive functions, both in healthy 
volunteers and in remitted depressed patients. However, not all functions are 
affected and there are between-group differences in effects. In healthy subjects, 
ATD affects facial emotion recognition, attention for neutral stimuli and 
attentional bias, in absence of any mood effects. ATD seems to impair decision 
making in healthy subjects, however results are conflicting. ATD lowered 
mood in FH+ subjects and impaired the recall of neutral and positive words, 
but not of negative words in both FH- and FH+ subjects. In recovered 
depressed subjects, ATD increased depressive symptoms and affected the 
processing of positive material; attention for neutral stimuli; startle response, 
initial memory, attentional bias; the recognition of happy facial expressions and 
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the processing of social threat cues.  No relationship between changes in mood 
and emotional information processing was found, except for the decreased 
recall of positive words following ATD in remitted depressed patients.
Discussion
The framework of this review is the theory that cognitive changes mediate the 
clinical effects of antidepressants. Three assumptions underlying this theory 
were formulated. 
The first assumption is that serotonin manipulations (including the 
administration of antidepressants) have reliable effects on cognition. In this 
context, the following aspects of emotional functioning have been investigated:
Results from several studies suggest a role for serotonin in the 
recognition of facial expressions of emotions, especially fear. These results have been 
found across a range of different procedures, however the effects on fear 
processing appear to be dependent on the length of treatment: In healthy 
subjects, an acute increase in serotonin function elevated the recognition of 
fear and happiness (Attenburrow et al., 2003; Bhagwagar et al., 2004; Harmer 
et al., 2003a), after seven days the recognition of fear and anger was decreased 
(Harmer et al., 2004; Harmer et al., 2006a), and after fourteen days the 
recognition of happiness was increased and the recognition of disgust was 
decreased in females (Murphy et al., 2006). The effects on fear processing also 
appear to be affected by vulnerability to depression: in recovered depressed 
individuals, a decreased recognition of fear was found following a single SSRI 
administration (Bhagwagar et al., 2004), which is contrary to the increased fear 
recognition found in healthy volunteers.  In  line with expectations, the effects 
of ATD seem to be opposite to those of acute SSRI- and tryptophan 
administration: ATD decreased the recognition of fear in healthy females but 
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not in men (Harmer et al., 2003c) and impaired the recognition of happiness in 
both healthy and recovered depressed subjects (Hayward et al., 2005). The 
reported differences between acute vs. sub-chronic administration and between 
different samples appear to be important and need further investigation since 
the underlying mechanisms are still unclear.
Different studies investigated the effects of ATD on attentional bias
using the Stroop test. Studies differed in the type of test (colour naming or 
counting) and type of stimuli (neutral and emotional; masked or unmasked) 
that were used. Despite these differences, the results are rather consistent. 
Attention for neutral stimuli is improved by ATD in both healthy women and 
recovered depressed subjects, as shown by a decreased interference for 
incongruent stimuli (Booij et al., 2005a; Evers et al., 2006). However, ATD has 
been found to increase attentional bias for negative stimuli in both healthy and 
recovered depressed subjects (Evers et al., 2006; Hayward et al., 2005; Munafò 
et al., 2006). Only in medicated recovered depressed subjects, this was 
accompanied by an increase in subjective depression (Munafò et al., 2006). 
One study found an increased interference for positive material in recovered 
depressed subjects following ATD, independent of mood change (Booij et al., 
2005a). Following fourteen days of tryptophan administration, a reduced 
attentional vigilance to negative words was found (Murphy et al., 2006). 
Overall, lowered serotonin function is found to improve attention for neutral 
stimuli and to increase attentional bias toward emotional stimuli in both 
healthy and recovered depressed subjects. Increased serotonin function may 
have the opposite effect.
Several studies have shown that serotonin manipulations affect 
emotional memory in healthy and recovered depressed individuals. Lowered 
serotonin function impairs the memory of positive material; increased 
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serotonin function improves the memory for positive material and impairs the 
memory for negative material. (Evers et al., 2005; Harmer et al., 2004; Klaassen 
et al., 2002; Luciana et al., 2001). Only one study found a link between 
serotonin induced changes in mood and recall for positive material (Booij et 
al., 2005c). However some studies reported negative results (Harmer et al., 
2006b; Hayward et al., 2005). 
Serotonin is suggested to play a role in decision making in healthy 
individuals, but results have been contradicting, perhaps due to methodological 
differences (Anderson et al., 2003; Rogers et al., 1999a; Rogers et al., 2003; 
Talbot et al., 2006). 
Interestingly, higher serotonin receptor binding potential was 
associated with unfavorable scores on dysfunctional attitudes in healthy 
volunteers, currently depressed (Meyer et al., 2003) and recovered depressed 
patients (Bhagwagar et al., 2006). Fourteen days of tryptophan administration 
in healthy subjects had no effect on dysfunctional attitudes (Murphy et al., 
2006). 
The effect of serotonin manipulations on attentional bias is most 
robust.  The role serotonin plays in the processing of facial expressions of fear 
and other emotions however needs further investigation since differences exist 
in the effects of acute vs. sub-chronic administration and between different 
samples. These differences appear to be important however the underlying 
mechanisms are still unclear. Therefore, future research, preferably from 
different research groups, will need to verify the exact mechanisms with which 
serotonin is linked to the recognition of certain facial expressions and the 
direction of this association. The findings of a link between serotonin receptor 
binding potential and dysfunctional attitudes seem very promising for future 
research on the biological correlates of emotional information processing. 
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Serotonin is also suggested to affect decision making and emotional memory; 
however more research is needed to clarify the role serotonin plays in these 
cognitive processes. In particular, it is unclear whether these effects are limited 
to certain serotonin manipulations and/ or certain study samples. The effect of 
serotonin on the specificity of autobiographical memories has only been 
investigated in healthy individuals and remains uncertain.
The second assumption stated that the cognitive effects of serotonin 
manipulations are also observed in currently depressed subjects starting 
antidepressant treatment. Only one study on the effects of SSRIs on emotional 
information processing in currently depressed patients could be found (Fava et 
al., 1994). However, this study did not assess acute and short-term cognitive 
changes but only performed pre- and post treatment assessments. It is 
therefore not suitable for our review. Evidence from other studies also 
indicates that dysfunctional attitudes decrease following antidepressant 
treatment, however these studies did not primarily investigate selective 
serotonergic antidepressants, but mainly cognitive therapy and tricyclic 
antidepressants (Beevers et al., 2003; DeRubeis et al., 1990; Peselow et al., 
1990; Simons et al., 1984). These results suggest that similar cognitive changes 
occur following cognitive as well as pharmacological treatment. Of note is that 
these studies have only looked at dysfunctional attitudes and not at the more 
automatic aspects of emotional information processing. It may well be that 
early in treatment, changes in for example attentional bias occur, which may 
relate to subsequent clinical improvement. Future research should investigate 
the effects of different antidepressant treatments on various forms of 
emotional information processing.                                                                                                                                                                                
Chapter 8
199
Some indirect evidence also exists on the link between serotonin and 
emotional information processing in depressed patients. An fMRI study in 
depressed patients found increased left amygdala activation in response to 
masked emotional faces, especially fearful faces. This was normalized following 
an eight week treatment with the antidepressant sertraline (Sheline et al., 2001). 
Since the amygdala plays a central role in the processing of emotions, especially 
fear, these results suggest that serotonergic antidepressants may exert their 
effects in part by normalizing dysfunctional emotional processing. 
The third assumption stated that the cognitive effects of 
antidepressants predict clinical response. No studies were found that 
investigated this assumption. Fava et al. (1994) found that the decreased level 
of dysfunctional attitudes following eight weeks of fluoxetine treatment was 
unrelated to symptomatic improvement. However, since only pre- and post 
treatment assessments were obtained, the temporal and causal relationship 
between cognitive changes and subsequent symptom change could not be 
explored, which makes this study unsuitable to investigate the third 
assumption. Simons et al. did find a link between cognitive changes and 
symptomatic improvement, and this was true for both cognitive therapy and 
tricyclic antidepressants (Simons et al., 1984). However, this study is also less 
suitable since it used the same design as Fava et al. and selective serotonergic 
antidepressants were not investigated. Various other studies looked at the 
mechanisms of change of pharmacotherapy compared to cognitive therapy 
(DeRubeis et al., 1990; Hollon et al., 2005; Rush et al., 1981). These studies 
have found that changes in cognition do not relate to subsequent changes in 
symptoms among pharmacotherapy patients, although substantial cognitive 
changes do occur. The authors explain this by the fact that in 
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pharmacotherapy, cognitive changes are not accompanied by the use of 
cognitive and behavioural strategies (e.g. meta-cognitive monitoring) 
(DeRubeis et al., 1990). However, besides cognitive measures that assess the 
goals of cognitive therapy (e.g. dysfunctional attitudes) other forms of 
emotional processing (e.g facial expression recognition, attentional bias) may 
also be relevant to study during treatment. Since dysfunctional attitudes have 
been found to be linked to serotonin receptor binding potential (Bhagwagar et 
al., 2006; Meyer et al., 2003), other forms of emotional processing may as well 
have serotonin-related correlates in the brain. In order to investigate the causal 
relationship between cognitive changes and subsequent symptomatic 
improvement, mood and (different types of) emotional information processing 
should be assessed regularly during the first two months of antidepressant 
treatment. 
The evidence discussed in this review is limited by the absence of 
studies in currently depressed patients. The large variety of cognitive tests 
makes it hard to draw definite conclusions. Most studies did not report power 
analyses and almost all studies are based on small sample sizes. However, the 
quality of the reviewed studies in terms of the methodology is satisfactory. 
Studies are comparable since most studies used a between-group design and 
matched their groups for age, gender and IQ or level of education. One study 
only included men (Park et al., 1994) whereas other studies only included 
women (Attenburrow et al., 2003; Bhagwagar et al., 2004; Evers et al., 2006; 
Harmer et al., 2003a; Murphy et al., 2002), thereby possibly influencing results 




Regarding the quality of the decision making studies, two 
inconsistencies should be noted. First, Anderson et al. (2003) used an 
imaginary gambling task instead of a computerized test, which may have 
caused the negative results. Second, despite of using the same gambling task, 
Talbot et al. (2006) found that ATD improved decision making in contrast to the 
impaired decision making found by Rogers et al. (1999a; 1999b). The authors
suggested a few explanations for this inconsistency (see Results section under 
Effects of ATD on decision making), however both studies seem to be set out 
equally well, and further replications are necessary 
The ATD studies differed in design (parallel or cross-over) and the 
exact depletion method used (amount of amino acids, amount of tryptophan 
added to the control mixture, adherence to a low-tryptophan diet before the 
session). These differences may have influenced results, for example in the case 
of control mixtures in ATD studies that increased plasma tryptophan levels, 
thereby increasing the contrast between ATD and the control procedure. Some 
studies used low-dose ATD as a control mixture (Booij et al., 2005a; Hayward 
et al., 2005; Munafò et al., 2006). However, the studies of Hayward et al. and 
Munafò et al. reported large decreases in plasma tryptophan following their 
low-dose and may better be referred to as high-dose ATD (Merens & Van der 
Does, 2007).
Although the hypothesis that cognitive effects of antidepressants 
predict clinical outcome is as of yet unsupported, there are promising 
directions for future research. Serotonin is certainly involved in various aspects 
of emotional information processing. However, a link between serotonin 
induced changes in mood and changes in emotional information processing 
has not been established. To fully explore this link, future research should be 
directed at currently depressed patients. Furthermore, studies should include 
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immediate as well as sub-chronic and long-term measurements of different 
aspects of emotional information processing to clarify a possible mediating role 
of cognitive changes in clinical outcome, as well as the pattern of change. 
Different cognitive domains are worth investigating, especially attentional bias, 
facial emotion recognition, decision making, dysfunctional attitudes and 
emotional memory. Studies should combine various outcome measures to 
investigate the effects of antidepressant treatment on different forms of 
emotional information processing. Subjective and objective mood measures 
should be obtained in order to make comparison between studies in healthy 
and (recovered) depressed patients possible. Also, apart from serotonergic 
antidepressants, other antidepressant treatments may be included to investigate 






The focus of this thesis was to investigate the effects of serotonin 
manipulations on mood and on neutral as well as emotional information 
processing in remitted and recovered depressed patients. In this discussion, 
first a summary will be given of the main findings. Then, the main findings of 
this thesis will be integrated and further discussed. Also, methodological
considerations are reported as well as directions for future research and the 
clinical implications of the findings.   
Summary of main findings
In Chapter 2, two studies were described that investigated neutral as well as 
emotional information processing in medicated, remitted depressed patients 
and healthy controls matched on age and gender. A wide range of cognitive 
functions was assessed, e.g. verbal and non-verbal memory, attentional bias, 
planning, facial expression recognition and response inhibition. The findings 
indicated that remitted depressed patients show an increased recognition of 
facial expression of fear compared to healthy controls. No other residual 
cognitive impairments were found. The results suggest that generally, cognitive 
impairments associated with depression tend to resolve with symptomatic 
improvement. However, specific impairment in certain aspects of emotional 
information processing may persist into the euthymic phase.
In Chapter 3, the effects of an alpha-lactalbumin-enriched diet on 
mood and cognitive performance were investigated in unmedicated recovered 
depressed patients and matched healthy controls. The alpha-lactalbumin diet 
increased the plasma tryptophan/LNAA ratio with 21% from morning to 
afternoon; the afternoon ratio was 73.8% higher in the alpha-lactalbumin 
condition compared to the placebo condition. The alpha-lactalbumin diet had 
no effect on mood, but improved abstract visual memory and impaired simple 
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motor performance. These effects were independent of history of depression. 
Alpha-lactalbumin did not change the encoding phase, working memory, 
perception or general motor speed. Thus, alpha-lactalbumin may specifically 
affect memory consolidation in an early phase. The memory effect of alpha-
lactalbumin is in line with other studies that show a link between serotonin and 
memory processes (Riedel et al., 1999; Schmitt et al., 2000; Sirviö et al., 1995). 
Supplements of alpha-lactalbumin may be useful for nutrition research in 
relation to age- or disease-related memory decline. However, the present 
findings should be further examined in different samples and also, the long-
term effects of alpha-lactalbumin should be investigated. The results of this 
study also support the suggestion that cognitive markers may be more sensitive 
makers for changes in 5- HT function than mood or symptom scales (Booij et 
al., 2005a). 
In Chapter 4, the effects of an alpha-lactalbumin-enriched diet and a 
casein (placebo) diet on mood and stress response were investigated in the 
same sample of unmedicated recovered depressed subjects and healthy 
controls as has been described in Chapter 3. During both diets, subjects 
underwent a computerized stress task, which affected mood in both 
conditions. Although the alpha-lactalbumin diet led to the expected rises in 
plasma tryptophan and tryptophan/LNAA ratio, only minimal effects were 
found on mood and cortisol response to experimental stress. The results were 
the same for recovered depressed patients and controls. We concluded that a 
one-day diet enriched with alpha-lactalbumin is not sufficient to prevent stress-
induced mood deterioration or a cortisol response in unmedicated, recovered 
depressed subjects. 
In Chapter 5, the effects of high-dose and low-dose ATD on mood 
and neutral as well as emotional information processing in remitted depressed 
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patients were reported. High-dose ATD increased depressive symptoms and 
induced a temporary depressive ‘relapse’ in half of the patients. High-dose 
ATD also decreased the recognition of fear and impaired learning and memory 
retrieval. The impaired learning occurred only in mood-responders. Low-dose 
ATD had no effects on mood but speeded the recognition of facial 
expressions of disgust. Furthermore, accurate recognition of sad faces at 
baseline was associated with mood response to ATD.  We concluded that the 
effect of low-dose ATD on mood and cognition seems to be quite limited. 
Also, facial expression recognition at baseline may predict mood-response to 
ATD.
In Chapter 6, the different doses (high-dose vs. low-dose) of acute 
tryptophan depletion were discussed. The magnitude of the reduction of 
plasma tryptophan levels following ATD depends on the amount and 
composition of the amino-acid mixture and whether a pre-test low-tryptophan 
diet is included. The regular ‘high-dose’ ATD consists of fifteen amino acids 
(100 g) and leads to reductions in plasma levels of  70-90% in five to six hours 
(Young et al., 1989). In the literature, different low-dose mixtures are studied. 
Sometimes the term ‘ low-dose’ is based on the amount of amino acids in the 
mixture, however using a mixture containing eight amino acids (31.2g), may 
decrease the plasma tryptophan/LNAA ratio by 87%, which is similar to the 
decrease found following regular ATD (Hayward et al., 2005; Munafò et al., 
2006). We used a low-dose mixture consisting of the same amount of amino 
acids as the regular ATD mixture (fifteen), but at quarter strength (25.7 g). This 
mixture reduced plasma tryptophan levels by 59%. In this chapter also the 
inter-individual variations in plasma tryptophan levels following ATD are 
discussed. Not much is known about the magnitude of inter-individual 
variations in plasma tryptophan levels; however we found some large 
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deviations from the mean decrease in the tryptophan/LNAA ratio following 
both low-dose and high-dose ATD. This could only be partly explained by the 
fact that several patients threw up. Since the individual variations in the degree 
of plasma tryptophan depletion can be substantial, the term low-dose is 
probably best used to describe an ATD method that uses substantially less 
amino-acids compared to the conventional mixture (Cowen et al., 2007).
In Chapter 7, the effects of ATD on heart rate variability were tested in 
remitted depressed patients. High-dose ATD increased heart rate both during 
rest and during the Dot-probe test. This is in line with previous findings that 
also showed an effect of ATD on heart rate (Booij et al., 2006b). However, 
although the effects of ATD on HRV in patients with a history of suicidal 
ideation were in the expected direction, none of these changes was statistically 
significant. Unfortunately, a replication of the differential effects in patients 
with and without a history of suicidal ideation (Booij et al., 2006b) was not 
possible due to a low number of patients without such a history. Our findings 
indicated that a low HRV may be related to mood and poor affective 
processing through changes in serotonin. However, the relation between HRV 
and serotonin function should be further investigated using larger samples. 
In Chapter 8, the literature on the acute and short-term effects of 
serotonin manipulations on mood and emotional information processing was 
reviewed. The hypothesis on which this chapter was based is that cognitive 
changes may mediate the symptomatic response to antidepressants. Because of 
a lack of studies directly testing this hypothesis, we focused on the short-term 
effects of serotonin manipulations on emotional information processing and 
mood in healthy and depression-vulnerable individuals and on the changes in 
emotional information processing and mood in depressed patients starting 
antidepressant treatment. Twenty-five studies were identified. Manipulations 
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were divided into four classes: SSRI administration, serotonin receptor agonist
or antagonist administration, tryptophan loading and tryptophan depletion. 
Serotonin manipulations were found to have reliable immediate (time range: 
one hour - 14 days) effects on attentional bias, facial emotion recognition, 
emotional memory, dysfunctional attitudes and decision making. This review 
was limited by the lack of studies directly testing the changes in emotional 
information processing in depressed patients starting antidepressant treatment. 
Therefore, the sequential link between serotonin induced changes in emotional 
processing and mood remains to be further investigated. 
Integration of main findings 
In this section of the Discussion, first a few comments will be made on
persisting cognitive impairments in recovered depressed patients. Second, the 
link between serotonin function and neutral as well as emotional information 
processing will be discussed. Third, the findings related to cortisol response to 
stress and heart rate variability will be evaluated. Also a few comments will be 
made about the effects of ATD on plasma tryptophan levels and somatic 
symptoms. Finally, the specificity of the ATD response will be discussed.
Persisting cognitive impairments in euthymic depressed patients
In addition to investigating the effects of serotonin manipulations on cognitive 
performance in depression-vulnerable patients, we also compared the cognitive 
performance of these patients to that of healthy controls in two separate 
studies. Characteristics of the two patient samples are outlined in Table 1. 
The level of residual cognitive impairment in remitted/recovered 
depressed patients is known to be associated to factors such as age, severity of 
residual depressive symptoms, number of previous episodes and medication 
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status (Elliott, 1998; Kessing, 1998; Weiland-Fiedler et al., 2004). However, 
despite the fact that our patient samples differed on these important factors -
the medicated remitted depressed patients were older, more chronic and 
suffered more residual depressive symptoms compared to the unmedicated 
recovered depressed patients- no differences in cognitive performance were 
found between the recovered/remitted patients and healthy controls, except 
for an increased fear recognition in the medicated remitted patient group. The 
lack of residual cognitive impairments in euthymic formerly depressed patients, 
especially with regard to the processing of neutral information, is strengthened 
by the fact that in the two studies combined, a wide variety of cognitive 
functions was assessed. Unfortunately no direct comparison of cognitive 
functioning between the two patient samples was possible, since different tests 
were administered in the two studies. However, since performance across a 
wide range of tests assessing neutral as well as emotional information 
processing was evaluated, we may conclude that cognitive impairments 
improve substantially with symptomatic recovery, which is in line with some 
previous studies (Elliott, 1998; Weiland-Fiedler et al., 2004), although results 
have been mixed (Paradiso et al., 1997). The fact that we did find a difference 
in the recognition of facial expression of fear between remitted depressed 
patients and controls is in line with other findings (Bhagwagar et al., 2004) and 




Table 1. Demographic and clinical characteristics of the two patient samples
Recovered depressed 
patients (n = 20)
Remitted depressed 
patients (n = 18)
Age (years) 30.0 (9.7) 44.4  (13.3)
Gender (M/F) 2 / 21 2 / 16
MADRS 1.3 (1.6) 9.0 (5.8)
Partial/ full remission 1 / 22 7 / 11




Single/recurrent 7 / 16 2 / 16
Medication status No current antidepressant 
medication
SSRI (n = 12)
SSNRI (n = 6)
Values are presented as means (SD). MADRS = Montgomery-Asberg Depression 
Rating Scale; SSRI = selective serotonin reuptake inhibitor; SSNRI = selective 
serotonin and noradrenalin reuptake inhibitor
Neutral and emotional information processing
In this thesis, we examined the effects of two different serotonin 
manipulations on various vulnerability factors for depression. The main 
outcome measure in this thesis was cognitive performance; the processing of 
neutral and emotional information. Both the alpha-lactalbumin enriched diet 
and acute tryptophan depletion had effects on cognitive processing. Although 
the effects of alpha-lactalbumin on plasma tryptophan and the 
tryptophan/LNAA ratio are smaller than the effects following ATD (the 
alpha-lactalbumin diet increased the tryptophan/LNAA ratio with 21% 
compared to a decrease of 59% following low-dose and 91% following high-
dose ATD), both manipulations had an effect on memory.
Alpha-lactalbumin improved recognition and speed of retrieval from 
short- and long-term abstract visual memory in both recovered depressed 
patients and healthy individuals. The memory effect of alpha-lactalbumin is in 
line with studies finding improved memory performance following increased 
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serotonin function (Harmer et al., 2002; Schmitt et al., 2005), although our 
study indicated that the memory effect of alpha-lactalbumin is not restricted to 
individuals vulnerable to depression. Our results are also mirrored in the 
impaired memory consolidation  following ATD in healthy volunteers (Riedel 
et al., 1999; Rubinsztein et al., 2001). In this thesis, ATD impaired verbal 
memory (learning and retrieval) in remitted depressed patients. The effect of 
ATD on memory is in line with the results in healthy and depression-
vulnerable individuals (Booij et al., 2005c; Hayward et al., 2005; Park et al., 
1994; Riedel et al., 1999; Schmitt et al., 2000). However, in contrast to previous 
studies, memory consolidation was not affected by ATD in our study.
The literature shows that serotonin manipulations have reliable effects 
on different forms of emotional information processing. In Chapter 8, four 
classes of serotonin manipulations were reviewed: SSRI administration; 
administration of a serotonin agonist or antagonist; tryptophan augmentation 
and acute tryptophan depletion and the effects in healthy and depression-
vulnerable individuals were evaluated. Evidence indicates that the recognition 
of facial expressions of emotions, attentional bias, emotional memory, decision 
making and the levels of dysfunctional attitudes are affected by changes in 
serotonin function. 
The effect of serotonin manipulations on attentional bias is most 
robust.  The role serotonin plays in the processing of facial expressions of fear 
and other emotions however needs further investigation since differences exist 
in the effects of acute vs. sub-chronic administration and between different 
samples. These differences appear to be important however the underlying 
mechanisms are still unclear. Therefore, future research, preferably from 
different research groups, will need to verify the exact mechanisms with which 
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serotonin is linked to the recognition of certain facial expressions and the 
direction of this association. The findings of a link between serotonin receptor 
binding potential and dysfunctional attitudes seem very promising for future 
research on the biological correlates of emotional information processing. 
Serotonin is also suggested to affect decision making and emotional memory; 
however more research is needed to clarify the role serotonin plays in these 
cognitive processes. In particular, it is unclear whether these effects are limited 
to certain serotonin manipulations and/ or certain study samples. The effect of 
serotonin on the specificity of autobiographical memories has only been 
investigated in healthy individuals and remains uncertain.
Our findings from the ATD study support the link between serotonin 
function and facial expression recognition. First, ATD affected the recognition 
of facial expressions of emotions: low-dose ATD speeded the recognition of 
facial expressions of disgust and high-dose ATD decreased the recognition of 
facial expressions of fear. Although we did not assess the effects of alpha-
lactalbumin on emotional information processing, evidence suggests that in 
healthy individuals the recognition of facial expressions of fear is increased by 
a diet enriched with alpha-lactalbumin (Attenburrow et al., 2003). Also, a 
fourteen day diet enriched with tryptophan (1g 3x/day) resulted in increased 
recognition of happiness and decreased recognition of disgust in healthy 
females (Murphy et al., 2006). The fact that we found a decreased recognition 
of fear following ATD is in line with results in healthy females (Harmer et al., 
2003c). Different serotonin manipulations (ATD, SSRI administration) are 
found to affect facial expression recognition in healthy as well as recovered 
depressed individuals (Bhagwagar et al., 2004; Harmer et al., 2003b; Harmer et 
al., 2003c; Harmer et al., 2004; Hayward et al., 2005). The effect on the 
recognition of fearful facial expressions seems most robust. However, the 
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direction of the effect of serotonin on facial expression recognition seems to 
depend on the timing of the administration (acute vs. repeated) and on the 
studied population, suggesting that there may be two separate processes 
involved. On the one hand an effect of SSRI administration on fear 
recognition, which reverses from acute to repeated administration. This is 
mirrored in the effects of SSRI administration on symptoms; anxiety 
symptoms may first increase at the start of SSRI treatment, followed by an 
eventual decrease in anxiety and other symptoms. On the other hand there is a 
positive effect of SSRIs on affective processing (: on the recognition of happy 
facial expressions, emotional memory and attentional bias) which is seen very 
early after administration of a single dose and is still observed after one week 
of treatment.
Secondly, our results indicate that mood-response to ATD may be related 
to better and faster recognition of facial expressions of sadness at baseline. The 
direction of the impairment in facial expression recognition (increased vs. 
decreased) seems to vary: our finding is opposite to results of a study on the 
effects of ATD in healthy female volunteers with a family history of 
depression: a stronger mood response to ATD was associated with a less
accurate recognition of negative facial emotions and a stronger right amygdala 
response to intense fearful faces compared to happy faces (Van der Veen et al., 
2007). However, in line with our findings, this suggests that performance (and 
brain activation) associated with facial expression recognition partly depend on 
the effect of ATD on mood. 
Thirdly, when compared to healthy controls, remitted depressed patients 
showed an increased recognition of facial expressions of fear. These findings 
suggest that the recognition of facial expression may be a persisting 
vulnerability factor, related to serotonin vulnerability. However what is unclear 
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is whether this impaired recognition of facial expressions is limited to the 
recognition of certain emotions or evolves around negative emotions in 
general. 
It is important to note that besides serotonin, other neurotransmitters, e.g. 
nor-epinephrine, are also related to the recognition of facial expressions of 
emotions (Harmer et al., 2003b; Harmer et al., 2004)
Cortisol response to stress
Contrary to expectations, we did not find a protective effect of an alpha-
lactalbumin enriched diet on stress-induced cortisol response in recovered 
depressed patients. Although this may be largely explained by the small effect 
of the stressor on cortisol, other possible explanations also need to be noted. 
Firstly, previous research did find a protective effect of alpha-lactalbumin on 
stress-induced cortisol, however only in healthy individuals with high 
neuroticism scores (Markus et al., 2000). High levels of neuroticism are known 
to predict depressive disorders (Kendler et al., 2006), however our findings 
suggest that high-neuroticism and a history of depression may be two different 
concepts in terms of serotonin vulnerability. Secondly, although evidence may 
point out that remitted depressed patients show blunted neuroendocrine 
responses to drugs that stimulate serotonin turnover (Bhagwagar et al., 2002a; 
Bhagwagar et al., 2002b; Flory et al., 1998), the effect of a diet rich in alpha-
lactalbumin may be weaker compared to a challenge using citalopram, d-
fenfluramine or intravenous tryptophan. Also important to note is that 
although the prolactin response to citalopram was blunted in recovered 
depressed patients, the cortisol response was not, suggesting that some aspects 
of HPA-axis dysfunction (in this case the blunted cortisol response) may be 




The possible link between serotonin and HRV has recently received more 
attention. Research has indicated that treatment with serotonergic 
antidepressants may have a beneficial effect on HRV in panic disorder patients 
and possibly also in depressed patients, although the results are mixed (Agelink 
et al., 2001; Glassman et al., 1998; Gorman & Sloan, 2000). Further evidence 
comes from a recent more experimental study in which ATD was found to 
affect HRV in medicated remitted depressed patients with a history of suicidal 
ideation (Booij et al., 2006b). We have tried to replicate these findings. 
However, due to unequal sample sizes, the analyses on differences between 
remitted depressed patients with and without a history of suicidal ideation 
could not be performed. Since little research has been done on the link 
between experimental changes in serotonin and HRV, no conclusion can be 
drawn as of now about a possible link between changes in serotonin and 
changes in HRV. The proposed mechanism of impulsivity as a mediator 
between serotonin and HRV (Booij et al., 2006b) seems promising, but 
requires further investigations especially in specific patient samples, e.g. 
patients suffering from impulse control disorders. It may be that HRV is 
affected by changes in serotonin levels, but only when measured over a longer 
period of time; it may also be that serotonin function is linked to cardiac 
function –heart rate and blood pressure-, but not to HRV per se (Agelink et al., 
2001). Overall, more research will need to be done on the possible link 




The effects of ATD on plasma tryptophan levels and somatic symptoms
It is not possible to measure central changes in serotonin in humans directly 
(Anderson et al., 1990a). Therefore blood plasma amino acid levels were 
obtained in both of our studies, giving a peripheral measure of serotonin 
function. Because tryptophan competes with the other essential amino acids 
for entry at the blood-brain-barrier, relative tryptophan depletion is thought to 
occur in the central nervous system (CNS) following ATD that parallels the 
changes measured in blood. Animal studies have confirmed that the oral ATD 
methods are able to lower CNS levels of tryptophan, serotonin and 5-
hydroxyindoleatic acid (5-HIAA), the major metabolite of serotonin in the 
cerebrospinal fluid (CSF) (Carpenter et al., 1998). Using lumbar punctures to 
sample CSF continuously, Carpenter et al. found that CSF tryptophan levels 
and plasma tryptophan levels were highly correlated, suggesting that ATD 
indeed results in substantial declines in central serotonin turnover (Carpenter et 
al., 1998).
Recently, different studies have investigated the effects of a low-dose 
tryptophan depletion mixture on plasma tryptophan levels (Booij et al., 2005a; 
Hayward et al., 2005; Munafò et al., 2006). However, the effects of low-dose 
ATD on plasma tryptophan levels seem to differ largely. Hayward et al. and 
Munafò et al. used the same mixture containing eight amino acids (31.2 g), 
which resulted in an 87% decrease of the ratio tryptophan/ LNAA. Our low-
dose mixture contained fifteen amino acids (25.7 g), which decreased the ratio 
tryptophan/LNAA with 59%. Although both mixtures were named low-dose 
based on the amount and composition of the amino-acid mixture, results 
indicate that the effects on plasma tryptophan levels may be in the range of 
those following regular (or ‘high-dose’) ATD. The behavioural effects also 
differed between these studies, which may be partly explained by the 
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differences in the effects on plasma tryptophan levels. We therefore suggest 
that the percentage decrease in plasma tryptophan levels should always be 
considered when reporting results of ATD. 
When examining the individual decreases in plasma ratio 
tryptophan/LNAA following both low-dose and high-dose ATD, we 
discovered large inter-individual variations (see Table 1 in Chapter 6). 
Especially low-dose ATD may result in both small (33 - 37%) as well as large 
(79 – 86%) decreases in plasma tryptophan/LNAA levels, the last resembling 
the effects of high-dose ATD (mean decrease of 91%). Since individual plasma 
tryptophan levels are never reported in the literature, not much is known about 
the variability in tryptophan levels in other ATD studies. It seems however 
important to investigate individual variations in the effects of ATD on plasma 
tryptophan levels in future studies, since the behavioural effects of ATD may 
depend on the effect of ATD on plasma tryptophan levels.
The large variations in post-ATD tryptophan levels in our study may 
be partly explained by the fact that a relatively large number of patients 
vomited in response to the ATD mixture. The unpleasant taste of ATD 
mixtures has been widely reported, as well as side-effects that may occur after 
ingestion of amino acid mixtures, such as nausea, dizziness and vomiting 
(Delgado et al., 1990; Lam et al., 1996). Since no lasting or serious side-effects 
of ATD were ever reported, the procedure is deemed safe. However, symptom 
provocation studies have been criticized for ethical reasons, especially in the 
USA (Miller & Rosenstein, 1997). Booij et al. reported the results of an 
evaluation of the ATD procedure by patients who underwent both low-dose 
and high-dose ATD (Booij et al., 2005c). The results indicated that individuals 
did not regret participating and despite the provocation of symptoms and the 
fact that the study had no direct benefit, some participants still experienced 
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personal advantages. However the number of patients experiencing side-effects 
was much higher in our sample compared to Booij et al. (2005c). Only one 
patient out of twenty-one in the Booij et al. study vomited following high-dose, 
compared to five out of eighteen in our study. Although the total number of 
side-effects decreased after both mixtures in the Booij et al. study, scores on 
‘nausea’ and ‘feel sick’ increased following both conditions. In our study the 
total number of side-effects increased following high-dose, but not following 
low-dose ATD. Significantly increased scores were found for ‘decreased 
appetite’, ‘increased nausea’ and ‘sweaty hands’. Symptoms were back to 
baseline the next morning, suggesting that indeed no lasting side effects are 
inflicted by ATD. Since we used the same batch of amino acids and the same 
design and procedure as Booij et al., it is not certain what has caused the 
difference in tolerability.
Specificity of the ATD response
There has been debate on whether ATD induces a true depressive relapse or 
whether the effects of ATD are attributable to an increase in physical 
symptoms of discomfort with the amino acid drink (Lam & Yatham, 2003). 
Booij et al. (2005c) concluded that ATD is a specific model of depressive 
relapse. The authors based this on a specific increase in depressive symptoms 
(MADRS and HDRS) and a lack of effect on the PANAS Negative scale and 
the Brief Anxiety Scale (BAS). In contrast to Booij et al., our findings showed 
an increase in depressive symptoms (MADRS and HDRS) as well as anxiety 
symptoms (BAS) and physical symptoms in response to high-dose ATD. 
Therefore, our results seem to disagree with the concept of ATD as a specific 
model for depressive relapse. However, the fact that we found an effect of 
ATD on anxiety symptoms is not surprising since serotonergic projections play 
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a role in both depression and anxiety disorders (Graeff et al., 1996). Also, 
serotonergic medication such as SSRIs appears to be effective in treating 
depressive as well as anxiety disorders (Vaswani et al., 2003). ATD studies have 
also been performed in anxiety disorder patients (Bell et al., 2001). The 
literature indicates that ATD increases anxiety and panic only when combined 
with a panicogenic challenge in healthy controls (Klaassen et al., 1998) and in 
untreated panic disorders patients (Miller et al., 2000). In medicated social 
anxiety patients ATD seems to reverse the therapeutic effects of SSRIs 
(Argyropoulos et al., 2004). ATD however does not appear to exacerbate 
symptoms in OCD (Bell et al., 2001). These studies indicate that ATD may be 




Both the alpha-lactalbumin and the ATD study were conducted in a 
randomized double-blind crossover within-subjects design. Therefore we did 
not have the problem of unknown group differences which is inherent to a 
between-subjects design. However, the downside of a within-subjects design is 
the fact that it is vulnerable to the effects of repeated testing. In the ATD 
study, patients performed the cognitive tests four times in total (at screening, 
once during the afternoon of each of the two sessions and at a post-
intervention session). The two sessions were separated by approximately a 
week. We calculated a baseline measure as a comparison for the two test 
sessions, based on the first and last assessment to adjust for the possible 
learning effects regarding the cognitive measures. In the alpha-lactalbumin 
study another procedure was used. The cognitive tests were first practiced at 
Chapter 9
220
the screening session. Thereafter, both groups performed the cognitive tests 
twice during each test session: in the morning before the alpha-lactalbumin or 
casein drink, and in afternoon. The test sessions in this study were separated by 
four weeks.
Secondly, in contrast to the alpha-lactalbumin study, we did not test the 
effects of ATD in healthy controls. However, evidence shows that our finding 
with regard to the effect of ATD on facial expression recognition is in line with 
results in healthy volunteers (Harmer et al., 2003c). This seems to suggest that 
this effect does not represent some form of depression vulnerability. However, 
our finding of a link between sad facial expression recognition and mood-
response was not found in healthy volunteers. Therefore, an increased baseline 
level of sadness recognition may represent increased depression vulnerability.
Statistical power
Another concern is the generalizability of the results, because of the small 
sample sizes in both studies. The ATD study included eighteen patients and 
the alpha-lactalbumin study included twenty patients and twenty-three healthy 
controls. These sample sizes are quite common in challenge studies, but 
replication of the results is warranted. However, since we used different 
inclusion criteria for the ATD and alpha-lactalbumin study, the patient samples 
of the two studies differed: unmedicated vs. medicated, recovered depressed 
patients vs. remitted depressed patients, history of single vs. multiple 
depressive episodes, etc. Also, the results of two experimental manipulations 
with opposite effects on serotonin function (increased vs. decreased) were 
coupled in this thesis. We feel both of these characteristics increased the scope 
of our results and strengthened the findings reported in this thesis. 
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The results from the ATD - heart rate variability study were limited by 
the fact that no equal subgroups of patients with and without a history of 
suicidal ideation could be formed. Therefore, the intended replication of the 
Booij et al. study (2006b) could not be performed. Our results do not support 
their finding that serotonin plays a role in HRV, however the small sample and 
unequal subgroups cause us to be careful about drawing conclusions from that 
study.
Literature review
One of the strengths of this thesis is the fact that in addition to two 
experimental studies, a literature review was performed on the effects of 
serotonin manipulations on emotional information processing and mood. 
Hereby we have provided a broader context to the current results and the 
possible clinical implications of the link between serotonin and emotional 
information processing. Also, the literature review provided us with a means to 
comprehensively discuss the status quo of the current research on the effects 
of serotonin manipulations, emotional information processing and depression. 
Our literature review is not the first but the last chapter (Chapter 8) of 
this thesis and was based on a hypothesis that was formed while doing the 
alpha-lactalbumin and ATD studies and studies by others: do serotonin 
induced changes in emotional processing lead up to symptomatic recovery in 
depressed patients starting antidepressant treatment? Since this hypothesis has 
not been studied directly, we decided to review the existing literature on the 
effects of serotonin manipulations on emotional information processing and 
mood. The review thus preludes part of the discussion since all evidence for 
serotonin induced changes in emotional information processing and mood are 
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discussed and evidence for a possible link between mood and emotional 
information processing was evaluated in Chapter 8. 
Information processing
We included a wide range of cognitive tests in both the ATD and alpha-
lactalbumin study. In Chapter 3 and 4 on the effects of alpha-lactalbumin, only 
findings related to neutral information processing were reported. We did 
include a test of emotional information processing in that study (an emotional 
version of the Stroop task) however alpha-lactalbumin did not affect 
performance on that test (Markus, personal communication, March 2007). 
Since the cognitive tests differed between the two studies, no indirect 
comparison could be made between the effects of ATD and alpha-lactalbumin. 
However, we used a wide range of tests in both studies, and therefore we 
covered a large domain of cognitive functioning, adding to the generalizibility 
of the results.
Cortisol response to stress
Regarding the effect of alpha-lactalbumin on stress-induced cortisol response, 
two remarks should be made. First, the results were limited by the fact that 
only minimal increases in mood and cortisol were found following the stress 
task. It may well be that the computerized stress-task we used, was not 
stressful enough since the induced stress posed no social-evaluative threat 
(Dickerson & Kemeny, 2004), thereby minimizing the cortisol response and 
negatively influencing the possible effect of alpha-lactalbumin on cortisol. 
Secondly, to minimize possible fluctuations in mood, we tested the women 
taking part in the alpha-lactalbumin study in their mid-to-late follicular phase 
or during the period they were actually taking the pill. This however may have 
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been problematic in case of the cortisol assessments. Since the cortisol 
response to stress may be dependent on gender, and for females on menstrual 
cycle or oral contraceptives (Kirschbaum et al., 1999), a possible gender effect 
may have confounded the effects of alpha-lactalbumin on cortisol response to 
stress. Since our subgroups of men and women (on and off oral 
contraceptives, or post-menopausal) were too small, we could not further 
investigate this. However, an alternative explanation for the lack of effect of 
alpha-lactalbumin on stress induced mood- and cortisol response is that a one 
day alpha-lactalbumin diet may be too weak to affect these responses in 
recovered depressed patients.
Directions for future research
Diet enriched with alpha-lactalbumin 
Our findings suggest that an alpha-lactalbumin enriched diet has effects on 
cognitive performance; however a one day alpha-lactalbumin diet may be too 
weak also to affect mood and cortisol responses to stress in recovered patients. 
Future studies may investigate a diet enriched with a higher dose of alpha-
lactalbumin or a longer duration of the diet. Since our results are contrary to 
previous findings (Markus et al., 2000), future research should investigate 
whether our results and Markus et al.’s can be replicated. If so, neuroticism and 
history of depression may not be equal constructs in terms of serotonergic 
vulnerability. 
We did not find an effect of alpha-lactalbumin on mood in 
unmedicated recovered depressed patients, which is comparable to the effect 
of ATD: a depressive response to ATD mainly occurs in SSRI treated patients 
(Booij et al., 2003). Therefore, it may well be that alpha-lactalbumin has a more 
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pronounced effect in recovered depressed patients taking an SSRI as opposed 
to unmedicated patients.
The biochemical specificity of alpha-lactalbumin enriched diets should 
be further investigated by combining alpha-lactalbumin enriched diets with 
monoamine depletion paradigms. Also, different placebo procedures should be 
developed since the casein diet resulted in an increase in tyrosine, which may 
affect cognitive performance (Deijen & Orlebeke, 1994).
ATD
Our results support the fact that ATD is a useful tool to investigate the link 
between serotonin and emotional processing in medicated remitted depressed 
patients. However, some important issues have come up that need to be 
further investigated.
First of all, the term low-dose ATD is used for different ATD dosages that 
may have very variable effects on plasma tryptophan levels. More research is 
needed to construct the optimal low-dose, which does not affect mood and is 
significantly different compared to the original high-dose ATD. Second, the 
experience of patients undergoing ATD should be systematically investigated 
to prevent unethical research strategies. Third, ATD may also be a useful tool 
to investigate the role of serotonin in anxiety disorders and anxiety symptoms 
in clinical populations. Fourth, more research is needed on the direction of the 
link between serotonin and facial expression recognition in healthy as well as 
depression vulnerable subjects. Fifth, the finding of a link between facial 
expression recognition and mood response to ATD seems promising with 
regard to research into vulnerability to serotonin and depression. 
Recent findings have indicated that future studies should focus on 
investigating the possible mediating effect of the polymorphism at the 
Chapter 9
225
serotonin transporter linked polymorphic region (5-HTTLPR) in the effects of 
ATD. ATD impaired verbal recall in healthy volunteers homozygous for the s 
allele at the 5-HTTLPR, while episodic memory was unimpaired in the ll 
genotype group (homozygous for the l allele) (Roiser et al., 2007). Mood was 
unaffected in both groups. Thus, this polymorphism may be a moderating 
factor in the link between ATD and cognitive performance. 
Emotional information processing
Our findings support the relevance of emotional information processing in the 
research on the role of serotonin in depression. The role serotonin plays in the 
processing of facial expressions of fear and other emotions needs further 
investigation since differences exist in the effects of acute vs. repeated 
administration and between different samples. The findings of a link between 
serotonin receptor binding potential and dysfunctional attitudes seem very 
promising but also require further investigation. More research is also needed 
on the role serotonin plays in decision making and emotional memory. In 
particular, it is unclear whether these effects are limited to certain serotonin 
manipulations and /or certain study samples.
There is of yet no direct evidence for a link between serotonin induced 
changes in mood and emotional information processing, however there are 
promising directions for future research. The effects of different antidepressant 
treatments on various forms of emotional information processing should be 
investigated to verify possible common effects on emotional information 
processing and their underlying mechanisms. Since studies on the effects of 
serotonin on mood and emotional information processing in currently 
depressed patients are lacking, future research should focus on clinical 
populations. Furthermore, future research should include immediate as well as 
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sub-chronic and long-term measurements of different aspects of emotional 
information processing to clarify a possible mediating role of cognitive changes 
in clinical outcome, as well as the pattern of change.
Biological vulnerability markers
Our results suggest that experimental manipulations of serotonin using either 
the ATD method or a diet enriched with alpha-lactalbumin, may not be 
suitable to investigate cortisol response to stress or heart rate variability. It is 
however important to note that very little research has been done investigating 
the effects of these methods on biological factors. The main focus has been to 
investigate the role of serotonin in cognitive processing, and our results 
support the notion that this may be the most fruitful scope of this kind of 
research.
Regarding the effect of alpha-lactalbumin on cortisol response to 
stress, more research is warranted on the specific effects of alpha-lactalbumin 
on neuro-endocrine measures. Evidence from both animal and human studies 
indicates that serotonin plays little role in control of basal cortisol release but is 
important in release of cortisol in response to stress (Porter et al., 2007). It 
therefore seems important to further investigate the specific mechanisms 
underlying this association.
Clinical implications 
Much is still unknown about the role serotonin plays in the development, 
maintenance and treatment of depressive disorders. This thesis has elucidated 
the relevance of emotional information processing in investigating the link 
between serotonin and depression. Although the research reported in this 
thesis was fundamental in nature, some remarks can be made about the clinical 
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relevance of the reported findings. First of all, the research on serotonin 
function in depression may bring us closer to optimal treatment for depressed 
patients. The literature on the effects of serotonin manipulations on mood and 
emotional information processing shows us that certain aspects of emotional 
information processing are related to serotonin function. Whether this 
association is involved in the therapeutic response to antidepressants needs to 
be further investigated. However, serotonin challenge studies such as ATD and 
the administration of an alpha-lactalbumin enriched diet provide us with 
important knowledge about the possible mechanisms underlying 
antidepressant action. Our finding that mood response to ATD was related to 
the recognition of sad facial expressions, suggests that some aspects of 
emotional information processing may be predictors of sensitivity to changes 
in serotonin. Therefore, neurotransmitter manipulation seems to be a useful 
method to study individual vulnerability and to gain insight into the 
relationship between cognition, serotonin and mood.
Although alpha-lactalbumin might be relatively easy to implement 
within a regular diet (Beulens et al., 2004), our results do not provide evidence 
for a particular clinical relevance of an alpha-lactalbumin diet in individuals 
with a history of depressive episodes, although a positive effect on memory 
was observed. Such a diet may be more relevant to stress-prone individuals 
(with high neuroticism scores) who are protected from the adverse effects of a 
stressor by an alpha-lactalbumin diet (Markus et al., 2000). Since we did find an 
effect of alpha-lactalbumin on memory in both healthy and recovered 
depressed individuals, an alpha-lactalbumin diet may be relevant for aging 
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Het manipuleren van de serotonine functie bij depressies
Een depressie is een van de meest invaliderende stoornissen ter wereld. 
Ongeveer een op de zes mensen in Amerika krijgt op enig punt in zijn/ haar 
leven een depressie, de precieze prevalentie wisselt per land. Meer vrouwen 
dan mannen worden depressief (ratio 2:1). De meeste nieuwe gevallen van een 
depressie komen voor gedurende de late adolescentie en in de jonge 
volwassenheid. De kernsymptomen van een depressie zijn een sombere 
stemming en anhedonie (niet in staat zijn plezier te beleven). Daarnaast kan er 
sprake zijn van een verminderde eetlust, slaapproblemen, vermoeidheid, 
gevoelens van waardeloosheid, verminderd concentratievermogen en gedachtes 
over de dood en suïcide.
De meest effectieve behandelingen van een depressie zijn 
antidepressieve medicatie, gestructureerde vormen van psychotherapie 
(bijvoorbeeld cognitieve gedragstherapie) of een combinatie van beide. 
Selectieve serotonine heropname remmers (SSRIs) vormen de meest gebruikte 
farmacologische behandeling voor depressies.
Aangezien het terugvalpercentage bij depressies erg hoog is, wordt er 
veel onderzoek gedaan naar de mechanismen die mogelijk een rol spelen in de 
ontwikkeling en het voortbestaan van een depressie. Kwetsbaarheid voor 
depressies kan gelegen zijn in cognitieve, biologische, psycho-sociale en 
genetische factoren. Het functioneren van verschillende neurotransmitters 
(serotonine, dopamine, norepinefrine) speelt een belangrijke rol met betrekking 
tot de biologische kwetsbaarheid voor depressies. 
Van serotonine is bekend dat het een belangrijke rol speelt bij het 
ontstaan van depressies. Verstoringen in het serotonine-systeem kunnen 
voorkomen op verschillende niveaus in zowel acute als in herstelde depressieve 
patiënten en in mensen met een familiegeschiedenis van depressies. Deze 
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neurobiologische basis voor depressies is verbonden met het 
werkingsmechanisme van antidepressieve medicatie: serotonerge antidepressiva 
verhogen de serotonine functie in de hersenen door de heropname van 
serotonine te verhinderen. Onderzoek naar serotonine is gebaseerd op 
indirecte methodes, aangezien een directe meting van serotonine in mensen 
problematisch is. Het experimenteel manipuleren van serotonine niveaus 
maakt het mogelijk de rol van serotonine in depressies en de werking van 
antidepressiva te onderzoeken. 
Het doel van dit proefschrift is om de effecten van twee verschillende 
serotonine manipulaties (acute tryptofaan depletie en een dieet verrijkt met het 
melkwei alfa-lactalbumine) op stemming en het verwerken van neutrale en 
emotionele informatie te onderzoeken in herstelde en herstellende depressieve 
patiënten. Het verband tussen serotonine en twee biologische 
kwetsbaarheidmaten voor depressies (de cortisol respons op stress en 
hartritmevariabiliteit) wordt ook onderzocht.
In Hoofdstuk 2 worden twee onderzoeken beschreven waarin gekeken werd 
naar het verwerken van neutrale en emotionele informatie door herstelde 
depressieve patiënten die medicatie gebruikten en gezonde controles, welke 
overeenkwamen wat betreft leeftijd en geslacht. Verschillende cognitieve 
functies werden gemeten, bijvoorbeeld verbaal en non-verbaal geheugen, 
aandachtsbias, plannen, gezichtsherkenning en respons inhibitie. De resultaten 
lieten een verhoogde herkenning van angstige gezichten zien bij herstelde 
depressieve patiënten vergeleken met controle proefpersonen. Er werden geen 
andere resterende cognitieve beperkingen gevonden. De resultaten wijzen er 
op dat cognitieve beperkingen die gepaard gaan met een depressie in de meeste 
gevallen verdwijnen als de depressieve symptomen afnemen. Specifieke 
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beperkingen in bepaalde aspecten van emotionele informatieverwerking blijven 
mogelijk bestaan nadat de patiënt hersteld is.
Alfa-lactalbumine is een proteïne rijk aan tryptofaan. Een dieet dat verrijkt is 
met alfa-lactalbumine verhoogt de ratio van tryptofaan tot de andere ‘large 
neutral amino acids’ (LNAAs), waardoor vervolgens het serotonine niveau in 
de hersenen stijgt. In Hoofdstuk 3 en 4 worden de effecten van een dieet 
verrijkt met alfa-lactalbumine op stemming, cortisol respons op stress en 
cognitief functioneren onderzocht. Drieëntwintig herstelde depressieve 
patiënten en twintig gezonde controles ontvingen alfa-lactalbumine en caseïne 
(placebo) op verschillende dagen, volgens een dubbelblind gerandomiseerd 
cross-over design. Op beide dagen ondergingen de proefpersonen een 
stresstaak. Stemming, cognitief functioneren en plasma aminozuren werden 
gemeten voor en na inname van de maaltijden.
Het alfa-lactalbumine dieet verhoogde de ratio tryptofaan/LNAA met 
21% van de ochtend tot de middag; de middag ratio was 73.8% hoger in de 
alfa-lactalbumine conditie vergeleken met de placebo conditie. Het alfa-
lactalbumine dieet had geen effect op stemming maar het verbeterde het 
abstract visueel geheugen en het verstoorde eenvoudig motorisch functioneren. 
Deze effecten waren in beide groepen aanwezig. Alfa-lactalbumine had geen 
effect op de opslagfase (‘encoding’), het werkgeheugen, waarneming of 
algemene motorische snelheid. Mogelijk heeft alfa-lactalbumine een specifiek 
effect op geheugen-consolidatie in een vroeg stadium. Het effect van alfa-
lactalbumine op het geheugen komt overeen met de resultaten van andere 
onderzoeken die een verband tussen serotonine en geheugenprocessen hebben 
aangetoond. Alfa-lactalbumine supplementen zouden nuttig kunnen zijn voor 
voedingsonderzoek met betrekking tot leeftijd- of ziekte gerelateerd 
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geheugenverlies. De huidige resultaten dienen echter nader onderzocht te 
worden in verschillende populaties en de lange termijn effecten van alfa-
lactalbumine moeten ook onderzocht worden. De resultaten van dit onderzoek 
ondersteunen het idee dat cognitieve factoren mogelijk sensitiever zijn voor 
veranderingen in de serotonine functie dan stemming. 
De gecomputeriseerde stresstaak beïnvloedde de stemming negatief in 
beide condities. Hoewel het alfa-lactalbumine dieet tot de verwachte verhoging 
in plasma tryptofaan en ratio tryptofaan/LNAA leidde, werden er slechts 
minimale effecten gevonden op stemming en de cortisol respons op de 
stresstaak. De effecten in de herstelde depressieve patiënten verschilden niet 
van de effecten in de controle groep. Een dieet verrijkt met alfa-lactalbumine 
gedurende één dag is dus niet voldoende om de door stress geïnduceerde 
verslechtering in stemming of de cortisol respons tegen te gaan.
Acute tryptofaan depletie (ATD) is een methode om de serotonine functie bij 
mensen tijdelijk te verlagen. Dit gebeurt door toediening van een 
aminozuurdrankje waarin tryptofaan ontbreekt. Onderzoek heeft veelvuldig 
bewezen dat ATD depressieve symptomen induceert in herstellende 
depressieve patiënten die een SSRI slikken. ATD beïnvloed ook het cognitief 
functioneren, zowel in patiënten als in gezonde groepen. De exacte oorsprong 
van de door ATD geïnduceerde cognitieve veranderingen bij depressies is 
vooralsnog onduidelijk. Ook onbekend is of er cognitieve veranderingen 
kunnen plaatsvinden na partiële (lage dosering) depletie.
In Hoofdstuk 5, 6 en 7 worden de resultaten besproken van een 
onderzoek naar de effecten van een lage en een hoge dosering tryptofaan 
depletie op stemming, neutrale en emotionele informatieverwerking en 
hartritmevariabiliteit in herstellende depressieve patiënten die serotonerge 
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antidepressiva gebruiken. Achttien herstellende depressieve patiënten 
ontvingen een hoge dosis en een lage dosis ATD in een dubbelblind, 
gerandomiseerd, binnen-proefpersoon cross-over design. Stemming werd 
gemeten voor en na de inname van het depletiedrankje. Vijf uur na inname 
voerden de patiënten een reeks cognitieve tests uit. Tijdens deze tests werden 
hartritme en hartritmevariabiliteit gemeten.
De hoge dosering ATD (vijftien aminozuren, 102.5 gram) verlaagde de 
ratio tryptofaan/LNAA met 84%. De lage dosering (op een kwart sterkte van 
de hoge dosering: vijftien aminozuren, 25.7 gram) verlaagde de ratio 
tryptofaan/LNAA met 59%. De hoge dosering ATD verhoogde het aantal 
depressieve symptomen en zorgde voor een tijdelijke terugval bij de helft van 
de patiënten. De hoge dosis verminderde de herkenning van angstige gezichten 
en verstoorde het leervermogen en ophalen van informatie uit het geheugen 
(‘retrieval’). Het verstoorde leervermogen kwam slechts voor bij de patiënten 
met een stemmingsrespons. De lage dosering had geen effect op stemming 
maar versnelde de herkenning van gezichtsuitdrukkingen van walging. De 
juiste herkenning van verdrietige gezichten bij baseline hield verband met de 
stemmingsrespons op ATD. Hoge dosering ATD verhoogde het hartritme 
tijdens rust en tijdens de aandachtstaak. ATD had echter geen significant effect 
op hartritmevariabiliteit in patiënten met een geschiedenis van suïcidaliteit. Een 
lage hartritmevariabiliteit houdt mogelijk wel verband met stemming en 
verstoorde verwerking van affectieve informatie door veranderingen in de 
serotonine functie. Er is echter meer onderzoek nodig naar de relatie tussen 
hartritmevariabiliteit en serotonine in grotere groepen.
In Hoofdstuk 6 worden de effecten van de verschillende ATD 
doseringen op plasma tryptofaan en de ratio tryptofaan/LNAA besproken. 
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Ook worden de inter-individuele verschillen in plasma tryptofaan in reactie op 
de verschillende ATD doseringen nader bekeken. 
In Hoofdstuk 8 wordt de literatuur besproken over de acute en korte-termijn 
effecten van serotonine manipulaties op stemming en emotionele 
informatieverwerking. De hypothese waarop dit hoofdstuk gebaseerd is, is dat 
cognitieve veranderingen mogelijk de symptomatische respons op 
antidepressiva mediëren. Omdat er geen onderzoeken zijn die deze hypothese 
direct getest hebben, hebben we ons gericht op de korte-termijn effecten van 
serotonine manipulaties op emotionele informatieverwerking en stemming. We 
hebben ons hierbij beperkt tot onderzoek bij gezonde personen en personen 
die kwetsbaar zijn om depressief te worden. Ook hebben we literatuur over de 
veranderingen in emotionele informatieverwerking en stemming in depressieve 
patiënten die starten met antidepressiva gezocht. Er werden vijfentwintig 
onderzoeken geïdentificeerd. Er werden vier groepen manipulaties 
onderscheiden: toediening van een SSRI, toediening van een serotonine 
receptor agonist of antagonist, tryptofaan toevoeging en tryptofaan depletie. 
Serotonine manipulaties bleken betrouwbare snelle (tijdsrange: 1 uur- 14 
dagen) effecten te hebben op aandachtsbias, de herkenning van emoties uit 
gezichten, emotioneel geheugen, disfunctionele attitudes en besluitvorming. Er 
is echter meer onderzoek nodig naar het verband tussen door serotonine 
geïnduceerde opeenvolgende veranderingen in emotionele 
informatieverwerking en stemming, vooral in depressieve patiënten.
Hoofdstuk 9 bevat een algemene discussie van de resultaten die vermeld 
worden in dit proefschrift. De bevindingen wijzen op een effect van alfa-
lactalbumine op cognitief functioneren, hoewel een dieet gedurende een dag te 
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zwak is om ook een effect op stress-geïnduceerde stemming en cortisol te 
bewerkstelligen in herstelde depressieve patiënten. Toekomstig onderzoek 
gericht op een hogere dosis alfa-lactalbumine of een langere duur van het dieet 
is gewenst.
De resultaten van het ATD onderzoek ondersteunen de bewering dat 
ATD een nuttige methode is om het verband tussen serotonine en emotionele 
informatieverwerking te onderzoeken in herstellende depressieve patiënten die 
antidepressiva gebruiken. Er is echter meer onderzoek nodig naar de optimale 
lage dosering, die geen effect heeft op stemming en significant verschilt van de 
originele hoge dosering. Ook dient de richting van het verband tussen 
serotonine en de herkenning van emoties uit gezichten verder onderzocht te 
worden in gezonde personen maar ook in personen die kwetsbaar zijn voor 
een depressie. De bevinding dat de herkenning van emoties uit gezichten 
verbonden is met de stemmingsrespons op ATD lijkt veelbelovend met 
betrekking tot onderzoek naar kwetsbaarheid voor serotonine en depressies.
Onze bevindingen ondersteunen de relevantie van emotionele 
informatieverwerking in het onderzoek naar de rol die serotonine speelt in 
depressies. De rol die serotonine speelt in de herkenning van angst en andere 
emoties uit gezichten verdient meer onderzoek aangezien er verschillen zijn in 
de effecten van acute vs. herhaalde toediening en tussen verschillende groepen. 
Er is tot op heden geen bewijs gevonden voor een verband tussen door 
serotonine opgewekte veranderingen in stemming en emotionele 
informatieverwerking maar er zijn veelbelovende bevindingen gedaan voor 
toekomstig onderzoek. Toekomstig onderzoek moet zich richten op klinische 
populaties en zal zowel acute als meer lange-termijn metingen moeten bevatten 
van verschillende vormen van emotionele informatieverwerking.
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Experimentele manipulaties van serotonine d.m.v. ATD of alfa-
lactalbumine zijn mogelijk niet geschikt om de cortisol respons op stress en 
hartritmevariabiliteit te onderzoeken. Er is echter maar weinig onderzoek 
gedaan naar de effecten van deze methodes op biologische 
kwetsbaarheidfactoren.
Het onderzoek naar de serotonine functie in depressies brengt ons mogelijk 
dichter bij de optimale behandeling voor depressieve patiënten. Sommige 
aspecten van emotionele informatieverweking lijken gerelateerd aan de 
serotonine functie. Of dit verband een rol speelt in de therapeutische respons 
op antidepressiva moet verder onderzocht worden. Onderzoek m.b.v. 
serotoninemanipulaties zoals ATD en alfa-lactalbumine biedt ons belangrijke 
kennis over de mogelijke mechanismen die een rol spelen in de werking van 
antidepressiva. Onze bevinding dat de stemmingsrespons op ATD gerelateerd 
is aan de herkenning van verdrietige gezichten, lijkt te wijzen op het feit dat 
sommige aspecten van emotionele informatieverwerking mogelijk voorspellers 




Eindelijk is het dan zo ver; ik mag beginnen aan het leukste deel van dit 
proefschrift. 
Allereerst ben ik heel veel dank verschuldigd aan alle mensen die hebben 
deelgenomen aan de verschillende onderzoeken. Ik heb veel bewondering voor 
het enthousiasme en doorzettingsvermogen waarmee jullie de 
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van PsyQ. Aan het hele team van WO: dank voor het leuke jaar op de 
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Sturm, de medewerkers van het laboratorium en de apotheek, Durk Fekkes 
(Erasmus MC), Kees Swenne en Hedde van de Vooren (Cardiologie LUMC).
Soms loopt onderzoek doen niet zoals je hoopt. Helaas is het sluitstuk van dit 
proefschrift nooit van de grond gekomen. Hoe hard we het ook hebben 
geprobeerd, zonder patiënten geen onderzoek. Veel dank ben ik verschuldigd 
aan Gerthe Veen (Psychiatrie LUMC/ Rijnveste), Irene van Vliet (Psychiatrie 
LUMC) en Jeroen Gast (Rijnveste). Aan jullie inzet heeft het zeker niet 
gelegen! 
Bij de verschillende onderzoeken die in dit proefschrift staan beschreven, heb 
ik hulp gekregen van enthousiaste studenten die me geholpen hebben met het 
verzamelen van data. Martine Blok, Ilse van der Meij, Iris Bulthuis, Adrie 
Seldenrijk, Julian Struijk en Tamara Woestenburg: heel erg bedankt voor jullie 
inzet! Shelley van der Veek, hartelijk dank voor jouw hulp bij het SSRI project 
en het testen van de controlegroep. Een deel van onze werkzaamheden bleef 
helaas onbeantwoord, maar het was fijn om het samen te doen! 
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Halverwege mijn aanstelling kwam ik terecht in 2B39 en dat was het begin van 
een bijzondere vriendschap met mijn twee kamergenootjes. Anne en Suzanne, 
wat was en is het gezellig met z’n drieën!! Zonder jullie aanwezigheid was ik 
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vind het fantastisch dat jullie mijn paranimfen willen zijn en ik ben heel erg 
trots op hoe we het alle drie voor elkaar hebben gekregen om ondanks de vele 
tegenslagen en de tanende motivatie alles tot een goed einde te brengen (ja 
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Ondanks dat heb ik van jullie veel steun ondervonden. Hoe vaak ik ook zeurde 
en klaagde, jullie leefden mee. Ik verkeer in de luxe positie dat ik op deze plek 
niet iedereen bij naam kan noemen, dat zou te veel ruimte innemen, maar weet 
dat ik jullie allemaal zeer dankbaar ben, zowel voor het luisterend’ oor als voor 
de afleiding die ik vaak goed kon gebruiken! 
Lieve Eef, jij bent mijn enige psycho-vriendin. Dank je wel voor alle 
gesprekken en adviezen over mijn toekomstige baan en over al het andere! 
Lieve Elles, als jij lacht, lach ik ook! Laten we dat nog lang blijven 
doen. Ik wil jou en Bart natuurlijk bedanken voor het contact met Joost. En 
Joost van der Kuil: duizend maal dank voor jouw hulp bij het ontwerpen van 
de omslag. Zonder jou was het zwart gebleven!
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Lieve Annemaart, ondanks het feit dat je met enige regelmaat naar het 
buitenland vertrekt, verliezen we elkaar niet uit het oog. Wie had dat gedacht 
toen we jaren geleden in de Beheerskamer naast elkaar terecht kwamen? Jouw 
onuitputtelijke energie en ambitie zijn bewonderenswaardig en inspirerend!
Lieve Jacobien, mijn verblijf in Boston was een onvergetelijke ervaring 
maar het allerleukst is dat ik er onze vriendschap aan heb overgehouden. Ik 
kom helaas voorlopig niet in Zeist wonen, maar hopelijk blijven we elkaar 
regelmatig spreken en zien, zodat ik de fijne kneepjes van het moederschap van 
je af kan kijken!
Lieve Willem en Henriette, wat ben ik dankbaar voor het feit dat jullie me altijd 
gesteund hebben. Ook in tijden dat ik het onderzoek verfoeide en me afvroeg 
waarom ik er ooit aan was begonnen, waren jullie daar om alles in het juiste 
perspectief te plaatsen. Ik vrees dat ik jullie kritische houding geërfd heb, maar 
toegegeven: stiekem komt ‘ie me goed van pas! De conclusie dat de wil om te 
promoveren genetisch bepaald is, mag je niet trekken bij n = 2, maar toch……
Machteld, lieve siss, onze werkvelden lijken in weinig op elkaar maar 
toch ben je altijd betrokken geweest bij mijn promotietraject. Jij bent en blijft 
de eerste die ik bel als er iets is, wat dan ook! Voor jou begon het leven bij 30 
(en hoe!); als dat voor mij ook geldt dan belooft de toekomst niets dan goeds.
De laatste bladzijde van mijn dankwoord kan maar voor een iemand bestemd 
zijn: 
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Lieve Ben, dat ik je vijf jaar geleden (weer) tegen het lijf liep, is het beste wat 
me ooit is overkomen. Jouw onvoorwaardelijke steun en liefde hebben ervoor 
gezorgd dat ik trots ben op dit boekje en hebben van mij een optimistischer 
mens gemaakt. Het jaar 2007 was voor ons beiden een aaneenschakeling van 
mijlpalen en spannende veranderingen op zowel werk als privé gebied. Nu 
kunnen we gaan genieten van alles wat we samen bereikt hebben. Met z’n 
drieën kan de toekomst nu al niet meer stuk! 
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